10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023 or
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                   

Commission File Number: 001-16391

Axon Enterprise, Inc.

(Exact name of registrant as specified in its charter)

Delaware	86-0741227
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
17800 North 85th Street
Scottsdale,  Arizona	85255
(Address of principal executive offices)	(Zip Code)

(480) 991-0797

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 Par Value	AXON	The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated Filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐     No  ☒

The number of shares of the registrant’s common stock outstanding as of May 5, 2023 was 73,885,305.

AXON ENTERPRISE, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023

			Page
Special Note Regarding Forward-Looking Statements			ii
PART I - FINANCIAL INFORMATION			1
	Item 1. Financial Statements		1
		Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022	1
		Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2023 and 2022	2
		Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022	3
		Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022	4
		Notes to Unaudited Condensed Consolidated Financial Statements	5
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		25
	Item 3. Quantitative and Qualitative Disclosures About Market Risk		34
	Item 4. Controls and Procedures		35
PART II - OTHER INFORMATION			35
	Item 1. Legal Proceedings		35
	Item 1A. Risk Factors		36
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		57
	Item 3. Defaults Upon Senior Securities		57
	Item 4. Mine Safety Disclosures		57
	Item 5. Other Information		58
	Item 6. Exhibits		59
	SIGNATURES		60

Special Note Regarding Forward-Looking Statements

This Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, beliefs, intentions and strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. From time to time, we also provide forward-looking statements in other materials we release to the public as well as verbal forward-looking statements. These forward-looking statements include, without limitation, statements regarding: proposed products and services and related development efforts and activities; expectations about the market for our current and future products and services; the impact of pending litigation; strategies and trends relating to subscription plan programs and revenues; our anticipation that contracts with governmental customers will be fulfilled; strategies and trends, including the amounts and benefits of, research and development investments; the sufficiency of our liquidity and financial resources; expectations about customer behavior; the impact on our investment portfolio of changes in interest rates; our potential use of foreign currency forward and option contracts; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; statements of management’s strategies, goals and objectives and other similar expressions; as well as the ultimate resolution of financial statement items requiring critical accounting estimates, including those set forth in our Annual Report on Form 10-K for the year ended December 31, 2022. Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. Words such as “may,” “will,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. However, not all forward-looking statements contain these identifying words.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions. The following important factors could cause actual results to differ materially from those in the forward-looking statements: our exposure to cancellations of government contracts due to appropriation clauses, exercise of a cancellation clause, or non-exercise of contractually optional periods; the ability of law enforcement agencies to obtain funding, including based on tax revenues; our ability to design, introduce and sell new products or features; our ability to defend against litigation and protect our intellectual property, and the resulting costs of this activity; our ability to win bids through the open bidding process for governmental agencies; our ability to manage our supply chain and avoid production delays, shortages, and impacts to expected gross margins; the impacts of inflation, macroeconomic conditions and global events; the impact of stock-based compensation expense, impairment expense, and income tax expense on our financial results; customer purchase behavior, including adoption of our software as a service delivery model; negative media publicity or sentiment regarding our products; the impact of product mix on projected gross margins; defects in, or misuse of, our products; changes in the costs of product components and labor; loss of customer data, a breach of security, or an extended outage, including by our third party cloud-based storage providers; exposure to international operational risks; delayed cash collections and possible credit losses due to our subscription model; changes in government regulations in the U.S. and in foreign markets, especially related to the classification of our products by the United States Bureau of Alcohol, Tobacco, Firearms and Explosives; our ability to integrate acquired businesses; our ability to attract and retain key personnel; litigation or inquiries and related time and costs; and counter-party risks relating to cash balances held in excess of FDIC insurance limits. Many events beyond our control may determine whether results we anticipate will be achieved. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. The following Report lists various important factors that could cause actual results to differ materially from expected and historical results. These factors are intended as cautionary statements for investors within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act. Readers can find them under the heading “Risk Factors” in the Report below, and investors should refer to them. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q, 8-K and 10-K reports to the SEC. Our filings with the SEC may be accessed at the SEC’s web site at www.sec.gov.

ii

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AXON ENTERPRISE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	March 31,		December 31,
	2023		2022
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	263,414	$	353,684
Marketable securities		54,810		39,240
Short-term investments		775,129		581,769
Accounts and notes receivable, net of allowance of $2,029 and $2,176 as of March 31, 2023 and December 31, 2022, respectively		379,887		358,190
Contract assets, net		216,869		196,902
Inventory		220,268		202,471
Prepaid expenses and other current assets		142,319		73,022
Total current assets		2,052,696		1,805,278
Property and equipment, net		172,674		169,843
Deferred tax assets, net		171,122		156,866
Intangible assets, net		11,270		12,158
Goodwill		44,982		44,983
Long-term investments		31,116		156,207
Long-term notes receivable, net		4,467		5,210
Long-term contract assets, net		54,886		45,170
Strategic investments		296,563		296,563
Other long-term assets		168,173		159,616
Total assets	$	3,007,949	$	2,851,894
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	65,988	$	59,918
Accrued liabilities		120,607		155,934
Current portion of deferred revenue		408,061		360,037
Customer deposits		13,961		20,399
Other current liabilities		7,510		6,358
Total current liabilities		616,127		602,646
Deferred revenue, net of current portion		250,366		248,003
Liability for unrecognized tax benefits		16,198		10,745
Long-term deferred compensation		7,983		6,285
Deferred tax liability, net		—		1
Long-term lease liabilities		35,045		37,143
Convertible notes, net		674,724		673,967
Other long-term liabilities		4,511		4,613
Total liabilities		1,604,954		1,583,403
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		—		—
Common stock, $0.00001 par value; 200,000,000 shares authorized; 73,874,062 and 71,474,581 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		1		1
Additional paid-in capital		1,262,099		1,174,594
Treasury stock at cost, 20,220,227 shares as of March 31, 2023 and December 31, 2022		(155,947)		(155,947)
Retained earnings		302,161		257,022
Accumulated other comprehensive loss		(5,319)		(7,179)
Total stockholders’ equity		1,402,995		1,268,491
Total liabilities and stockholders’ equity	$	3,007,949	$	2,851,894

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

AXON ENTERPRISE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except per share data)

	Three Months Ended March 31,
	2023		2022
Net sales from products	$	219,389	$	176,204
Net sales from services		123,654		80,222
Net sales		343,043		256,426
Cost of product sales		107,584		79,352
Cost of service sales		31,357		21,335
Cost of sales		138,941		100,687
Gross margin		204,102		155,739
Operating expenses:
Sales, general and administrative		116,567		90,129
Research and development		70,927		48,416
Total operating expenses		187,494		138,545
Income from operations		16,608		17,194
Interest and other income, net		25,276		55,299
Income before provision for income taxes		41,884		72,493
Provision for (benefit from) income taxes		(3,255)		17,622
Net income	$	45,139	$	54,871
Net income per common and common equivalent shares:
Basic	$	0.62	$	0.77
Diluted	$	0.61	$	0.76
Weighted average number of common and common equivalent shares outstanding:
Basic		72,638		70,950
Diluted		73,880		72,349
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$	45,139	$	54,871
Foreign currency translation adjustments		1,676		(1,072)
Unrealized gain (loss) on available-for-sale investments		184		(489)
Comprehensive income	$	46,999	$	53,310

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

AXON ENTERPRISE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

											Accumulated
				Additional							Other		Total
	Common Stock			Paid-in		Treasury Stock			Retained		Comprehensive		Stockholders’
	Shares	Amount		Capital		Shares	Amount		Earnings		Loss		Equity
Balance, December 31, 2022	71,474,581	$	1	$	1,174,594	20,220,227	$	(155,947)	$	257,022	$	(7,179)	$	1,268,491
Issuance of common stock	154,500		—		33,650	—		—		—		—		33,650
Issuance of common stock under employee plans, net	335,629		—		(34,841)	—		—		—		—		(34,841)
Stock options exercised	1,901,535				54,346	—		—		—		—		54,346
Stock-based compensation	—		—		34,350	—		—		—		—		34,350
Issuance of common stock for business combination contingent consideration	7,817		—		—	—		—		—		—		—
Net income	—		—		—	—		—		45,139		—		45,139
Other comprehensive income, net	—		—		—	—		—		—		1,860		1,860
Balance, March 31, 2023	73,874,062	$	1	$	1,262,099	20,220,227	$	(155,947)	$	302,161	$	(5,319)	$	1,402,995

AXON ENTERPRISE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

											Accumulated
				Additional							Other		Total
	Common Stock			Paid-in		Treasury Stock			Retained		Comprehensive		Stockholders’
	Shares	Amount		Capital		Shares	Amount		Earnings		Loss		Equity
Balance, December 31, 2021	70,896,856	$	1	$	1,095,229	20,220,227	$	(155,947)	$	109,883	$	(1,317)	$	1,047,849
Issuance of common stock	—		—		(70)	—		—		—		—		(70)
Issuance of common stock under employee plans, net	99,802		—		(1,388)	—		—		—		—		(1,388)
Stock-based compensation	—		—		25,088	—		—		—		—		25,088
Net income	—		—		—	—		—		54,871		—		54,871
Other comprehensive loss, net	—		—		—	—		—		—		(1,561)		(1,561)
Balance, March 31, 2022	70,996,658	$	1	$	1,118,859	20,220,227	$	(155,947)	$	164,754	$	(2,878)	$	1,124,789

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

AXON ENTERPRISE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Three Months Ended March 31,
	2023		2022
Cash flows from operating activities:
Net income	$	45,139	$	54,871
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		6,689		5,755
Amortization of issuance cost		756		—
Coupon interest expense		863		—
Loss on disposal and abandonment of intangible assets		10		40
Loss on disposal and impairment of property, equipment, and other assets, net		146		106
Unrealized gains on strategic investments and marketable securities, net		(15,570)		(55,851)
Stock-based compensation		34,350		25,088
Deferred income taxes		(9,660)		18,029
Unrecognized tax benefits		855		1,365
Bond amortization		(3,890)		159
Noncash lease expense		1,395		1,556
Provision for expected credit losses		28		228
Change in assets and liabilities:
Accounts and notes receivable and contract assets		(50,431)		7,495
Inventory		(15,811)		(14,260)
Prepaid expenses and other assets		(64,348)		(7,074)
Accounts payable, accrued and other liabilities		(37,043)		(9,580)
Deferred revenue		50,199		16,037
Net cash provided by (used in) operating activities		(56,323)		43,964
Cash flows from investing activities:
Purchases of investments		(145,124)		—
Proceeds from call / maturity of investments		81,088		7,200
Purchases of property and equipment		(8,513)		(17,098)
Proceeds from disposal of property and equipment		—		87
Purchases of intangible assets		(125)		(37)
Strategic investments		—		(500)
Net cash used in investing activities		(72,674)		(10,348)
Cash flows from financing activities:
Net proceeds from equity offering		33,650		(71)
Proceeds from options exercised		39,181		—
Income and payroll tax payments for net-settled stock awards		(34,841)		(1,388)
Net cash provided by (used in) financing activities		37,990		(1,459)
Effect of exchange rate changes on cash and cash equivalents		779		(157)
Net increase (decrease) in cash and cash equivalents		(90,228)		32,000
Cash and cash equivalents and restricted cash, beginning of period		355,552		356,438
Cash and cash equivalents and restricted cash, end of period	$	265,324	$	388,438
Supplemental disclosures:
Cash and cash equivalents	$	263,414	$	386,367
Restricted cash (Note 1)		1,910		2,071
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	265,324	$	388,438
Cash paid for income taxes, net of refunds	$	20,936	$	334
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	$	1,130	$	888
Receivables from options exercised	$	15,165	$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Note 1 - Organization and Summary of Significant Accounting Policies

Axon Enterprise, Inc. (“Axon”, the “Company”, "we", or "us") is a market-leading provider of law enforcement technology solutions. Our mission is to protect life in service of promoting peace, justice and strong institutions.

Our headquarters in Scottsdale, Arizona houses our executive management, sales, marketing, certain engineering, manufacturing, finance and other administrative support functions. Our global software hub is located in Seattle, Washington, and we also have subsidiaries and / or offices located in Australia, Canada, Finland, France, Germany, Hong Kong, India, Italy, the Netherlands, Spain, the United Kingdom, and Vietnam.

The accompanying unaudited condensed consolidated financial statements include the accounts of Axon Enterprise, Inc. and our subsidiaries. All material intercompany accounts, transactions, and profits have been eliminated.

Basis of Presentation and Use of Estimates

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2022, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2022. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:

● product warranty reserves,

● inventory valuation,

● revenue recognition,

● reserve for expected credit loss,

● valuation of goodwill, intangible and long-lived assets,

● valuation of strategic investments,

● recognition, measurement and valuation of current and deferred income taxes,

● stock-based compensation, and

● recognition and measurement of contingencies and accrued litigation expense.

Actual results could differ materially from those estimates.

Segment Information

Our operations comprise two reportable segments: the development, manufacture and sale of fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share and analyze video and other digital evidence (collectively, the "Software and Sensors" segment); and the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (collectively, the “TASER” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform

5

an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 15.

Geographic Information and Major Customers / Suppliers

For the three months ended March 31, 2023, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three months ended March 31, 2023, no customer represented more than 10% of total net sales. At March 31, 2023 and December 31, 2022, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets.

We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., China, Republic of Korea, Malaysia, Mexico, Sri Lanka, Taiwan, and Vietnam. We may source from other countries as well. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases. Although we have experienced supply chain disruptions relating to materials and port constraints, we have remained focused on closely managing our supply chain. We continue to bolster our strategic relationships in our supply chain, identifying secondary/alternate sourcing, adjusting build plans accordingly, and building in logistic modes in support of our increasing demand while working to minimize disruption to customers. We acquire most of our components on a purchase order basis and do not currently have significant long-term purchase contracts with most component suppliers.

Income per Common Share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The effects of outstanding stock options, unvested restricted stock units, our 2027 convertible senior notes (the “Notes” or “2027 Notes”), and warrants to acquire the number of shares of our common stock (the “Warrants” or “2027 Warrants”) are excluded from the computation of diluted net income per share in periods in which the effect would be antidilutive. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator for basic and diluted earnings per share:
Net income	$	45,139	$	54,871
Denominator:
Weighted average shares outstanding		72,638		70,950
Dilutive effect of stock-based awards		1,242		1,399
Diluted weighted average shares outstanding		73,880		72,349
Net income per common share:
Basic	$	0.62	$	0.77
Diluted	$	0.61	$	0.76

6

Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Stock-based awards		1,469		2,942
2027 Notes		3,017		—
2027 Warrants		3,017		—
Total potentially dilutive securities		7,503		2,942

For additional information regarding our convertible senior notes, refer to Note 9.

Standard Warranties

We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated on a quarterly basis based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying consolidated balance sheets.

Changes in our estimated product warranty liabilities were as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Balance, beginning of period	$	811	$	2,822
Utilization of reserve		(438)		(1,434)
Warranty expense		2,928		116
Balance, end of period	$	3,301	$	1,504

Fair Value Measurements and Financial Instruments

We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.

● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.

7

● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability.

We have cash equivalents and investments, which at March 31, 2023 comprised money market funds, commercial paper, corporate bonds, term deposits, U.S. Government bonds, municipal bonds, agency bonds and U.S. Treasury inflation-protected securities. Cash equivalents and investments at December 31, 2022 also included certificates of deposit and U.S. Treasury bills. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other long-term assets as of March 31, 2023 and December 31, 2022 was $5.1 million and $4.3 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.

We have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net.

We have strategic investments in eight unconsolidated affiliates as of March 31, 2023. The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic investments in privately held companies, we utilize observable data available to us as discussed further in Note 6.

We have convertible senior notes, for which the fair value is determined based on the closing trading price per $1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the Notes at March 31, 2023 to be a Level 2 measurement as they are not publicly traded. The fair value of the Notes is primarily affected by the trading price of our common stock and market interest rates.

Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet.

Restricted Cash

Restricted cash balances were $1.9 million as of March 31, 2023 and December 31, 2022, respectively. The balances were primarily related to funds held in an international bank account securing a guarantee and funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately $1.8 million was included in prepaid expenses and other assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.

Valuation of Goodwill, Intangibles and Long-lived Assets

We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.

We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year.

8

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

Note 2 - Revenues

Nature of Products and Services

The following tables present our revenues by primary product and service offering (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
TASER Devices (Professional)	$	67,472	$	—	$	67,472	$	63,164	$	—	$	63,164
Cartridges		46,800		—		46,800		37,825		—		37,825
Axon Evidence and Cloud Services		7,201		118,314		125,515		3,017		79,939		82,956
Extended Warranties		7,670		14,085		21,755		6,679		9,061		15,740
Axon Body Cameras and Accessories		—		38,797		38,797		—		38,517		38,517
Axon Fleet Systems		—		32,972		32,972		—		13,820		13,820
Other (1) (2)		5,139		4,593		9,732		3,675		729		4,404
Total	$	134,282	$	208,761	$	343,043	$	114,360	$	142,066	$	256,426

(1) TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.

(2) Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room and Axon Air.

The following table presents our revenues disaggregated by geography (in thousands):

	Three Months Ended March 31,
	2023				2022
United States	$	290,938	85	%	$	214,214	84	%
Other countries		52,105	15			42,212	16
Total	$	343,043	100	%	$	256,426	100	%

Contract Balances

The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the three months ended March 31, 2023 (in thousands):

	March 31, 2023
Contract assets, net	$	271,755
Contract liabilities (deferred revenue)		658,427
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period		133,707

9

Contract liabilities (deferred revenue) consisted of the following (in thousands):

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
Warranty:
TASER	$	13,333	$	18,198	$	31,531	$	14,207	$	17,618	$	31,825
Software and Sensors		28,105		15,467		43,572		26,229		15,338		41,567
		41,438		33,665		75,103		40,436		32,956		73,392
Hardware:
TASER		46,575		16,896		63,471		49,361		12,640		62,001
Software and Sensors		61,554		106,398		167,952		50,426		109,227		159,653
		108,129		123,294		231,423		99,787		121,867		221,654
Services:
TASER		6,016		9,425		15,441		7,637		9,501		17,138
Software and Sensors		252,478		83,982		336,460		212,177		83,679		295,856
		258,494		93,407		351,901		219,814		93,180		312,994
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
TASER	$	65,924	$	44,519	$	110,443	$	71,205	$	39,759	$	110,964
Software and Sensors		342,137		205,847		547,984		288,832		208,244		497,076
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

Remaining Performance Obligations

As of March 31, 2023, we had approximately $4.8 billion of remaining performance obligations, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. The remaining performance obligations are limited only to arrangements that meet the definition of a contract under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, as of March 31, 2023. We expect to recognize between 15% - 25% of this balance over the next twelve months, and generally expect the remainder to be recognized over the following ten years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.

10

Note 3 - Cash, Cash Equivalents and Investments

The following tables summarize our cash, cash equivalents, marketable securities, and available-for-sale investments at March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	213,446	$	—	$	—	$	213,446	$	213,446	$	—	$	—	$	—
Level 1:
Money market funds		49,968		—		—		49,968		49,968		—		—		—
Agency bonds		160,615		39		(230)		160,424		—		—		154,688		5,736
Treasury bills		41,079		6		(2)		41,083		—		—		41,083		—
Marketable securities		90,000		—		(35,190)		54,810		—		54,810		—		—
Subtotal		341,662		45		(35,422)		306,285		49,968		54,810		195,771		5,736
Level 2:
State and municipal obligations		3,026		—		(14)		3,012		—		—		3,012		—
Term deposits		175,000		—		—		175,000		—		—		175,000		—
Corporate bonds		241,401		45		(1,081)		240,365		—		—		226,468		13,897
U.S. government		43,948		—		(158)		43,790		—		—		32,307		11,483
Treasury inflation-protected securities		2,525		17		—		2,542		—		—		2,542		—
Commercial paper		140,029		—		—		140,029		—		—		140,029		—
Subtotal		605,929		62		(1,253)		604,738		—		—		579,358		25,380
Total	$	1,161,037	$	107	$	(36,675)	$	1,124,469	$	263,414	$	54,810	$	775,129	$	31,116

As of March 31, 2023, we had $375.6 million of available-for-sale investments with unrealized losses. Of the $375.6 million of available-for-sale investments with unrealized losses, $17.6 million have been in a continuous unrealized loss position for 12 months or longer, with total gross unrealized losses of $0.6 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases.

During the year ended December 31, 2021, we acquired 9,000,000 shares of common stock of Cellebrite DI Ltd (“CLBT”) with a fair value of $90.0 million. The CLBT common stock is recorded as marketable securities in the accompanying condensed consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net. During the three months ended March 31, 2023, we recorded an unrealized gain on marketable securities of $15.6 million relating to CLBT.

11

	As of December 31, 2022
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	143,744	$	—	$	—	$	143,744	$	143,744	$	—	$	—	$	—
Level 1:
Money market funds		2,669		—		—		2,669		2,669		—		—		—
Agency bonds		164,486		6		(263)		164,229		—		—		69,862		94,367
Treasury bills		121,650		18		(3)		121,665		113,100		—		8,565		—
Marketable securities		90,000		—		(50,760)		39,240		—		39,240		—		—
Subtotal		378,805		24		(51,026)		327,803		115,769		39,240		78,427		94,367
Level 2:
State and municipal obligations		4,980		—		(33)		4,947		—		—		4,947		—
Certificate of deposits		5,002		—		—		5,002		—		—		5,002		—
Term deposits		200,000		—		—		200,000		25,000		—		175,000		—
Corporate bonds		257,422		33		(1,159)		256,296		28,883		—		168,074		59,339
U.S. Government		30,525		—		(159)		30,366		—		—		30,366		—
Treasury inflation-protected securities		2,503		—		(2)		2,501		—		—		—		2,501
Commercial paper		160,241		—		—		160,241		40,288		—		119,953		—
Subtotal		660,673		33		(1,353)		659,353		94,171		—		503,342		61,840
Total	$	1,183,222	$	57	$	(52,379)	$	1,130,900	$	353,684	$	39,240	$	581,769	$	156,207

Note 4 - Expected Credit Losses

We are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, notes receivable, and contract assets is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible.

We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions.

The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands):

	Three Months Ended March 31, 2023
	United States		Other countries		Total
Balance, beginning of period	$	3,064	$	566	$	3,630
Provision for expected credit losses		(76)		104		28
Amounts written off charged against the allowance		(353)		(5)		(358)
Balance, end of period	$	2,635	$	665	$	3,300

12

As of March 31, 2023 and December 31, 2022, the allowance for expected credit losses for each type of customer receivable was as follows (in thousands):

	March 31, 2023		December 31, 2022
Accounts receivable and notes receivable, current	$	2,029	$	2,176
Contract assets, net		1,211		1,360
Long-term notes receivable, net of current portion		60		94
Total allowance for expected credit losses on customer receivables	$	3,300	$	3,630

Note 5 - Inventory

Inventories are stated at the lower of cost, determined on the first-in, first-out (“FIFO”) basis, or net realizable value, net of an inventory valuation allowance. We use a standard cost methodology to determine the cost basis for its inventories. Costs include allocations for materials, labor, and overhead. All variances between actual costs and standard costs are apportioned to inventory and cost of goods sold based upon inventory turnover. We evaluate inventory on a quarterly basis for obsolete or slow-moving items to ascertain if the recorded allowance is reasonable and adequate. Additional provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value.

Inventory consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Raw materials	$	86,607	$	72,740
Finished goods		133,661		129,731
Total inventory	$	220,268	$	202,471

Note 6 - Strategic Investments

Strategic investments include investments in a number of non-public technology-driven companies. We account for strategic investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investments. The investments are measured at cost less impairment, adjusted for observable price changes and are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

In conjunction with certain of our strategic investments, we have the ability to commit additional capital over time through warrants and call options; for some investments, the exercisability and exercise prices are conditional on the achievement of certain performance metrics.

13

The following tables provide a roll-forward of the balance of strategic investments (in thousands):

	Three Months Ended March 31, 2023								Three Months Ended March 31, 2022
	Strategic investments		Warrants			Call options	Total		Strategic investments		Warrants			Total
Balance, beginning of period	$	277,676	$	1,654	$	17,233	$	296,563	$	80,775	$	2,745	$	83,520
Investments		—		—		—		—		500		—		500
Observable price changes:
Unrealized gains		—		—		—		—		41,893		28,539		70,432
Unrealized losses		—		—		—		—		—		—		—
Exercises		—		—		—		—		—		—		—
Sales		—		—		—		—		—		—		—
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563	$	123,168	$	31,284	$	154,452

	Inception to date
	Strategic investments		Warrants			Call options	Total
Investments	$	109,482	$	3,047	$	17,233	$	129,762
Observable price changes:
Realized gains		12,312		—		—		12,312
Unrealized gains		74,817		29,073		—		103,890
Unrealized losses		(1,108)		(377)		—		(1,485)
Exercises		96,719		(30,089)		—		66,630
Sales		(14,546)		—		—		(14,546)
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563

As part of our strategy, we continuously evaluate opportunities for strategic investments that align with our mission. Examples of investment areas include real-time crime center software, drones and related software, biometric sensors, and weapon detection solutions.

Note 7 - Variable Interest Entities

We evaluate our investments and other significant relationships to determine whether any investee is a variable interest entity (“VIE”). If we conclude that an investee is a VIE, we evaluate our power to direct the activities of the investee, our obligation to absorb the expected losses of the investee and our right to receive the expected residual returns of the investee to determine whether we are the primary beneficiary of the investee. If we are the primary beneficiary of a VIE, we consolidate such entity and reflects the non-controlling interest of other beneficiaries of that entity.

We determine whether we are the primary beneficiary of a VIE by performing an analysis that principally considers:

● The VIE’s purpose, design, and risks the VIE was designed to create and pass through to its variable interest holders;

● The VIE’s capital structure;

● The terms between the VIE and its variable interest holders and other parties involved with the VIE; and

● Related-party affiliations.

14

The table below presents a summary of the nonconsolidated VIEs in which we hold variable interests:

	March 31, 2023		December 31, 2022
Total nonconsolidated variable interest entities:
Carrying value of variable interest - assets	$	11,530	$	11,530
Carrying value of variable interest - liabilities		—		—
Maximum exposure to loss:
Non-public equity (1)		11,530		11,530
Total	$	11,530	$	11,530

⁽¹⁾ The maximum exposure to loss is limited to the carrying value of the interest.

In the table above:

● The nature of our variable interest is described in the row under maximum exposure to loss.

● Our exposure to the obligations of the VIE is limited to our interest in the entity.

The primary purpose of our U.S-based, nonconsolidated VIE investments is to create strategic partnerships with market-leading providers of law enforcement technology solutions. We present all variable interests in unconsolidated VIEs as strategic investments within the long-term assets section of the condensed consolidated balance sheet.

We have provided financial support to the nonconsolidated VIEs in exchange for preferred equity as well as warrants and call options that give us the ability to commit additional capital overtime. Financial support provided to the nonconsolidated VIEs is used to continue to finance their operations. We have no explicit or implicit arrangements to provide additional financial support to the VIEs and we have no liabilities to the VIEs as of March 31, 2023 and December 31, 2022.

Note 8 - Accrued Liabilities

Accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Accrued salaries, benefits and bonus	$	63,975	$	97,882
Accrued professional, consulting and lobbying fees		6,840		3,861
Accrued warranty expense		3,301		811
Accrued income and other taxes		7,486		13,559
Accrued inventory in transit		11,318		10,548
Other accrued expenses		27,687		29,273
Accrued liabilities	$	120,607	$	155,934

Note 9 – Convertible Senior Notes

2027 Notes

In December 2022, we issued $690.0 million aggregate principal amount of our 0.50% Convertible Senior Notes due 2027 in a private offering, which aggregate principal amount included the exercise in full of the initial purchasers’ option to purchase up to an additional $90.0 million principal amount of the Notes. The Notes mature on December 15, 2027 and bear interest at a fixed rate of 0.50% per annum, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023. The total net proceeds from the issuance of the Notes, after deducting initial purchasers' discounts and commissions and estimated debt issuance costs of $16.2 million, were approximately $673.8 million. The effective interest rate for the Notes was 0.99% and included interest payable and amortization of debt issuance cost.

15

If we undergo a fundamental change (as defined in the indenture governing the Notes), holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, but excluding the fundamental change repurchase date. In addition, following certain corporate events or if we issue a notice of redemption, it will increase the conversion rate for holders who elect to convert their notes in connection with such corporate event or during the relevant redemption period.

The following table summarizes the carrying value of the Notes (in thousands):

	March 31, 2023		December 31, 2022
Principal	$	690,000	$	690,000
Unamortized debt issuance costs		(15,276)		(16,033)
Convertible notes carrying amount, net	$	674,724	$	673,967

We consider the fair value of the Notes to be a Level 2 measurement. The estimated fair value of the Notes at March 31, 2023 and December 31, 2022 is based on the closing trading price per $1,000 of the Notes as of the last day of trading for each period as follows (in millions):

	March 31, 2023		December 31, 2022
2027 Notes	$	812.3	$	687.3

Interest expense related to the Notes was as follows (in thousands):

	March 31, 2023		December 31, 2022
Contractual interest expense	$	863	$	211
Amortization of debt issuance costs		756		198
Total interest expense	$	1,619	$	409

Note Hedge

To reduce the impact of potential economic dilution upon conversion of the Notes, we entered into a convertible note hedge transaction (the “Note Hedge” or “2027 Note Hedge”) with certain investment banks, with respect to our common stock, concurrently with the issuance of the 2027 Notes.

	Purchase Price		Shares Purchased
2027 Note Hedge	$	194,994		3,016,680

The Note Hedge covers shares of our common stock at a strike price per share that corresponds to the initial conversion price of the respective Notes, subject to adjustment, and are exercisable upon conversion of the Notes. If exercised, we may elect to receive cash, shares of our common stock, or a combination of cash and shares. We have accounted for the aggregate amount of purchase price for the Note Hedge as a reduction to additional paid-in capital. The Note Hedge will expire upon the maturity of the Notes. The Note Hedge is intended to reduce the potential economic dilution upon conversion of the Notes in the event that the fair value per share of our common stock at the time of exercise is greater than the conversion price of the Notes. The Note Hedge is a separate transaction and is not part of the terms of the Notes. Holders of the Notes do not have any rights with respect to the Note Hedge. The Note Hedge does not impact earnings per share, as it was entered into to offset any dilution from the Notes. As of March 31, 2023, 3,016,680 shares remain subject to the Note Hedge.

16

Note Warrants

	Proceeds		Shares		Strike Price		First Expiration
2027 Warrants	$	124,269		3,016,680	$	338.86		March 15, 2028

Separately, we entered into warrant transactions with certain investment banks, whereby we sold warrants to acquire, subject to adjustment, the number of shares of our common stock shown in the table above. If the average market value per share of our common stock, on each expiration date exceeds the strike price of the Warrants expiring on that day, such Warrants would have a dilutive effect on our earnings per share to the extent we report net income. According to the terms of the Warrants, the Warrants will be automatically exercised over a 60-trading day period beginning on the first expiration date as set forth above.

Note 10 - Income Taxes

We file income tax returns for federal purposes and in many states, as well as in multiple foreign jurisdictions. Our tax filings remain subject to examination by applicable tax authorities for a certain length of time, generally three to four years, but can be up to ten years in some jurisdictions following the tax year to which these filings relate.

Deferred Tax Assets

Net deferred income tax assets at March 31, 2023, primarily include R&D capitalization net of amortization, deferred revenue, convertible debt net of amortization, accruals and reserves, and stock-based compensation expense partially offset by accelerated depreciation expense, unrealized investment gains, and valuation allowance reserve. Our total net deferred tax assets at March 31, 2023 were $171.1 million.

In preparing our condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating our ability to recover our deferred income tax assets, management considers all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining our provision for income taxes, our deferred tax assets and liabilities, and our future taxable income for purposes of assessing our ability to utilize any future tax benefit from our deferred tax assets.

As of March 31, 2023, management continues to believe the positive evidence from projected future earnings outweighs the negative evidence and a valuation allowance is only needed on specific deferred tax assets. We have concluded that a valuation allowance is necessary against unrealized investment losses as well as transaction costs incurred in connection with certain investments. Additionally, we do have Arizona R&D tax credits expiring unutilized each year; therefore, management has concluded that it is more likely than not that our Arizona R&D deferred tax asset will not be realized, and a valuation allowance has been recorded against this net asset.

In Australia, we have determined that sufficient deferred tax liabilities will reverse in order to realize all assets except one long-lived intangible where there is not an expectation that the asset may be realized. Therefore, we continue to recognize a partial valuation allowance for Australia.

We complete R&D tax credit studies for each year that an R&D tax credit is claimed for federal and state income tax purposes. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $22.3 million as of March 31, 2023. Should the unrecognized benefit of $22.3 million be recognized, our effective tax rate would be favorably impacted. Approximately $5.0 million of the unrecognized tax benefit associated with R&D credits has been netted against the R&D deferred tax asset.

17

Effective Tax Rate

Our overall effective tax rate for the three months ended March 31, 2023, after discrete period adjustments, was -7.8%. Before discrete adjustments, the tax rate was 22.8%, which differs from the federal statutory rate, primarily due to the impact of R&D tax credits and a decrease in valuation allowance offset by the executive compensation limitation under Internal Revenue Code ("IRC") Section 162(m) and an increase in unrecognized tax benefits, on projected pre-tax income for the year. The effective tax rate was favorably impacted by a $13.0 million discrete tax benefit primarily associated with net windfalls related to stock-based compensation for restricted stock units (“RSUs”) and performance stock units (“PSUs”) that vested and stock options that were exercised during the three months ended March 31, 2023, primarily attributed to the vesting of tranche 10 of the XSPP in March 2023.  

Note 11 - Stockholders’ Equity

CEO Performance Award

On May 24, 2018, our stockholders approved the Board of Directors’ grant of 6,365,856 stock option awards to Patrick W. Smith, our CEO (the “CEO Performance Award”). The CEO Performance Award consists of 12 vesting tranches with a vesting schedule based entirely on the attainment of both operational goals (performance conditions) and market capitalization goals (market conditions), assuming continued employment either as the CEO or as both Executive Chairman and Chief Product Officer and service through each attainment date. Each of the 12 vesting tranches of the CEO Performance Award have a 10-year contractual term and will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of the following eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA have been met for the previous four consecutive fiscal quarters. Adjusted EBITDA for purposes of the CEO Performance Award is defined as net income (loss) attributable to common stockholders before interest expense, interest and other income (such as dividends) earned on investments in marketable securities, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense.

Revenue Goal (1) (in thousands)	Achievement Status	Adjusted EBITDA (in thousands)	Achievement Status
Goal #1, $710,058	Achieved	Goal #1, $125,000	Achieved
Goal #2, $860,058	Achieved	Goal #2, $155,000	Achieved
Goal #3, $1,010,058	Achieved	Goal #3, $175,000	Achieved
Goal #4, $1,210,058	Achieved	Goal #4, $190,000	Achieved
Goal #5, $1,410,058	Not Applicable	Goal #5, $200,000	Achieved
Goal #6, $1,610,058	Not Applicable	Goal #6, $210,000	Achieved
Goal #7, $1,810,058	Not Applicable	Goal #7, $220,000	Achieved
Goal #8, $2,010,058	Not Applicable	Goal #8, $230,000	Achieved

(1) In connection with the business acquisition that was completed during the three months ended September 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement.

Stock-based compensation expense associated with the CEO Performance Award is recognized over the longer of the expected achievement period for each pair of market capitalization and operational goals, beginning at the point in time when the relevant operational goal is considered probable of being met. The probability of meeting an operational goal and the expected achievement point in time for meeting a probable operational goal are based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis. Even though no tranches of the CEO Performance Award vest unless a market capitalization and a matching operational goal are both achieved, stock-based compensation expense is recognized when an operational goal is considered probable of achievement regardless of whether a market capitalization goal is actually achieved. Stock-based compensation represents a non-cash expense and is recorded in sales, general, and administrative operating expense on our consolidated statements of operations and comprehensive income.

18

The first eleven market capitalization goals have been achieved as of March 31, 2023 while the final market capitalization goal was achieved in April 2023. As of March 31, 2023, 5.8 million stock options have been certified by the Compensation Committee and vested. As twelve operational goals have been achieved or are considered probable of achievement, we recorded stock-based compensation expense of $246.0 million related to the CEO Performance Award from the grant date through March 31, 2023, with no unamortized expense remaining. The number of stock options that are expected to vest upon certification by the Compensation Committee related to the remaining tranche is approximately 0.5 million shares.

On March 28, 2023, the Company's Board of Directors approved a new stock option grant to our CEO (the “2023 CEO Performance Award”), which is subject to shareholder approval at our upcoming Annual Meeting of Shareholders.  The 2023 CEO Performance Award will consist of 10 vesting tranches, each equal to 0.5% of the Company's outstanding common stock as of March 27, 2023, the business day prior to the date the award was approved by the Board of Directors. The stock options comprising the 2023 CEO Performance Award will have a per share exercise price equal to $218.59, which reflects the closing price for a share of the Company’s common stock as of the last trading day immediately preceding the grant date. The 2023 CEO Performance Award will not have a financial statement impact unless and until it is approved by shareholders at the Annual Meeting in May 2023.

eXponential Stock Performance Plan

On February 12, 2019, our shareholders approved the 2019 Stock Incentive Plan (the “2019 Plan”), which was adopted by the Board of Directors to reserve a sufficient number of shares to facilitate our eXponential Stock Performance Plan (“XSPP”) and grants of eXponential Stock Units (“XSUs”) under the plan. Initial awards under the plan were granted in January 2019, with additional employee awards granted since that date.

The XSUs are grants of Restricted Stock Units (“RSUs”), each with a term of approximately nine years, that vest in 12 equal tranches. Each of the 12 tranches will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA (CEO Performance Award) have been met for the previous four consecutive fiscal quarters. Beginning with the quarter ended June 30, 2021, new XSU grants are divided into a reduced number of tranches depending on employee eligibility and current market capitalization attainment.

The XSPP contains an anti-dilution provision incorporated into the plan based on shareholder feedback, which affects the calculation of the market capitalization goals in the plan. The plan defines a maximum number of shares outstanding that may be used in the calculation of the market capitalization goals (the “XSU Maximum”). If the actual number of shares outstanding exceeds the XSU Maximum guardrail, then the lower pre-defined number of shares in the XSU Maximum, rather than the higher actual number of shares outstanding, is used to calculate market capitalization for the determination of the market capitalization goals in the XSPP, which, together with the operational goals, determines whether XSUs vest for participating employees.

The XSU Maximum is defined as the actual number of shares outstanding on the original XSU grant date of January 2, 2019, increased by a 3% annual rate over the term of the XSPP and by shares issued upon the exercise of CEO Performance Award options. The XSU Maximum is also adjusted for acquisitions, spin-offs or other changes in the number of outstanding shares of common stock, if such changes have a corresponding adjustment on the market capitalization goals.

The market capitalization and operational goals are identical to the CEO Performance Award, but a different number of shares is used to calculate the market capitalization goals if shares outstanding exceed the XSU Maximum. Additionally, because the grant date is different than that of the CEO Performance Award, the measurement period for market capitalization is not identical. As of March 31, 2023, actual shares outstanding exceeded the XSU Maximum. Accordingly, market capitalization as calculated for the purposes of achieving additional goals uses the lower XSU Maximum share amount rather than actual shares outstanding.

19

The first ten market capitalization goals had been achieved as of March 31, 2023, and the final two market capitalization goals were achieved in April 2023. As all twelve operational goals have been achieved, we recorded stock-based compensation expense of $191.3 million related to the XSU awards from their respective grant dates through March 31, 2023. The number of XSU awards that would vest related to the remaining two tranches is approximately 0.8 million shares. As of March 31, 2023, we had $9.3 million of total unrecognized stock-based compensation expense, which will be recognized over a weighted-average period of 0.9 years.

Restricted Stock Units

The following table summarizes RSU activity for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,565	$	145.38
Granted	73		192.07
Released	(103)		135.31
Forfeited	(32)		152.72
Units outstanding, end of period	1,503		148.20	$	338,003

Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $224.85 multiplied by the number of RSUs outstanding. As of March 31, 2023, there was $176.3 million in unrecognized compensation costs related to RSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.2 years. RSUs are released when vesting requirements are met.

Certain RSUs that vested in the three months ended March 31, 2023 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to RSUs were approximately one thousand and had a value of $0.2 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital.

Performance Stock Units

The following table summarizes PSU activity, inclusive of XSUs, for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,369	$	43.43
Granted	—		—
Released	(401)		33.95
Forfeited	(12)		30.24
Units outstanding, end of period	956		47.58	$	214,939

Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $224.85 per share, multiplied by the number of PSUs outstanding. As of March 31, 2023, there was $12.3 million in unrecognized compensation costs related to PSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the PSUs over a weighted average period of 1.0 years. PSUs are released when vesting requirements are met.

Certain PSUs that vested in the three months ended March 31, 2023 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash

20

to the appropriate taxing authorities. Total shares withheld related to PSUs were 160 thousand and had a value of $34.7 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital.

Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2023 (number of options and aggregate intrinsic value in thousands):

				Weighted
		Weighted		Average
	Number	Average		Remaining
	of	Exercise		Contractual	Aggregate
	Options	Price		Life (years)	Intrinsic Value
Options outstanding, beginning of year	2,438	$	28.58
Granted	—		—
Exercised	(1,901)		—
Expired / terminated	—		—
Options outstanding, end of period	537		28.58	4.91	$	105,284
Options exercisable, end of period	6		28.58	4.91		1,165

Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock of $224.85 on March 31, 2023.

Of the total stock options exercised during the three months ended March 31, 2023, 0.9 million were immediately sold to cover the exercise price and the option holder’s tax obligation for the applicable income and other employment taxes. As of March 31, 2023, total options outstanding included 0.5 million unvested performance-based stock options, which relate to the CEO Performance Award and are probable of achievement.

Stock-based Compensation Expense

The following table summarizes the composition of stock-based compensation expense for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Cost of product sales and service sales	$	1,320	$	1,108
Sales, general and administrative expenses		15,445		12,982
Research and development expenses		17,585		10,998
Total stock-based compensation expense	$	34,350	$	25,088

Stock Incentive Plan

In May 2022, our shareholders approved the Axon Enterprise, Inc. 2022 Stock Incentive Plan (the “2022 Plan”) authorizing an additional 2.5 million shares, plus remaining available shares under prior plans, for issuance under the new plan. Combined with the 2019 Plan and other legacy stock incentive plans, there are 2.7 million shares available for grant as of March 31, 2023.

Stock Repurchase Plan

In February 2016, our Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of our outstanding common stock subject to stock market conditions and corporate considerations. During the three months ended March 31, 2023 and 2022, no common shares were purchased under the program. As of March 31, 2023, $16.3 million remains available under the plan for future purchases. Any future purchases will be discretionary.

21

At-the-Market equity offering

During the three months ended March 31, 2023, we sold 154,500 shares of our common stock under our "at-the-market" equity offering program (the “ATM”). We generated approximately $34.2 million in aggregate gross proceeds from sales under the ATM.  Aggregate net proceeds from the ATM were $33.7 million after deducting related expenses, including commissions to the sales agent and issuance costs of $0.5 million.

We may sell up to a total of 3.0 million shares of our common stock under the ATM, with 2.3 million shares remaining as of March 31, 2023. The ATM expires on April 20, 2024. We intend to use the net proceeds from this offering for general corporate purposes, which may include, among other things, providing capital to satisfy a portion of the tax obligations related to the vesting and settlement of stock compensation awards granted to our executive officers and other employees under our stock incentive plans, to support our growth, and to acquire or invest in product lines, products, services, technologies or facilities.

Note 12 - Line of Credit

In December 2022, we entered into a Credit Agreement that provides for a senior unsecured multi-currency revolving credit facility in an aggregate principal amount of up to $200.0 million, $30.0 million of which is available for the issuance of letters of credit. The credit agreement will mature on the earlier of December 15, 2027 or the date that is six months prior to the stated maturity date of the 0.50% convertible senior notes due 2027 unless such Notes have been redeemed, repurchased, converted or defeased in full. Additionally, the credit agreement has an accordion feature which allows for an increase in the total line of credit up to $300.0 million, subject to each lender’s sole discretion.

At March 31, 2023 and December 31, 2022, there were no borrowings under the line. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of March 31, 2023 we had letters of credit outstanding of approximately $7.0 million under the facility and available borrowing of $193.0 million, excluding amounts available under the accordion feature. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest expense, taxes, depreciation and amortization ("EBITDA") ratio. EBITDA for the purposes of the credit agreement excludes investment interest income.

We are required to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, of no greater than 3.50 to 1.00 based upon a trailing four fiscal quarter period. At March 31, 2023, our leverage ratio was 0.78 to 1.00. Additionally, we must comply with a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense, of no less than 3.50 to 1.00 based upon a trailing four fiscal quarter end. We are compliant with the consolidated interest coverage ratio, which is not meaningful for the three months ended March 31, 2023.

Note 13 - Commitments and Contingencies

Product Litigation

As a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products.  We are currently named as a defendant in four lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn.  They seek compensatory and sometimes punitive damages, often in unspecified amounts.

We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results

22

of operations, or cash flows. We are self-insured for the first $5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period.

The litigation information in this note is current through the date of these financial statements.

U.S. Federal Trade Commission Litigation

The U.S. Federal Trade Commission (“FTC”) filed an administrative enforcement action in January 2020 regarding our May 2018 acquisition of an insolvent body worn camera competitor, Vievu LLC. The FTC alleges the merger was anticompetitive and adversely affected the body worn camera and digital evidence management market for “large metropolitan police departments,” which we deny. The administrative hearing is presently stayed pending our federal court constitutional challenges to the FTC’s structure. Even if we ultimately are required to divest Vievu and other assets, we do not expect that any such result will interfere with our ability to meet contractual obligations or implement our solutions.

Prior to the FTC’s enforcement action, on January 3, 2020 we sued the FTC in federal court in the District of Arizona for declaratory and injunctive relief alleging the FTC’s structure is unconstitutional. The district court dismissed the action, without prejudice, for lack of jurisdiction and the Ninth Circuit affirmed in a split decision. The U.S. Supreme Court granted our petition for certiorari in January 2022 and heard oral argument on November 7, 2022. On April 17, 2023, the Supreme Court issued a unanimous decision in Axon’s favor, confirming district court jurisdiction for constitutional challenges to the structure and existence of federal agencies like the FTC. The case will be remanded to district court for further proceedings on the merits of Axon’s claims.    

As always, we are open to evaluating strategic alternatives to litigation if achievable on terms agreeable to the FTC and Axon and determined to be in the best interests of shareholders and customers.

General

From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time.

Based on our assessment of outstanding litigation and claims as of the date of these financial statements, we have determined that it is not reasonably probable that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

Off-Balance Sheet Arrangements

Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At March 31, 2023, we had outstanding letters of credit issued under our credit facility

23

of $7.0 million that are expected to expire throughout 2023 and 2024. Additionally, we had $14.0 million of outstanding surety bonds at March 31, 2023, with $3.5 million expiring in 2023 and $10.5 million expiring in 2024.

Note 14 – Accumulated Other Comprehensive Income (loss)

The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands):

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2022	$	(1,251)	$	(5,928)	$	(7,179)
Other comprehensive income		184		1,676		1,860
Balance, March 31, 2023	$	(1,067)	$	(4,252)	$	(5,319)

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2021	$	(207)	$	(1,110)	$	(1,317)
Other comprehensive loss		(489)		(1,072)		(1,561)
Balance, March 31, 2022	$	(696)	$	(2,182)	$	(2,878)

Note 15 - Segment Data

Our operations comprise two reportable segments: the TASER segment and the Software and Sensors segment.

Information relative to our reportable segments was as follows (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
Net sales from products	$	127,081	$	92,308	$	219,389	$	111,154	$	65,050	$	176,204
Net sales from services		7,201		116,453		123,654		3,206		77,016		80,222
Net sales		134,282		208,761		343,043		114,360		142,066		256,426
Cost of product sales		50,583		57,001		107,584		40,625		38,727		79,352
Cost of service sales		180		31,177		31,357		—		21,335		21,335
Cost of sales		50,763		88,178		138,941		40,625		60,062		100,687
Gross margin	$	83,519	$	120,583	$	204,102	$	73,735	$	82,004	$	155,739
Research and development	$	16,080	$	54,847	$	70,927	$	9,896	$	38,520	$	48,416

24

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition as of March 31, 2023, and results of operations for the three months ended March 31, 2023 and 2022, should be read in conjunction with the condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and related notes in our 2022 Annual Report on Form 10-K filed with the SEC on February 28, 2023. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in such forward-looking statements as a result of certain factors, including but not limited to those described under “Item 1a. Risk Factors.” See also "Special Note Regarding Forward-Looking Statements" on page ii of this Quarterly Report on Form 10-Q.

Overview

Axon is a technology leader in global public safety. Our moonshot goal is to cut gun-related deaths between police and the public by 50% before 2033. Axon is building the public safety operating system of the future by integrating a suite of hardware devices and cloud software solutions that lead modern policing. Axon’s suite includes TASER energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. Axon’s growing global customer base includes first responders across international, federal, state, and local law enforcement, fire, corrections, and emergency medical services, as well as the justice sector, commercial enterprises, and consumers.

Our revenues for the three months ended March 31, 2023 were $343.0 million, an increase of $86.6 million, or 33.8%, from the comparable period in the prior year. We had income from operations of $16.6 million compared to $17.2 million for the same period in the prior year. Gross margin dollars increased $48.4 million but decreased slightly as a percentage of revenue compared to the three months ended March 31, 2022, reflecting increases in nonrecurring inventory reserves and other cost adjustments. Operating expenses increased $48.9 million, reflecting an increase in salaries, benefits, and bonus expense and increases in sales, marketing, and commissions expense, as well as an increase in stock-based compensation expense. Net income of $45.1 million included an unrealized gain of $15.6 million related to changes in fair value for our marketable securities related to our investment in CLBT, compared to net income of $54.9 million for the comparable period in the prior year, which included unrealized gains of $70.4 million related to observable price changes for our existing investments and related warrants and an unrealized loss of $14.6 million related to our investment in CLBT.

25

Results of Operations

Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022

The following table presents data from our condensed consolidated statements of operations as well as the percentage relationship to total net sales of items included in our statements of operations (dollars in thousands):

	Three Months Ended March 31,
	2023				2022
Net sales from products	$	219,389	64.0	%	$	176,204	68.7	%
Net sales from services		123,654	36.0			80,222	31.3
Net sales		343,043	100.0			256,426	100.0
Cost of product sales		107,584	31.4			79,352	31.0
Cost of service sales		31,357	9.1			21,335	8.3
Cost of sales		138,941	40.5			100,687	39.3
Gross margin		204,102	59.5			155,739	60.7
Operating expenses:
Sales, general and administrative		116,567	34.0			90,129	35.1
Research and development		70,927	20.7			48,416	18.9
Total operating expenses		187,494	54.7			138,545	54.0
Income from operations		16,608	4.8			17,194	6.7
Interest and other income, net		25,276	7.4			55,299	21.6
Income before provision for income taxes		41,884	12.2			72,493	28.3
Provision for (benefit from) income taxes		(3,255)	(1.0)			17,622	6.9
Net income	$	45,139	13.2	%	$	54,871	21.4	%

The following table presents our revenues disaggregated by geography (in thousands):

	Three Months Ended March 31,
	2023				2022
United States	$	290,938	85	%	$	214,214	84	%
Other countries		52,105	15			42,212	16
Total	$	343,043	100	%	$	256,426	100	%

International revenue increased compared to the prior year comparable period, but decreased slightly as a percentage of total revenue. The increase in domestic revenue was driven by demand for the premium versions of our products and bundles.  

26

Net Sales

Net sales by product line were as follows (dollars in thousands):

	Three Months Ended March 31,								Dollar		Percent
	2023				2022				Change		Change
TASER segment:
TASER Devices (Professional)	$	67,472	19.7	%	$	63,164	24.6	%	$	4,308	6.8	%
Cartridges		46,800	13.6			37,825	14.8			8,975	23.7
Axon Evidence and Cloud Services		7,201	2.1			3,017	1.2			4,184	138.7
Extended Warranties		7,670	2.2			6,679	2.6			991	14.8
Other (1)		5,139	1.5			3,675	1.4			1,464	39.8
Total TASER segment		134,282	39.1			114,360	44.6			19,922	17.4
Software and Sensors segment:
Axon Body Cameras and Accessories		38,797	11.3			38,517	15.0			280	0.7
Axon Fleet Systems		32,972	9.6			13,820	5.4			19,152	138.6
Axon Evidence and Cloud Services		118,314	34.5			79,939	31.2			38,375	48.0
Extended Warranties		14,085	4.1			9,061	3.5			5,024	55.4
Other (2)		4,593	1.4			729	0.3			3,864	530.0
Total Software and Sensors segment		208,761	60.9			142,066	55.4			66,695	46.9
Total net sales	$	343,043	100.0	%	$	256,426	100.0	%	$	86,617	33.8	%

(1) TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.

(2) Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room and Axon Air.

Net sales for the TASER segment increased 17.4% primarily due to an increase of $9.0 million in cartridge revenue. The increase in cartridge revenue is due to an increase in unit sales, partially offset by lower average selling prices. Net sales for TASER devices (professional) also increased $4.3 million in the quarter due to increased unit sales and higher average selling prices. We started shipping our next generation device, TASER 10, in Q1 2023. Axon Evidence and cloud services revenue increased $4.2 million due to an increase of software revenue tied to our VR solution and TASER devices. The increase in other revenue was favorably impacted by an increase in VR hardware revenue, partially offset by a decrease in consumer device sales.

Net sales for the Software and Sensors segment increased 46.9% for the three months ended March 31, 2023 as compared to the prior year quarter as we continued to add users and associated devices to our network. The increase in the aggregate number of users and the revenue per user drove the majority of the increase in Axon Evidence and cloud services revenue of $38.4 million. The $19.2 million increase in Axon Fleet systems revenue was primarily driven by higher unit sales and higher average selling prices as we continue to see strong demand since the release of Fleet 3 in 2021. An increase in cameras, docks and Fleet systems in the field drove the $5.0 million increase in extended warranties, as most of those devices are sold with extended warranties. Demand for Signal Sidearm and Interview Room drove the $3.9 million increase in other revenue.  

We consider total company future contracted revenues a forward-looking performance indicator. As of March 31, 2023, we had approximately $4.8 billion of total company future contracted revenue, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. We expect to recognize between 15% - 25% of this balance over the next twelve months, and expect the remainder to be recognized over the following ten years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.

27

Gross Margin

As a percentage of net sales, gross margin for the TASER segment decreased to 62.2% from 64.5% for the three months ended March 31, 2023 and 2022, respectively. The decrease is primarily a result of nonrecurring inventory reserves and other cost adjustments in the quarter, partially offset by higher average selling prices and favorable product mix.  

As a percentage of net sales, gross margin for the Software and Sensors segment increased slightly to 57.8% from 57.7% for the three months ended March 31, 2023 and 2022, respectively. Within the Software and Sensors segment, hardware gross margin decreased to 38.2% for the three months ended March 31, 2023 compared to 40.5% for the same period in 2022 due to unfavorable product mix, partially offset by lower freight expense. Service margins increased to 73.2% for the three months ended March 31, 2023 from 72.3% for the same period in 2022 due to improved margins on professional services and savings on cloud hosting costs.

Sales, General and Administrative Expenses

Sales, general and administrative ("SG&A") expenses were comprised as follows (dollars in thousands):

	Three Months Ended March 31,						Dollar		Percent
	2023			2022			Change		Change
Total sales, general and administrative expenses	$	116,567		$	90,129		$	26,438	29.3
Sales, general, and administrative as a percentage of net sales		34.0	%		35.1	%

Salaries, benefits, and bonus expense increased $17.4 million in comparison to the prior year comparable period. An increase of $9.1 million in salaries, benefits, and bonus expense was attributable to an increase in headcount and higher wages. Additionally, $6.4 million was attributed to payroll taxes related to the vesting of one tranche of our XSPP in March 2023 and payroll taxes for CEO option exercises completed during the quarter ended March 31, 2023. An increase of $1.4 million was related to 401(k) matching contributions due to an increase in headcount and higher wages.

Sales and marketing and travel expenses increased $5.9 million in comparison to the prior year comparable period. The increase was partially attributable to a $2.5 million increase related to trade shows and seminars as we hosted our annual public safety training conference TASERCON in January 2023. Additionally, sales commissions increased $1.7 million, tied to higher revenue. The increase also reflects a $1.8 million increase in travel expenses, reflecting an increase of in-person customer meetings and increased expense related to our in-person annual company kickoff meeting in January 2023.

Stock-based compensation expense increased $2.5 million in comparison to the prior year comparable period, which was attributable to an increase of $1.7 million in expense related to the XSPP, partially offset by a $0.8 million decrease related to the CEO Performance Award. The increase in stock-based compensation expense related to XSPP was due to the attainment of the tenth market capitalization goal in March 2023. Also contributing to the total increase in stock-based compensation expense is expense related to time-based awards due to higher headcount.

Research and Development Expenses

Research and development ("R&D") expenses were comprised as follows (dollars in thousands):

	Three Months Ended March 31,						Dollar		Percent
	2023			2022			Change		Change
Total research and development expenses	$	70,927		$	48,416		$	22,511	46.5
Research and development as a percentage of net sales		20.7	%		18.9	%

Within the TASER segment, R&D expense increased $6.2 million. An increase of $3.0 million in salaries, benefits and bonus expense and an increase of $1.9 million related to stock-based compensation expense reflected higher

28

headcount. Additionally, indirect manufacturing costs and supplies increased $1.1 million related to the development of next generation products.

R&D expense for the Software and Sensors segment increased $16.3 million, reflecting an increase of $8.6 million in salaries, benefits, and bonus expense due to higher headcount and increased wages. Additionally, there was a $4.7 million increase related to stock-based compensation expense, primarily related to increased headcount.

Interest and Other Income, Net

Interest and other income, net was $25.3 million for the three months ended March 31, 2023, compared to income of $55.3 million for the same period in 2022, in which we recorded an unrealized gain of $70.4 million related to observable price changes for our existing investments and related warrants, and a $14.6 million unrealized loss related to our investment in CLBT. During the first quarter of 2023, we recorded a $15.6 million unrealized gain on marketable securities related to our investment in CLBT and $10.6 million of interest income related to our investment portfolio.

Provision for Income Taxes

The provision for income taxes was a benefit of $3.3 million for the three months ended March 31, 2023, which was an effective tax rate of -7.8%. Our estimated full year effective income tax rate for 2023, before discrete period adjustments, is 22.8%, which differs from the federal statutory rate primarily due to the impact of R&D tax credits and decrease in valuation allowance offset by the executive compensation limitation under Internal Revenue Code ("IRC") Section 162(m) and an increase in unrecognized tax benefits, on projected pre-tax income for the year. The effective tax rate was favorably impacted by a $13.0 million discrete tax benefit associated with net windfalls related to stock-based compensation for RSUs and PSUs that vested and stock options that were exercised during the three months ended March 31, 2023, primarily attributed to the vesting of tranche 10 of the XSPP in March 2023.

Net Income

We recorded net income of $45.1 million for the three months ended March 31, 2023 compared to net income of $54.9 million for the same period in 2022. Net income per basic share was $0.62 for the three months ended March 31, 2023 compared to $0.77 net income per basic share for the same period in 2022. Net income per diluted share was $0.61 for the three months ended March 31, 2023 compared to $0.76 net income per diluted share for the same period in 2022.

29

Three Months Ended March 31, 2023 Compared to the Three Months Ended December 31, 2022

Net Sales

Net sales by product line were as follows (dollars in thousands):

	Three Months Ended				Three Months Ended				Dollar		Percent
	March 31, 2023				December 31, 2022				Change		Change
TASER segment:
TASER Devices (Professional)	$	67,472	19.7	%	$	69,075	20.5	%	$	(1,603)	(2.3)	%
Cartridges		46,800	13.6			47,541	14.1			(741)	(1.6)
Axon Evidence and Cloud Services		7,201	2.1			6,890	2.0			311	4.5
Extended Warranties		7,670	2.2			7,580	2.3			90	1.2
Other (1)		5,139	1.5			5,651	1.7			(512)	(9.1)
Total TASER segment		134,282	39.1			136,737	40.6			(2,455)	(1.8)
Software and Sensors segment:
Axon Body Cameras and Accessories		38,797	11.3			43,882	13.1			(5,085)	(11.6)
Axon Fleet Systems		32,972	9.6			23,177	6.9			9,795	42.3
Axon Evidence and Cloud Services		118,314	34.5			113,225	33.7			5,089	4.5
Extended Warranties		14,085	4.1			13,695	4.1			390	2.8
Other (2)		4,593	1.4			5,426	1.6			(833)	(15.4)
Software and Sensors segment		208,761	60.9			199,405	59.4			9,356	4.7
Total net sales	$	343,043	100.0	%	$	336,142	100.0	%	$	6,901	2.1	%

(1) TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.

(2) Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room and Axon Air.

Net sales within the TASER segment decreased by approximately $2.5 million or 1.8% as compared to the prior quarter, primarily due to a slight decrease in the units of TASER devices and cartridges related to seasonality with Q1 typically carrying lower volumes during the year. A decrease of $0.5 million in other revenue is attributable to decreased revenue from TASER professional services. Partially offsetting the decrease in TASER segment revenue is an increase in Axon Evidence and cloud services revenue tied to TASER devices and VR hardware.

Within the Software and Sensors segment, net sales increased $9.4 million or 4.7% during the three months ended March 31, 2023 compared to the prior quarter. Net sales of Axon Fleet systems increased $9.8 million due to increased units and higher average selling prices. Unit increases of Axon Fleet primarily drove the $5.1 million increase in Axon Evidence and cloud revenue due to increased professional services revenue related to Fleet installations. Partially offsetting the increases in the Software and Sensors segment is a decrease of $5.1 million of Axon Body cameras and accessories due to decreased units and lower average selling price related to seasonality and strong sales in the fourth quarter.

Non-GAAP Measures

To supplement our financial results presented in accordance with GAAP, we present the non-GAAP financial measures of EBITDA and Adjusted EBITDA. Our management uses these non-GAAP financial measures in evaluating our performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented below.

● EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, taxes, depreciation and amortization.

30

● Adjusted EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, taxes, depreciation, amortization and non-cash stock-based compensation expense.

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing our operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

● these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to our GAAP financial measures;

● these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, our GAAP financial measures;

● these non-GAAP financial measures should not be considered to be superior to our GAAP financial measures; and

● these non-GAAP financial measures were not prepared in accordance with GAAP and investors should not assume that the non-GAAP financial measures presented in this Quarterly Report on Form 10-Q were prepared under a comprehensive set of rules or principles.

EBITDA and Adjusted EBITDA reconciles to net income as follows (in thousands):

	Three Months Ended
	March 31,		December 31,		March 31,
	2023		2022		2022
Net income	$	45,139	$	29,175	$	54,871
Depreciation and amortization		6,689		6,210		5,755
Interest expense		1,724		474		8
Investment interest (income) loss		(11,390)		(4,614)		346
Provision for (benefit from) income taxes		(3,255)		5,555		17,622
EBITDA	$	38,907	$	36,800	$	78,602
Non-GAAP adjustments:
Stock-based compensation expense		34,350		31,722		25,088
Unrealized gains on strategic investments and marketable securities, net		(15,570)		(6,445)		(55,851)
Transaction costs related to strategic investments and acquisitions		843		64		871
Loss on disposal and abandonment of intangible assets		10		42		40
Loss on disposal and impairment of property, equipment and other assets, net		146		3,488		106
Costs related to FTC litigation		—		250		4
Payroll taxes related to XSPP vesting and CEO Award option exercises		6,392		—		—
Adjusted EBITDA	$	65,078	$	65,921	$	48,860

Liquidity and Capital Resources

Summary

As of March 31, 2023, we had $263.4 million of cash and cash equivalents, a decrease of $90.3 million as compared to December 31, 2022. Cash and cash equivalents and investments totaled $1.07 billion, representing a decrease of $22.0 million from December 31, 2022.

31

Our most significant source of liquidity continues to be funds generated by operating activities and available cash and cash equivalents and short-term investments. In addition, our $200.0 million revolving credit facility is available for additional working capital needs or investment opportunities. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio. “SOFR” is defined as a rate equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York or a successor administrator of the secured overnight financing rate.

As of March 31, 2023, we had letters of credit outstanding of $7.0 million, leaving the net amount available for borrowing of $193.0 million. The credit agreement will mature on the earlier of December 15, 2027 or the date that is six months prior to the stated maturity date of the 0.50% convertible senior notes due 2027 unless such Notes have been redeemed, repurchased, converted or defeased in full. Additionally, the credit agreement has an accordion feature which allows for an increase in the total line of credit up to $300.0 million, subject to each lender’s sole discretion. At March 31, 2023 and December 31, 2022, there were no borrowings under the line.

There can be no assurance that we will continue to generate cash flows at or above current levels or that we will be able to maintain our ability to borrow under our revolving credit facility.

Our agreement with the bank requires us to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, of no greater than 3.50 to 1.00 based upon a trailing four fiscal quarter period. At March 31, 2023, our net leverage ratio was 0.78 to 1.00. Additionally, we must comply with a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense, of no less than 3.50 to 1.00 based upon a trailing four fiscal quarter end. We are compliant with the consolidated interest coverage ratio, which is not meaningful for the quarter ended March 31, 2023.

Based on our strong balance sheet at March 31, 2023 and successful convertible senior notes offering completed during 2022, we believe financing will be available, both through our existing credit line and possible additional financing. However, there is no assurance that such funding will be available on terms acceptable to us, or at all. We believe that our sources of funding will be sufficient to satisfy our currently anticipated cash requirements including capital expenditures, working capital requirements, potential acquisitions or investments, income and payroll tax payments for net-settled stock awards, and other liquidity requirements through at least the next 12 months. We and our Board of Directors may consider repurchases of our common stock. Further repurchases of our common stock would take place on the open market, would be financed with available cash and are subject to authorization as well as market and business conditions.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities (in thousands):

	Three Months Ended March 31,
	2023		2022
Operating activities	$	(56,323)	$	43,964
Investing activities		(72,674)		(10,348)
Financing activities		37,990		(1,459)
Effect of exchange rate changes on cash and cash equivalents		779		(157)
Net increase (decrease) in cash and cash equivalents and restricted cash	$	(90,228)	$	32,000

Operating activities

Net cash used in operating activities in the first three months of 2023 of $56.3 million reflects net income of $45.1 million, non-cash income statement items totaling $16.0 million, and a decrease of $117.4 million for the net change in operating assets and liabilities. Included in the non-cash items were $34.4 million in stock-based compensation expense, a decrease of $9.7 million in deferred income taxes, net, $6.7 million in depreciation and amortization expense, and a $15.6 million gain on the change in fair value of marketable securities. Cash provided by operations was favorably

32

impacted by increased deferred revenue of $50.2 million, which was primarily attributable to increased sales where the customer is invoiced before performance occurs. Offsetting this activity was an increase of accounts and notes receivables and contract assets of $50.4 million, an increase in prepaid expenses and other assets of $64.3 million, an increase of $15.8 million in inventory, and a decrease in accounts payable, accrued and other liabilities of $37.0 million. Of the increase in prepaid expenses and other assets, $33.0 million was primarily driven by a receivable for proceeds from shares sold to cover the tax liability and option cost for options exercised during the first three months of 2023, but received in April 2023. The increase in accounts and notes receivable and contract assets is due to increased sales and timing of satisfied performance obligations compared to customer payments of accounts receivable. Inventory increases were a result of advance purchases to support future sales. The decrease in accounts payable, accrued and other liabilities was driven primarily by the timing of the annual bonus payout.

Net cash provided by operating activities in the first three months of 2022 of $44.0 million reflects net income of $54.9 million, non-cash income statement items totaling $3.5 million, and a decrease of $7.4 million for the net change in operating assets and liabilities. Included in the non-cash items were $25.1 million in stock-based compensation expense, a decrease of $18.0 million in deferred tax assets, net, $5.8 million in depreciation and amortization expense, and a $70.4 million gain on the change in fair value of strategic investments, offset by an unrealized loss of $14.6 million on marketable securities. Cash provided by operations was impacted by increased deferred revenue of $16.0 million, which was primarily attributable to increased sales. Additionally, accounts and notes receivable and contract assets decreased by $7.5 million, primarily as a result of improved collection timing. Offsetting this activity was an increase of $14.3 million in inventory, an increase in prepaid expenses and other assets of $7.1 million, and a decrease in accounts payable, accrued and other liabilities of $9.6 million. The increase in inventory was primarily driven by the proactive buildup required to meet future demand. The increase in prepaid expenses and other assets was driven by the timing of payments and an increase in deferred cost of goods sold.  The decrease in accounts payable, accrued and other liabilities was driven primarily by the timing of the annual bonus payout.

Investing activities

We used $72.7 million of cash for investing activities during the first three months of 2023. Cash outflows from investing activities included $64.0 million for the purchase of available-for-sale investments, net of proceeds from calls and maturities. Property and equipment purchases totaled $8.5 million.

We used $10.3 million in investing activities during the first three months of 2022. Cash inflows from investing activities included proceeds from available-for-sale investments of $7.2 million. The inflows were offset by $17.1 million for the purchase of property and equipment and $0.5 million for a strategic minority investment.

Financing activities

Net cash provided by financing activities was $38.0 million during the first three months of 2023 and was primarily attributable to proceeds of $39.2 million from the exercise of stock options where shares were sold to cover the exercise price and net proceeds of $33.7 million received from our ATM offering. Partially offsetting net cash provided by financing activities was $34.8 million for the payment of income and payroll taxes on behalf of employees who net-settled stock awards during the period related to the vesting of tranche 10 of the XSPP.

Net cash used in financing activities was $1.5 million during the first three months of 2022 and was attributable to the payment of income and payroll taxes on behalf of employees who net-settled stock awards during the period.

Off-Balance Sheet Arrangements

The discussion under the heading off-balance sheet arrangements in Note 13 of the notes to our condensed consolidated financial statements within this Quarterly Report on Form 10-Q is incorporated by reference herein.

33

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of operation is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances, and we evaluate our estimates and assumptions on an ongoing basis. While we do not believe that a change in these estimates is reasonably likely, there can be no assurance that our actual results will not differ from these estimates. 

Our significant accounting policies are discussed in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There have been no significant changes to these policies for the three months ended March 31, 2023.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We typically invest in a limited number of financial instruments, consisting principally of investments in money market accounts, certificates of deposit, corporate and municipal bonds with a typical long-term debt rating of “A” or better by any nationally recognized statistical rating organization, denominated in U.S. dollars. All of our cash equivalents and investments are treated as “available-for-sale”.  We report available-for-sale investments at fair value as of each balance sheet date and record any unrealized gains or losses within accumulated other comprehensive income (loss) as a component of stockholders’ equity. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in interest and other income (expense), net within the condensed consolidated statements of operations. When the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made. The credit-related impairment amount is recognized in the consolidated statements of operations. Credit losses are recognized through the use of an allowance for credit losses account in the condensed consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If we have the intent to sell the security or it is more likely than not that we will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the condensed consolidated statements of operations. Based on investment positions as of March 31, 2023, a hypothetical 100 basis point increase in interest rates across all maturities would result in a $3.0 million decline in the fair market value of the portfolio. Such losses would only be realized if we sold the investments prior to maturity.

Additionally, we have access to a $200.0 million line of credit borrowing facility which bears interest at SOFR 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net leverage ratio and consolidated interest coverage ratio. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit, which totaled $7.0 million at March 31, 2023. At March 31, 2023, there was no amount outstanding under the line of credit, and the available borrowing under the line of credit was $193.0 million. We have not borrowed any funds under the line of credit since its inception; however; should we need to do so in the future, such borrowings could be subject to adverse or favorable changes in the underlying interest rate.

Exchange Rate Risk

Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, in each case compared to the U.S. dollar, related to transactions by our foreign subsidiaries. The majority of our sales to international customers are transacted in foreign currencies and therefore are subject to exchange rate fluctuations on these transactions. The cost of our products to our customers increases when the U.S. dollar strengthens against their local currency, and we may have more sales and expenses denominated in foreign currencies in future years which could increase our foreign exchange rate risk. Additionally, intercompany sales to our non-U.S. dollar functional currency international subsidiaries are transacted in U.S. dollars which could increase our foreign exchange rate risk caused by foreign currency transaction gains and losses.

34

To date, we have not engaged in any currency hedging activities. However, we may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, certain firmly committed transactions, forecasted future cash flows and net investments in foreign subsidiaries. However, we may choose not to hedge certain foreign exchange exposures for a variety of reasons, including but not limited to the prohibitive economic cost of hedging particular exposures. As such, fluctuations in currency exchange rates could harm our business in the future.

Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer are responsible for the evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that because a material weakness exists in our internal control over financial reporting, as further described below, our disclosure controls and procedures were not effective as of March 31, 2023.

Specifically, during the year ended December 31, 2022, we identified a material weakness in our internal controls stemming from control deficiencies with respect to the risks of understatement of software and services revenue and overstatement of deferred revenue. This material weakness in internal control over financial reporting resulted from a failure to effectively manage the migration of triggering events for certain software and services performance obligations during the quote-to-cash phase of the implementation of our Enterprise Resource Planning (“ERP”) and related systems in 2021.  Additionally, there were limited instances of invoicing errors resulting from ineffective change management of the quote-to-cash systems implementation.  The manual business processes for tracking open software and services performance obligations and for monitoring billing events were not sufficiently robust to prevent the errors. The related business processes and account reconciliation detective controls were not designed to operate with a sufficient degree of precision to identify these errors on a timely basis.  These deficiencies resulted in immaterial understatements of revenue that accumulated over time and were corrected in the fourth quarter of 2022 as disclosed in Note 1 of the consolidated financial statements in Part II, Item 8 of the Annual Report on Form 10-K filed February 28, 2023.

To remediate the material weakness described above, we are designing and implementing new business processes and automation of integrations between our systems as well as enhancing our reconciliation controls and monitoring procedures to properly ensure transactions are identified and recorded timely and accurately.

We are in the process of documenting, assessing and testing the necessary changes in our internal control over financial reporting as part of our efforts to comply with Section 404 of the Sarbanes-Oxley Act.  

The material weaknesses will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.  As remediation has not yet been completed and tested, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of March 31, 2023 at a level that provides reasonable assurance as of the last day of the period covered by this report. 

PART II - OTHER INFORMATION

Item 1.    Legal Proceedings

The discussion under the headings Product Litigation and U.S. Federal Trade Commission Litigation in Note 13 of the notes to our condensed consolidated financial statements included within this Quarterly Report on Form 10-Q is incorporated by reference herein.

35

Item 1A. Risk Factors

Risk Factor Summary

The following is only a summary of the principal risks that may materially adversely affect our business, financial condition, results of operations and cash flows. The following should be read in conjunction with the more complete discussion of the risk factors we face, which are set forth more fully in “Part I. Item 1A. Risk Factors.”

Strategic Risks

● If law enforcement agencies do not continue to purchase and use our products and services, our growth prospects, operating results and financial conditions will be materially adversely affected.

● If our TASER CEDs do not continue to be widely accepted, our growth prospects will be diminished.

● If we are unable to design, introduce, sell and deploy new products or new product features successfully, our business and financial results could be adversely affected.

● We face risks associated with rapid technological change and new competing products.

● Our future success is dependent on our ability to expand sales through direct sales and distributors and our inability to increase direct sales or recruit new distributors would negatively affect our sales.

● Acquisitions of, or investments in, other companies, products, or technologies could disrupt our business, dilute stockholder value, and adversely affect our operating results.

● Our failure to retain executive officers, including Patrick W. Smith, could adversely impact our business.

Operational Risks

● Unavailability of materials or higher costs could adversely affect our financial results.

● Material adverse developments in domestic and global economic conditions, or the occurrence of other world events, could materially adversely affect our revenue and results of operations.

● To the extent demand for our products increases, our future success will be dependent upon our ability to manage our growth and to increase manufacturing production capacity.

● Delays in product development schedules could adversely affect our revenues and cash flows.

● We expend significant resources in anticipation of a sale and may receive no revenue in return.

● Changes in civil forfeiture laws may affect our customers’ ability to purchase our products.

● Catastrophic events could materially adversely affect our business, results of operations and/or financial condition.

● If our security measures or those of our third-party cloud storage providers are breached and unauthorized access is obtained to customers’ data or our data, customers may curtail or stop using our service and we may incur significant legal and financial exposure and liabilities.

● Defects or disruptions in our services could impact demand for our services and subject us to substantial liability.

● Defects in our products could reduce demand for our products or result in product recalls and result in a loss of sales, delay in market acceptance and damage to our reputation.

● Our international operations expose us to additional risks that could adversely affect our business.

● We depend on our ability to attract and retain our key management, sales and technical personnel.

● If we fail to comply with federal, state or local regulations applicable to TASER 10 we may be subject to governmental actions or litigation which could materially harm our business.

● If we fail to maintain effective internal control over financial reporting or identify a material weakness or significant deficiency, our ability to accurately and timely report our financial condition and results of operations could be adversely affected, investor confidence could diminish, and the value of our common stock may decline.

Financial Risks

● An increasing percentage of our revenue is derived from subscription billing arrangements which may result in delayed cash collections and may increase customer credit risk on receivables and contract assets.

36

● We may experience a decline in gross margins due to a shift in product sales to software and sensors products and services which may continue to carry a lower gross margin than that of TASER devices.

● Software-as-a-Service revenue for Axon Evidence is recognized over the terms of the contracts, which may be several years, and, as such, trends in new business may not be immediately reflected in our operating results.

● Most of our end-user customers are subject to budgetary and political constraints that may prevent sales.

● Due to government funding rules, certain of our contracts are subject to various cancellation clauses, which could allow our customers to cancel or not exercise options to renew contracts in the future.

● The open bidding process creates uncertainty in predicting future contract awards.

● We maintain most of our cash balances, some of which are not insured, at three depository institutions.

● Stock transactions may have a material, unpredictable impact on our results of operations and may result in dilution to existing shareholders.

● Our financial performance is subject to risks associated with changes in the value of the U.S. dollar versus local currencies.

● Unanticipated changes in our effective tax rate and additional tax liabilities may impact our operating results.

● Our revenues and operating results may fluctuate unexpectedly, which may cause our stock price to decline.

Legal and Compliance Risks

● We may face personal injury, wrongful death, product liability and other liability claims that harm our reputation and adversely affect our sales and financial condition.

● Other litigation, government inquiries and regulatory actions may subject us to significant costs and judgments and divert management attention from our business.

● We have been, and may be subject to intellectual property infringement and other claims, which could incur substantial litigation costs, result in significant damage awards, inhibit our use of certain technologies, and divert management attention from our business.

● If we are unable to protect our intellectual property, the value of our brands and products may decrease and we may lose our competitive market advantage.

● We may be limited in our ability to enforce patent rights internationally to only those jurisdictions in which our patent applications have been granted.

● A variety of new and existing laws and/or interpretations could materially and adversely affect our business.

o Our business could be adversely affected by rules and regulations governing our radio spectrum devices.

o Changes in statutes, regulations, and interpretation outside of our control may result in our products being classified or reclassified as firearms and could substantially reduce our private citizen market.

o Failure to comply with U.S. federal regulations could disrupt our operations.

o Our inability to obtain export licenses or classifications on a timely basis for sales of our products to our international customers could adversely affect our international sales.

o Inability to comply with federal regulation of foreign national employees could curtail our ability to execute research and development and production related to CED technology.

o Our product sales may be adversely affected by state and local governmental regulation of our TASER-branded devices.

o Certain jurisdictions prohibit, restrict, or require a permit for importation, sale, possession or use of CEDs, including in some countries by law enforcement agencies, limiting our international sales opportunities.

o Abrupt changes to domestic and international regulation of imports and exports of components in our supply chain can result in delays or interruptions to final product supplies.

o Any failure to properly maintain or license our foreign operations could limit our ability to sell, support, or develop our products and services both internationally and in the U.S. market.

o We may be adversely impacted by environmental or climate change disclosure litigation and new, or changes in, environmental safety laws, regulations or rules.

o Our inability to adequately address privacy concerns, or comply with applicable laws, regulations, policies, industry standards and guidance, contractual obligations, or other legal obligations, could result in significant regulatory and third party liability and increased costs and may adversely affect our business.

37

● We are subject to evolving corporate governance and public disclosure regulations and expectations that could expose us to numerous risks.

Risks Related to our Convertible Notes

● Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow to pay our substantial debt.

● The conditional conversion feature of our Notes, if triggered, may adversely affect our operating results.

● Conversion of the Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.

● Changes in the accounting treatment for the Notes may have a material effect on our reported financial results.

● The convertible note hedge and warrant transactions may affect the value of the Notes and our common stock.

● We are subject to counterparty risk with respect to the convertible note hedge transactions.

Because of the following factors, as well as other variables affecting our operating results, our past financial performance may not be a reliable indicator of our future performance and historical trends should not be used to anticipate our results or trends in future periods. You should carefully consider the trends, risks and uncertainties described below and other information in this Quarterly Report on Form 10-Q and subsequent reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of the following trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Strategic Risks

We are substantially dependent on acceptance of our products by law enforcement markets throughout the world. If law enforcement agencies do not continue to purchase and use our products and services, our growth prospects, operating results and financial conditions will be materially adversely affected.

Our largest customer segment is U.S. state and local law enforcement. Axon has a customer relationship with over 95% of state and local law enforcement agencies in the United States. At any point, whether or not related to the performance of our products and services, law enforcement agencies may elect to no longer purchase our CEDs or other products and services. For example, in the past, we believe that our sales were adversely impacted by negative coverage and publicity surrounding our products and services and their use. If law enforcement agencies no longer purchase our products and services, or materially decrease their purchases, our growth prospects, operating results and financial condition will be materially adversely affected.

We substantially depend on sales of our TASER CEDs, and if these products do not continue to be widely accepted, our growth prospects will be diminished.

In each of the years ended December 31, 2022, 2021 and 2020, we derived a significant portion of our revenues from sales of TASER brand devices and related cartridges, whether on a standalone basis or as part of a bundled offering, and expect to depend on sales of these products for a significant portion of our revenue for the foreseeable future. A decrease in the selling prices of, or demand for these products, or their failure to maintain broad market acceptance, would significantly harm our growth prospects, operating results and financial condition.

If we are unable to design, introduce, sell and deploy new products or new product features successfully, our business and financial results could be adversely affected.

Our future success will depend on our ability to develop new products or new product features that achieve market acceptance in a timely and cost-effective manner. The development of new products and new product features is complex, time consuming and expensive, and we may experience delays in completing the development and introduction of new

38

products. We may choose to carry higher levels of inventory to mitigate the risk of production delays, which may in turn expose us to an increased risk of obsolescence.

We have devoted, and continue to devote, significant resources to develop and deploy our cloud-based productivity and real-time operations SaaS solutions, which we continue to broadly deploy to a large number of customers. Customers' requirements for these products are complex and varied. If we cannot develop scalable solutions that can be consistently configured for customers with minimal effort or grow a professional services team that can consistently configure our products to meet the requirements of large numbers of customers in a timely and cost-effective manner, our ability to broadly scale our cloud-based productivity and real-time operations SaaS solutions could be negatively impacted, and our business prospects, operating results and financial condition could be negatively impacted.

We cannot provide any assurance that products that we may develop in the future will achieve market acceptance. If we fail to develop new products or new product features on a timely basis that achieve market acceptance, our business, financial results and competitive position could be adversely affected.

We face risks associated with rapid technological change and new competing products.

The technology associated with law enforcement devices and software is receiving significant attention and is rapidly evolving. The introduction of products embodying new technologies and the emergence of new industry standards can render existing products obsolete and unmarketable. Additionally, our products and services are expected to meet and keep pace with evolving security standards and requirements of our industry and customers, including those of the U.S. federal government and international governments. While we have some patent protection in certain key areas of our Axon device, CED and SaaS technology, new technology may result in competing products that operate outside our patents and could present significant competition for our products, which could adversely affect our business, financial results and competitive position.

Our future success is dependent on our ability to expand sales through direct sales and distributors and our inability to increase direct sales or recruit new distributors would negatively affect our sales.

Our distribution strategy is to pursue sales through multiple channels which is principally through direct sales and independent distributors. We are focusing on direct sales to larger agencies through our regional sales managers and our inability to grow sales to these agencies in this manner would materially adversely affect our business prospects, operating results and financial condition. In addition, our inability to establish relationships with and retain law enforcement equipment distributors, who we believe can successfully sell our products, would materially adversely affect our business prospects, operating results and financial condition. If we do not competitively price our products, meet the requirements of our distributors or end-users, provide adequate marketing support, or comply with the terms of our distribution arrangements, our distributors may fail to aggressively market our products or may terminate their relationships with us. These developments would likely have a material adverse effect on our sales. Our reliance on the sales of our products by others also makes it more difficult to predict our revenues, cash flow and operating results.

In certain states and foreign jurisdictions we have decided to pursue sales directly with law enforcement customers, rather than working through established distribution channels. Our customers may have strong working relationships with distributors and we may face resistance to this change. If we do not overcome this resistance and effectively build a direct relationship with our customers, sales may be adversely affected.

Acquisitions of, or investments in, other companies, products, or technologies may require significant management attention and could disrupt our business, dilute stockholder value, and adversely affect our operating results.

Our business strategy may include acquiring other complementary products, technologies or businesses. Identifying and negotiating these transactions can be time-consuming, difficult and expensive, and our ability to close these transactions may be subject to third-party approvals, such as government regulatory approvals and certifications, which are beyond our control. Consequently, we can make no assurance that these transactions once undertaken and announced, will close. 

These kinds of acquisitions or investments may result in unforeseen operating difficulties and expenditures. If we acquire businesses or technologies, we may not be able to integrate the acquired personnel, operations, and technologies

39

successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:

● inability to integrate or benefit from acquired technologies, products, personnel or services in a profitable manner;

● inability to correct or achieve regulatory approvals or certifications;

● unanticipated costs or liabilities associated with the acquisition, including potential liabilities due to litigation and potential identified or unknown security vulnerabilities in acquired technologies that expose us to additional security risks or delay our ability to integrate the product into our offerings or recognize the benefits of our investment;

● differences between our values and those of an acquired company, as well as potential disruptions to our workplace culture or how we are perceived by investors;

● incurrence of acquisition-related costs, including costs related to integration activities;

● difficulty integrating the accounting and information systems, operations, and personnel of the acquired business;

● augmenting the acquired technologies and platforms to the levels that are consistent with our brand and reputation;

● difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;

● challenges converting the acquired company’s revenue recognition policies and forecasting the related revenues, including subscription-based revenues and software license revenues;

● potential write-offs of acquired assets or investments, and potential financial and credit risks associated with acquired customers;

● difficulty converting the customers of the acquired business onto our platform and contract terms;

● diversion of management’s attention and other company resources;

● harm to our existing business relationships with business partners and customers as a result of the acquisition;

● the potential loss of key employees;

● use of resources that are needed in other parts of our business; and

● use of substantial portions of our available cash to consummate the acquisition.

We cannot assure you that the anticipated benefits of any acquisition or investment would be realized or that we would not be exposed to unknown liabilities or risks. Integrating an acquired technology, asset or business into our operations can be challenging, complex and costly and we cannot assure you that we will be successful or that the anticipated benefits of the acquisitions that we complete will be realized or outweigh their costs. If our integration and development efforts are not successful and the anticipated benefits of the acquisitions that we complete are not achieved, our business, operating results, financial condition, and prospects could be adversely affected.

In connection with these types of transactions, we may issue additional equity securities that would dilute our stockholders, use cash that we may need in the future to operate our business, incur debt on terms unfavorable to us or that we are unable to repay, incur large charges or substantial liabilities, encounter difficulties integrating diverse business

40

cultures and values, and become subject to adverse tax consequences, substantial depreciation, or deferred compensation charges. These challenges could adversely affect our business, operating results, financial condition, and prospects.

We are highly dependent on the services of our executive officers, including Patrick W. Smith, our Chief Executive Officer.

Our future success depends upon our ability to retain executive officers, specifically Patrick W. Smith, and any failure to do so could adversely impact our business, prospects, new product development, financial condition and operating results.

Among other qualifications, Patrick W. Smith is the founder of Axon and brings extensive executive leadership experience in the technology industry, including the management of worldwide operations, sales, service, and support as well as technology innovation as he currently holds 45 U.S. patents. Mr. Smith has been instrumental in building the public safety operating system of the future by integrating a suite of hardware devices and cloud software solutions that lead to modern policing and help save lives. From the early days of founding the organization to today as a market leader, Mr. Smith’s expertise has brought forth entirely new product categories, including the less-lethal TASER de-escalation platform, body-worn cameras and cloud software that lead to modernized public safety.

The loss of any of our senior management, including Patrick W. Smith, could interrupt our ability to execute our business plan, as such individuals may be difficult to replace.

Operational Risks

Unavailability of materials or higher costs could adversely affect our financial results.

We depend on certain domestic and international suppliers for the delivery of components used in the assembly of our products. Our reliance on third-party suppliers creates risks related to our potential inability to obtain an adequate supply of components or sub-assemblies and reduced control over pricing and timing of delivery of components and sub-assemblies. Specifically, we depend on suppliers of sub-assemblies, machined parts, injection molded plastic parts, printed circuit boards, custom wire fabrications and other miscellaneous customer parts for our products. Although we have and are implementing additional long-term agreements with strategic suppliers to mitigate the risk of supply continuity, there remains risk across our supply chain while we extend our supplier contract program, and there is no guarantee that supply will not be interrupted. Additionally, if our suppliers do not accurately forecast and effectively allocate production or if they are not willing to allocate sufficient production to us, or they decommit to us previously agreed to supply levels, it may reduce our access to components and require us to search for new suppliers. As the scale of our hardware production increases, we will also need to accurately forecast, purchase, warehouse and transport components at high volumes to our manufacturing facilities. If we are unable to accurately match the timing and quantities of component purchases to our actual needs, we may incur unexpected production disruption, storage, transportation and write-off costs, which may harm our business and operating results.

Single or sole-source components used in the manufacture of our products may become unavailable or discontinued. Delays caused by industry allocations or obsolescence may take weeks or months to resolve. In some cases, parts obsolescence may require a product re-design to ensure quality replacement components. These delays could cause significant delays in manufacturing and loss of sales, leading to adverse effects significantly impacting our financial condition or results of operations and could harm our reputation. For example, revenue from TASER 7 for 2021 was impacted by approximately $35.0 million for orders that were scheduled to ship prior to December 31, 2021, but could not be fulfilled due to the delayed receipt of a manufacturing component for our TASER 7 devices. Additionally, Axon Body revenue was impacted by approximately $15.5 million for orders that were scheduled to ship prior to December 31, 2021, but could not be fulfilled due to supply chain constraints for our Axon Body 3 devices.

Due to the unique requirements of the TASER 10, we purchase our raw materials from a limited number of suppliers. Some of the raw materials that are used in the TASER 10 may be subject to fluctuations in market price which we may be unable to pass through to our customers to offset market fluctuations. Because of the unique requirements of the TASER 10, we cannot change suppliers easily. Any delay or interruption in the supply of these raw materials could impair our ability to manufacture and deliver the TASER 10, harm our reputation or cause a reduction in revenues.

41

A significant number of our raw materials or components comprise petroleum-based products or incur some form of landed cost associated with transporting the raw materials or components to our facility. Our freight and import costs and the timely delivery of our products could be adversely impacted by a number of factors which could reduce the profitability of our operations, including: higher fuel costs; potential port closures; customs clearance issues; increased government regulation or regulatory changes for imports of foreign products into the U.S.; delays created by terrorist attacks or threats, public health issues, national disasters or work stoppages; and other matters. Any interruption of supply for any material components of our products could significantly delay the shipment of our products and have a material adverse effect on our revenues, profitability and financial condition. For example, there have been disruptions in the semi-conductor supply chain that could negatively impact our ability to make our products.

International or domestic geopolitical or other events, including the imposition of new or increased tariffs and/or quotas by the U.S. government on any of these raw materials or components and other government trade policies, could adversely impact the supply and cost of these raw materials or components, and could adversely impact our revenues, profitability and financial condition. In particular, the implementation of tariffs and trade restrictions as well as changes in trade policies between the U.S. and China have in the past led to some increases in our supply costs and have made it more difficult to obtain suppliers, and may in the future have an adverse effect on our supply chain from a cost and sourcing perspective. We source certain raw materials from China, as do some of our suppliers. We may be unable to transition away from China to other jurisdictions or obtain secondary sources for raw materials which could result in a material adverse effect on our revenues, profitability and financial condition.

Material adverse developments in domestic and global economic conditions, or the occurrence of other world events, could materially adversely affect our revenue and results of operations.

Various factors contribute to the uncertain economic environment, including the conflict between Russia and Ukraine, the increase in, and volatility of, interest rates, high inflation, an actual recession or fears of a recession, trade policies and tariffs and geopolitical tensions. Our inability to offset price inflation in our materials, components, shipping, or labor through increased prices to customers with long-term fixed contracts and formula-based or long-term fixed price contracts with suppliers could adversely affect our business, financial condition and results of operations. Global supply chain and labor market challenges could also negatively affect our performance as well as the performance of our suppliers. Interest rate increases have also created financial market volatility and could further negatively impact financial markets, lead to an economic downturn or recession or have an adverse effect on our operating results. Economic slowdowns can also negatively impact municipal and state tax collections and put pressure on law enforcement budgets which may increase the risk that our customers will be unable to appropriate funds for existing or future contracts with us. In addition, geopolitical risks could affect our customers’ budgets and policies. These and other factors may adversely affect customer demand and ability to pay, cause decrease in sales, and negatively impact the realizability of our accounts and notes receivable and contract assets.

To the extent demand for our products increases, our future success will be dependent upon our ability to manage our growth and to increase manufacturing production capacity.

To the extent demand for our products increases significantly in future periods, one of our key challenges will be to increase our production capacity to meet sales demand while maintaining product quality. Our primary strategies to accomplish this include introducing additional shifts, increasing the physical size of our assembly facilities, the hiring of additional production staff, and the implementation of additional customized manufacturing automation equipment. The investments we make in this equipment may not yield the anticipated labor and material efficiencies. Our inability to meet any future increase in sales demand or effectively manage our expansion could have a material adverse effect on our revenues, operating results and financial condition.

Delays in product development schedules may adversely affect our revenues and cash flows.

The development of CEDs, devices, sensors and software is a complex and time-consuming process. New products and enhancements to existing products can require long development and testing periods. Our focus on our SaaS platform also presents complex development issues. Significant delays in new product or service releases or significant problems in creating new products or services could adversely affect our business, operating results, cash flows and competitive position.

42

We expend significant resources in anticipation of a sale due to our lengthy sales cycle and may receive no revenue in return.

Generally, law enforcement and corrections agencies consider a wide range of issues before committing to purchase our products, including product benefits, training costs, the cost to use our products in addition to, or in place of, other products, budget constraints and product reliability, safety and efficacy. The length of our sales cycle may range from a few weeks to as long as several years. Adverse publicity surrounding our products or the safety of such products has in the past, and could in the future, lengthen our sales cycle with customers. In the past, we believe that our sales were adversely impacted by negative publicity surrounding our products or the use of our products. We may incur substantial selling costs and expend significant effort in connection with the evaluation of our products by potential customers before they place an order. If these potential customers do not purchase our products, we will have expended significant resources and received no revenue in return.

Changes in civil forfeiture laws may affect our customers’ ability to purchase our products.

Some of our customers use funds seized through civil forfeiture proceedings to fund the purchase of our products. Legislative changes could impact our customers’ ability to seize funds or use seized funds to fund purchases. Changes in civil forfeiture statutes or regulations could limit the amount of funds available to our customers, which could adversely affect the sale of our products.

Catastrophic events could materially adversely affect our business, results of operations and/or financial condition.

A disruption or failure of our systems or operations in the event of a major earthquake, weather event (including those caused or exacerbated by the effects of climate change), fire, explosion, failure to contain hazardous materials, industrial accident, utility failure, cyber-attack, terrorist attack, public health crisis, pandemic, or other catastrophic event could cause delays in completing sales, providing services, or performing other mission-critical functions. A catastrophic event that results in the destruction or disruption of any of our critical business or information technology systems could harm our ability to conduct normal business operations and our operating results as well as expose us to claims, litigation and governmental investigations and fines.

Public health emergencies such as the COVID-19 global pandemic have adversely affected workforces, economies, and financial markets globally, and led to an economic downturn in the past and may do so again in the future. As an essential provider of products and services for law enforcement and other first responders, we remain focused on protecting the health and well-being of our employees while assuring the continuity of our business operations.

If our backup and mitigation plans are not sufficient to minimize business disruption, our financial results could be adversely affected. We are continuously monitoring our operations and intend to take appropriate actions to mitigate the risks arising from catastrophic events, but there can be no assurances that we will be successful in doing so.

If our security measures or those of our third-party cloud storage providers are breached and unauthorized access is obtained to customers’ data or our data, our network, data centers and service may be perceived as not being secure, customers may curtail or stop using our service and we may incur significant legal and financial exposure and liabilities.

Security breaches of Axon body worn cameras, docks, fleet vehicle cameras, signal devices and Axon Evidence and other cloud services or products which could result in the unauthorized release, gathering, monitoring, misuse, loss or destruction of our clients’ data. Additionally, breaches of our network or data security measures or those of our third-party cloud storage providers could disrupt the security of our internal systems and business applications, impair our ability to provide services to our clients and protect the privacy of their data, result in product development delays, result in theft or misuse of our intellectual property or other assets, require us to allocate more resources to improve technologies, or otherwise adversely affect our business. Any security breach could result in a loss of confidence in the security of our services, damage our reputation, disrupt our business, lead to legal liability, and negatively impact our future sales.

Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, grow more complex over time, and generally are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Moreover, our security measures and those of our third-party

43

service providers or customers may not detect such security breaches if they occur. Although we have developed systems and processes that are designed to protect our data and user data, to prevent data loss, and to prevent or detect security breaches, we cannot assure that such measures will provide absolute security, and we may incur significant costs in protecting against or remediating cyber-attacks.

We devote significant resources to engineer secure products and ensure security vulnerabilities are mitigated, and we require our third-party service providers to do so as well; however, security breaches that have not had a material effect on our business or our third-party service providers have occurred and will continue to occur, including as a result of third-party action, employee error, and malfeasance or otherwise.  Remote-work arrangements may also make our systems and employees more susceptible to attack. Breaches could occur during transfer of data-to-data centers or at any time, and result in unauthorized physical or electronic access to our data or our customers’ data. Third parties may attempt to fraudulently induce employees or customers into disclosing sensitive information such as usernames, passwords or other information in order to gain access to our data or our customers’ data. Additionally, hackers may develop and deploy viruses, worms, and other malicious software programs that attack or gain access to our networks and data centers. Increasing socioeconomic and political instability in some countries has heightened these risks. In addition, retaliatory acts by Russia in response to Western sanctions could include cyber-attacks that could directly or indirectly impact our operations.

A security breach could expose us to a risk of loss or inappropriate use of proprietary and sensitive data, or the denial of access to this data. A real or perceived security breach could also result in a loss of confidence in the security of our service, disrupt our business, damage our reputation, lead to legal liability, negatively impact our future sales and significantly harm our growth prospects, operating results and financial condition.

Defects or disruptions in our services could impact demand for our services and subject us to substantial liability.

We currently serve our Axon Evidence customers from third-party cloud storage providers based in the U.S. and other countries. The use of these cloud storage providers gives us greater flexibility in efficiently delivering a more tailored, scalable customer experience, but also exposes us to additional risks and vulnerabilities. Lack of availability of this infrastructure could be due to a number of potential causes including technical failures, natural disasters, fraud or security attacks that we cannot predict or prevent. Interruptions in our service, or loss or corruption of digital evidence, may reduce our revenue, cause us to issue credits or pay penalties, cause customers to file litigation against us, cause customers to terminate their subscriptions and adversely affect our renewal rates and our ability to attract new customers. Our business will also be harmed if our customers and potential customers believe our service is unreliable.

Since our customers use our services for important aspects of their operations, any errors, defects, disruptions in service or other performance problems could hurt our reputation and may damage our customers’ operations. As a result, customers could elect to not renew our services or delay or withhold payment to us. We could also lose future sales or customers may make warranty or other claims against us, which could result in an increase in our warranty expense, an increase in collection cycles for and decline in the collectability of accounts receivable, and an increase in the expense and risk of litigation.

Defects in our products could reduce demand for our products or result in product recalls and result in a loss of sales, delay in market acceptance and damage to our reputation.

Complex components and assemblies used in our products may contain undetected defects that are subsequently discovered at any point in the life of the product. Defects in our products could result in a loss of sales, delay in market acceptance, damage to our reputation and increased warranty costs, which could adversely affect our business, financial results and competitive position.

Additionally, we are subject to the U.S. Consumer Products Safety Act of 1972, as amended by the Consumer Product Safety Improvement Act of 2008, which empowers the Consumer Products Safety Commission to exclude from the market products that are found to be unsafe or hazardous, and similar laws under foreign jurisdictions. Under certain circumstances, the Consumer Products Safety Commission or comparable foreign agency could require us to repurchase or recall one or more of our products. If we were required to remove, or we voluntarily remove, our products from the market, our reputation could be tarnished, and we might have large quantities of finished products that we could not sell.

44

Our international operations expose us to additional risks that could harm our business, operating results, and financial condition.

Our international operations are significant, and we plan to continue to grow internationally by acquiring existing entities or setting up new legal entities in new markets. In certain international markets, we have limited operating experience and may not benefit from any first-to-market advantages or otherwise succeed. Our international operations additionally expose us to other risks, including the following:

● Restrictions on foreign ownership and investments, and stringent foreign exchange controls that might prevent us from repatriating cash earned in countries outside the U.S.

● Import and export requirements; tariffs, trade disputes and barriers, product certification requirements, sanctions, and customs classifications which may prevent us from offering products or providing services to a particular market or obtaining necessary parts and components to manufacture products leading to potentially decreased sales and increased operating costs.

● Longer payment cycles in some countries, increased credit risk, and higher levels of payment fraud.

● Uncertainty regarding liability for our products and services, including uncertainty as a result of local laws and lack of legal precedent.

● Different labor laws and customs, existence of workers’ councils and labor unions, and other challenges caused by distance, language, and cultural differences, making it harder to do business in certain jurisdictions.

● Our suite of TASER devices are regulated by the U.S. Bureau of Industry and Security and require licenses for exportation abroad. Changes in U.S. Foreign Policy, foreign governmental status, and evolving human rights objectives may all impact Axon’s ability to obtain said licenses.

Additionally, changes in international local political, economic, regulatory, tax, social, and labor conditions may adversely harm our business and compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, environmental regulations, tax and statutory financial regulations, internal control and disclosure rules, privacy and data protection requirements, anti-corruption laws, such as the U.S. Foreign Corrupt Practices Act, and other local laws prohibiting corrupt payments to governmental officials, and competition regulations, among others.

Violations of these laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially adversely affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.

We depend on our ability to attract and retain our key management, sales and technical personnel.

Our success depends upon the continued service of our key management personnel. Our success also depends on our ability to continue to attract, retain and motivate qualified technical employees. Although we have employment agreements with our officers and other members of our executive management team, the employment of such persons is “at-will” and either we or the employee can terminate the employment relationship at any time, subject to the applicable terms of the employment agreements. In particular, we expect to continue to face significant challenges in hiring personnel, particularly for executive-level engineering talent, whether as a result of competition with other companies or other factors.

We currently have unique equity incentives designed to attract and retain long-term employees. We utilize these plans to align pay and performance and drive shareholder returns while reducing near-term cash expenditures. Our equity incentives and ongoing stock and option grants are subject to having sufficient shares under our stock plan and any new plans or increases in the number of shares available for grant under existing plans must be approved by our shareholders. If we are unable to obtain shareholder approval, we may be unable to attract and retain top talent. Our ability to attract,

45

retain, and motivate employees may also be adversely affected by stock price volatility. The loss of the service of one or more of our key personnel could adversely impact our business, prospects, financial condition and operating results.

If we fail to comply with federal, state or local regulations applicable to our firearm product, TASER 10, we may be subject to governmental actions or litigation which could materially harm our business, operating results, and financial condition.

TASER 10 is primarily regulated by the ATF, which licenses the manufacture, sale, and import of firearms in the United States.  The primary federal laws are the National Firearms Act of 1934, or NFA, the Gun Control Act of 1968, or GCA, and the Firearms Owners’ Protection Act of 1986, or FOPA, which have been amended from time to time. 

The ATF conducts periodic audits of our Arizona facilities which hold federal firearms licenses. If we fail to comply with ATF rules and regulations, the ATF may limit our TASER 10 activities or growth, fine us, or, ultimately, suspend our ability to produce and sell the TASER 10 product line. There are also various state laws, regulations, and local ordinances relating to firearm characteristics, features, and sales. Axon and local distributors must comply with state and local laws, regulations, and ordinances pertaining to firearm and magazine sales in the jurisdictions where TASER 10 is sold. Additionally, certain TASER 10 components are regulated for import into the U.S. by ATF and are subject to ATF import permits which limits Axon’s ability to source from some suppliers leading to a potential decrease in supply chain agility. Supply chain constraints or an inability to source TASER 10 components could have a material adverse effect on our business, prospects, financial condition and operating results. 

Federal and state legislatures frequently consider legislation relating to the regulation of firearms, including the amendment or repeal of existing legislation. Existing laws may also be affected by future judicial rulings and interpretations. These possible changes to existing legislation or the enactment of new legislation may seek to restrict the makeup of a firearm, mandate the use of certain technologies in a firearm, remove existing legal defenses in lawsuits, set minimum age limits to purchase certain firearms, or ban the sale and, in some cases, the ownership of various types of firearms and accessories. Such restrictions or bans could have a material adverse effect on our business, prospects, financial condition and operating results.

If we fail to maintain effective internal control over financial reporting or identify a material weakness or significant deficiency in our internal control over financial reporting, our ability to report our financial condition and results of operations in a timely and accurate manner could be adversely affected, investor confidence in our company could diminish, and the value of our common stock may decline.

Preparing our consolidated financial statements involves a number of complex manual and automated processes, which are dependent upon individual data input or review and require significant management judgment. One or more of these processes may result in errors that may not be detected and could result in a material misstatement or other errors in our consolidated financial statements. Such errors may be more likely to occur when implementing new systems and processes, particularly when implementing evolving and complex accounting rules. The Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) requires, among other things, that as a publicly-traded company we disclose whether our internal control over financial reporting and disclosure controls and procedures are effective.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. While we continually undertake steps to improve our internal control over financial reporting as our business changes, we may not be successful in making the improvements and changes necessary to be able to identify and remediate control deficiencies or material weaknesses on a timely basis. For example, we identified a material weakness in our internal controls over revenue recognition and the reporting of deferred revenue for the year ended December 31, 2022 which we are working to remediate as further discussed in Item 9A. Controls and Procedures. If we are unable to successfully remediate any current or future material weaknesses in our internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected; our liquidity, access to capital markets and perceptions of our creditworthiness may be adversely affected; we may be unable to maintain compliance with securities laws, stock exchange listing requirements and debt instruments covenants regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; we may suffer defaults under our debt instruments; and our stock price may decline.

46

Financial Risks

An increasing percentage of our revenue is derived from subscription billing arrangements which may result in delayed cash collections and may increase customer credit risk on receivables and contract assets.

Our strategy includes continuing to shift an increasing amount of our business to a subscription model, to better match the municipal budgeting process of our customers as well as to allow for multiple product offerings to be bundled into existing subscriptions. This is in contrast to a traditional CED sale in which the entire amount being charged for the hardware is invoiced upon shipment. This impacts liquidity in a commensurate fashion, with the cash for the subscription or installment purchase received in multiple installments rather than up front. While we record an estimate of expected credit losses and perform ongoing reviews of trade accounts receivables, if we become aware of information related to the creditworthiness of a major customer, or if future actual default rates on receivables in general differ from those currently anticipated, we may have to adjust our expected credit loss reserve, which could adversely affect our business, financial condition or operating results.

We may experience a decline in gross margins due to a shift in product sales to software and sensors products and services which may continue to carry a lower gross margin than that of TASER products and services.

We continue to invest in the growth of the Software and Sensors segment, and this expected growth may result in a higher percentage of total revenues comprising Software and Sensors products and services. Certain hardware and professional services in this segment may carry lower gross margins compared to software services and to hardware in the TASER segment. For example, in 2022, gross margin as a percentage of net sales for the Software and Sensors segment was 59.5% while it was 63.3% for the TASER segment, and may continue to be lower in the future, thus potentially decreasing our consolidated gross margin.

SaaS revenue for Axon Evidence is recognized over the terms of the contracts, which may be several years, and, as such, trends in new business may not be immediately reflected in our operating results.

Our SaaS service revenue is generally recognized ratably over the terms of the contracts, which generally range from one to ten years. As a result, most of the SaaS revenue we report each quarter is the result of agreements entered into during previous quarters. Consequently, current trends, whether positive or negative, in this portion of our business may not be fully reflected in our revenue results for several periods.

Most of our end-user customers are subject to budgetary and political constraints that may delay or prevent sales.

Most of our end-user customers are government agencies. These agencies often do not set their own budgets and therefore, have limited control over the amount of money they can spend. In addition, these agencies experience political pressure that may dictate the manner in which they spend money. As a result, even if an agency wants to acquire our products, it may be unable to purchase them due to budgetary or political constraints, particularly in challenging economic environments. There can be no assurance that the economic, budgeting or political issues will not worsen and adversely impact sales of our products. Some government agency orders may also be canceled or substantially delayed due to budgetary, political or other scheduling delays, which frequently occur in connection with the acquisition of products by such agencies, and such cancellations may accelerate or be more severe than we have experienced historically. Federal agencies may be particularly impacted by governmental impasse regarding continued government funding and debt limit constraints.

Due to government funding rules, certain of our contracts are subject to appropriation, termination for convenience, or similar cancellation clauses, which could allow our customers to cancel or not exercise options to renew contracts in the future.

Although we have entered into contracts for the delivery of products and services in the future and anticipate the contracts will be completed, if agencies do not appropriate money in future year budgets, terminate contracts for convenience or if other cancellation clauses are invoked, revenue and cash associated with these bookings will not ultimately be recognized, and could result in a reduction to bookings and revenue.

47

The open bidding process creates uncertainty in predicting future contract awards.

Many governmental agencies purchase products and services through an open bidding process. Generally, a governmental entity will publish an established list of requirements requesting potential vendors to propose solutions for the established requirements. To respond successfully to these requests for proposals, we must accurately estimate our cost structure for servicing a proposed contract, the time required to establish operations for the proposed client, and the likely terms of any other third-party proposals submitted. We cannot guarantee that we will win any bids in the future through the request for proposal process, or that any winning bids will ultimately result in contracts on favorable terms. Our failure to secure contracts through the open bidding process, or to secure such contracts on favorable terms, may adversely affect our revenues and gross margins.

We maintain most of our cash balances, some of which are not insured, at two depository institutions.

We maintain the majority of our cash and cash equivalents accounts at two depository institutions. As of March 31, 2023, the aggregate balances in such accounts at these two institutions were $227.9 million. Our balances with these and other institutions regularly exceed Federal Deposit Insurance Corporation insured limits for domestic deposits and various foreign deposit insurance programs covering our deposits in Australia, Canada, Finland, France, Germany, Hong Kong, India, Italy, the Netherlands, Spain, the United Kingdom, and Vietnam.

We could suffer losses with respect to the uninsured balances if the depository institutions failed (such as the bank failures at several U.S. banks in spring 2023) and the institution’s assets were insufficient to cover its deposits and/or the governments did not take actions to support deposits in excess of existing insurance limits. Any such losses or delays in access to funds as a result of such events could have a material adverse effect on our liquidity, financial condition and results of operations.

Stock transactions may have a material, unpredictable impact on our results of operations and may result in dilution to existing shareholders.

We have historically granted and expect to continue to grant stock-based compensation to key employees and non-employee directors as a means of attracting and retaining highly qualified personnel. All stock-based awards are required to be recognized in our financial statements based on their grant date fair values. The amount recognized for stock compensation expense could vary depending on a number of assumptions or changes that may occur.

Changes in the subjective and probability-based assumptions can materially affect the estimates of the fair value of the awards and timing of recognition of stock-based compensation expense and consequently, the related amount recognized in our statements of operations and comprehensive income.

If we achieve specific operational goals and the covered employees complete the requisite service conditions for the performance-based awards with multiple service, performance, and market conditions, including our CEO Performance Award and our eXponential Stock Performance Plan ("XSPP"), we will recognize stock compensation expense regardless of whether the market conditions are achieved and the underlying tranches vest. In addition, we have granted, subject to shareholder approval at our upcoming Annual Meeting of Stockholders, a new CEO performance award comprised of 10 tranches of stock options, the vesting of which is based on rapidly escalating goals for growth in both our share price and operational plan.  If approved by shareholders, we will also recognize stock compensation expense related to the new CEO performance award, regardless of whether the market conditions are achieved and the underlying tranches vest.

As we continue to mature, the incentives to attract, retain, and motivate employees provided by our equity awards or by future arrangements may not be as effective as in the past. We may also issue equity securities to pay for acquisitions and grant stock-based awards to retain the employees of acquired companies. If we issue significant equity to attract additional employees, to retain our existing employees, or related to acquisitions, we could incur substantial additional share-based compensation expense and the ownership of our existing stockholders would be further diluted, which could depress the market price for our stock.

48

Our financial performance is subject to risks associated with changes in the value of the U.S. dollar versus local currencies.

For current and potential international customers whose contracts are denominated in U.S. dollars, the relative change in local currency values creates relative fluctuations in our product pricing. These changes in international end-user costs may result in lost orders and reduce the competitiveness of our products in certain foreign markets. Additionally, intercompany sales to our non-U.S. dollar functional currency international subsidiaries are transacted in U.S. dollars which could increase our foreign exchange rate risk caused by foreign currency transaction gains and losses.

For non-U.S. dollar denominated sales, weakening of foreign currencies relative to the U.S. dollar generally leads us to raise international pricing, potentially reducing demand for our products. Should we decide not to raise local prices to fully offset the dollar’s strengthening, the U.S. dollar value of our foreign currency denominated sales and earnings would be adversely affected. We do not currently engage in hedging activities. Fluctuations in foreign currency could result in a change in the U.S. dollar value of our foreign denominated assets and liabilities including accounts receivable. Therefore, the U.S. dollar equivalent collected on a given sale could be less than the amount invoiced causing the sale to be less profitable than contemplated.

We also import selected components which are used in the manufacturing of some of our products. Although our purchase orders are generally in U.S. dollars, weakness in the U.S. dollar could lead to price increases for the components.

Unanticipated changes in our effective tax rate and additional tax liabilities may impact our operating results.

We are subject to income taxes in the U.S. and various jurisdictions outside of the U.S. Our effective tax rate could fluctuate due to changes in the mix of earnings and losses in countries with differing statutory tax rates. Our tax expense could also be impacted by changes in non-deductible expenses, changes in excess tax benefits related to exercises of stock options and vesting of restricted stock units, changes in the valuation of deferred tax assets and liabilities and our ability to utilize them, the applicability of withholding taxes, and changes in our liability for unrecognized tax benefits.

We are subject to potential tax examinations in multiple jurisdictions. While we regularly evaluate new information that may change our judgment resulting in recognition, derecognition or change in measurement of a tax position taken, there can be no assurance that the final determination of any examinations will not have an adverse effect on our operating results and financial position.

Our tax provision could also be impacted by changes in federal, state or international tax laws including fundamental tax law changes applicable to corporate multinationals, including proposals by the current U.S. president or Congress.

Additionally, we may be subject to additional tax liabilities due to changes in non-income-based taxes resulting from changes in federal, state, city or international tax laws, changes in taxing jurisdictions’ administrative interpretations, decisions, policies, and positions, results of tax examinations, settlements or judicial decisions, changes in accounting principles, changes to the business operations, including acquisitions, as well as the evaluation of new information that results in a change to a tax position taken in a prior period.

Our revenues and operating results may fluctuate unexpectedly from quarter-to-quarter, which may cause our stock price to decline.

Our revenues and operating results have varied significantly in the past and may vary significantly in the future due to various factors, including, but not limited to:

● budgetary cycles of municipal, state and federal law enforcement and corrections agencies;

● market acceptance of our products and services;

● the timing of large domestic and international orders;

● the outcome of any existing or future litigation;

● adverse publicity surrounding our products, the safety of our products, or the use of our products;

49

● changes in our sales mix;

● new product introduction costs;

● increased raw material expenses;

● changes in our operating expenses, including stock-based compensation expense;

● changes in foreign currency exchange rates, inflation, and interest rates;

● inventory obsolescence;

● existing or future tariffs; and

● regulatory changes that may affect the marketability of our products.

As a result of these and other factors, we believe that period-to-period comparisons of our operating results may not be meaningful in the short term, and our performance in a particular period may not be indicative of our performance in any future period.

Legal and Compliance Risks

We may face personal injury, wrongful death, product liability and other liability claims that harm our reputation and adversely affect our sales and financial condition.

Our CED products are often used in aggressive confrontations that may result in serious, permanent bodily injury or death to those involved. Our CED products may be associated with these injuries. A person, or the family members of a person, injured or killed in a confrontation or otherwise in connection with the use of our products, may bring legal action against us to recover damages on the basis of theories including wrongful death, personal injury, negligent design, defective product, product performance issues, or inadequate warnings or training. We are currently subject to a number of such lawsuits and have been and may be in the future subject to significant adverse judgments and settlements. We may also be subject to lawsuits involving allegations of criminal misuse of our products. We have no control over how our products and services are used by our customers or other end-users and cannot assure they are used consistent with our specifications and design. While our products are designed to be non-lethal, we cannot guarantee they will be used in a manner consistent with our intent and any such use exposes us to litigation, reputational harm and controversy. If successful, wrongful death, personal injury, misuse and other claims could have a material adverse effect on our operating results and financial condition and could result in negative publicity about our products. Similar to product liability claims, we face exposure to class action lawsuits related to the design, performance, safety, or advertising of our products. Such class action lawsuits could also result in substantial monetary judgments, injunctions related to the sale of products, and potentially harm our reputation.

Although we maintain product liability insurance in amounts that we believe are reasonable, we may not be able to maintain such insurance on acceptable terms, if at all, and product liability claims may exceed the amount of insurance coverage available to us. Because we manufacture and sell CEDs, insurance carriers may decide not to insure our products or our company in the future. We incur significant legal expenses in defending these cases, and significant litigation could also result in a diversion of management’s attention and resources, negative publicity and a potential award of monetary damages in excess of our insurance coverage. The outcome of any litigation is inherently uncertain and there can be no assurance that our existing or any future litigation will not have a material adverse effect on our business, financial condition or operating results.

Other litigation, government inquiries and regulatory actions may subject us to significant costs and judgments and divert management attention from our business.

We have been or could in the future be involved in numerous other litigation, government inquiries and regulatory matters relating to our products, employees, contracts and business relationships, including litigation against persons or entities we believe have infringed on our intellectual property, infringement litigation filed against us, litigation against a competitor, enforcement actions filed against us, and litigation involving the U.S. Federal Trade Commission (FTC).

50

Such matters have resulted, and are expected to continue to result in, substantial costs to us, including in the form of attorneys’ fees and costs, damages, fines or other penalties, whether pursuant to a judgment or settlement, and diversion of our management’s attention, which could adversely affect our business, financial condition or operating results. There is also a risk of adverse judgments, as the outcome of litigation is inherently uncertain.

We have been, and may be in the future, subject to intellectual property infringement and other claims, which could incur substantial litigation costs, result in significant damage awards, inhibit our use of certain technologies, and divert management attention from our business.

Many companies own intellectual property rights that are directly or indirectly related to public safety technologies. These companies periodically demand licensing agreements or engage in litigation based on allegations of infringement or other violations of their patents, trademarks, copyrights, or trade secrets. Non-practicing entities also have patents they have been granted or otherwise acquired, including patents that are directly or indirectly related to public safety technologies. These entities may seek compensation for perceived infringement of their patents, including by filing claims against us, independent of the merit of any such claims. As we enter new markets, expand into new product categories, and otherwise offer new products, services, and technologies, additional intellectual property claims may be filed against us by these companies, entities, and other third parties. Intellectual property claims may also be filed against us as our current products, services, and technologies gain additional market share.

If our products, services, or technologies were found to infringe a third-party’s proprietary rights, we could be forced to discontinue use of the protected technology or enter into costly royalty or licensing agreements in order to be able to sell our products. Such royalty and licensing agreements may not be available on terms acceptable to us or at all. We could also be required to pay substantial damages, fines or other penalties, indemnify customers or distributors, cease the manufacture, use, or sale of infringing products or processes, make proprietary source code publicly available, and/or expend significant resources to develop or acquire non-infringing technologies. Our suppliers may not provide, or we may not be able to obtain, intellectual property indemnification sufficient to offset all damages, fines or other penalties resulting from any claims of intellectual property infringement brought against us or our customers. There is no guarantee that our use of conventional technology searching and brand clearance searching will identify all potential rights holders. Rights holders may demand payment for past infringements and/or force us to accept costly license terms or discontinue use of protected technology and/or works of authorship that may include, for example, photos, videos, and software. Our current research and development focus on developing software-based products, including that which is related to artificial intelligence or virtual reality, increases this risk.

If we are unable to protect our intellectual property, the value of our brands and products may decrease and we may lose our competitive market advantage.

Our future success depends upon our proprietary technology. Our protective measures for this proprietary technology include patents, trademarks, copyrights, and trade secret protection. However, these protective measures, as well as our efforts to pursue such protective measures, may prove inadequate. For example, the value of intellectual property protection in certain countries may not be apparent until after such protection can no longer be pursued. As such, our intellectual property protection may not extend to all countries in which our products are distributed or will be distributed in the future. Though we work to protect our innovations, we may not be able to obtain protection for certain innovations. For example, we may be unable to patent some software-based products. The scope of any patent protection we have obtained, or may obtain, may not prevent others from developing and selling competing products. Despite our efforts, any intellectual property protection we obtain may be later determined to be insufficient or ineffective.

Our protective measures may prove inadequate for reasons outside of our control. Varying intellectual property laws across countries may lead to differences in protection between such countries. In certain countries in which our products are distributed, the ability to effectively enforce intellectual property rights may not exist. Patent requirements differ by country and certain domestic or foreign laws may prohibit us from satisfying these requirements, creating a risk that some of our international patents may become unenforceable. Patents for older technologies, such as those first introduced in our M26 and X26 models of CEDs, have expired or will expire due to statutory limits on patent term. Despite policies and efforts to maintain secrecy, trade secrets and other confidential information, such information could be compromised by employees, partners, or other third parties.

51

Once established, there is no guarantee that our intellectual property rights will remain in force. Issued patents may be re-examined and subsequently ruled invalid or unenforceable. Our registered trademarks may also be diminished or lost. For example, there is a risk that our “TASER” trademark could become synonymous with the general product category of “conducted energy devices”. The right to stop others from misusing our trademarks and service marks in commerce depends, to some extent, on our ability to show evidence of enforcement of our rights against such misuse in commerce. Our efforts to stop improper use, if ineffective, may lead to loss of trademark and service mark rights, brand loyalty and notoriety among our customers and prospective customers.

Our intellectual property may also be at risk if we are unable to defend against enforcement actions, such as that filed by the FTC regarding our acquisition of Vievu LLC from Safariland LLC on May 3, 2018. For additional discussion of this matter, refer to Note 13 to the consolidated financial statements included in Part II, Item 8 of this Quarterly Report on Form 10-Q. If successful, the FTC is seeking a divestiture of Vievu along with Axon assets sufficient to stand up a viable competitor.

Inability to protect our intellectual property could negatively impact our commercial efforts and competitive market advantage. Regardless of outcome, the prosecution of patent and other intellectual property claims is both costly and time consuming. Unauthorized use of our proprietary technology could divert our management’s attention from our business, and could result in a material adverse effect on our business, financial position, and operating results.

We may be limited in our ability to enforce patent rights internationally to only those jurisdictions in which our patent applications have been granted.

Our U.S. patents protect us from imported infringing products coming into the U.S. from abroad. We have made applications for patents in a few foreign countries; however, these may be inadequate to protect markets for our products in other foreign countries. Each patent is examined and granted according to the law of the country where it was filed independent of whether a U.S. patent on similar technology was granted. Certain foreign countries have patent working requirements that require a patent owner to practice a patented invention with the respective country. A patent in a foreign country may be subject to cancellation, forfeiture, compulsory license, or other penalty if the claimed invention has not been worked in that country. Meeting the requirements of working an invention differs by country and ranges from sales in the country to manufacturing in the country. U.S. export law, or the laws of some foreign countries, may prohibit us from satisfying the requirements for working the invention, creating a risk that some of our international patents may become unenforceable. In a country in which we do not have a patent or a country in which our patent in that country is unenforceable or unenforced, other companies and makers of similar products and services may be able to copy our products or features of our products without consequence, thus limiting our ability to capture market share or protect our technology, which could materially harm our growth prospects and operating results.

A variety of new and existing laws and/or interpretations could materially and adversely affect our business.

As detailed in “Item I. Business – Government Regulation” we are subject to a variety of laws and regulations in the United States and abroad that involve matters central to our business, including privacy, data protection and personal information, rights of publicity, content, intellectual property, advertising, marketing, distribution, data security, data retention and deletion, electronic contracts and other communications, competition, consumer protection, telecommunications, product liability, taxation, labor and employment, economic or other trade prohibitions or sanctions, securities law compliance, and online payment services. The introduction of new products, expansion of our activities in certain jurisdictions, or other actions that we may take may subject us to additional laws, regulations, or other government scrutiny. In addition, foreign data protection, privacy, content, competition, and other laws and regulations can impose different obligations or be more restrictive than those in the United States.

These U.S. federal and state and foreign laws and regulations, which in some cases can be enforced by private parties in addition to government entities, are constantly evolving and can be subject to significant change. As a result, the application, interpretation, and enforcement of these laws and regulations are often uncertain and may be interpreted and applied inconsistently from country to country and inconsistently with our current policies and practices. New laws and regulations (or new interpretations of existing laws and regulations) may require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices.

52

The costs of compliance with these laws and regulation are high and are likely to increase in the future. Additionally, these laws and regulations, or any associated inquiries or investigations or other government actions, may delay or impede the development of new products, result in negative publicity, require significant management time and attention, and subject us to remedies that may harm our business, including fines or demands or orders that we modify or cease existing business practices. For example, as has been reported in the press, there is a grand jury investigation being conducted by the U.S. Attorney’s Office for the Northern District of Illinois. We have fully cooperated with the investigation and continue to do so. While we conducted an extensive internal investigation into, among other things, lobbying activities, and have found no indication of any wrongdoing by any Axon employee, there can be no assurance that this matter will not harm our business.

Radio Spectrum and Unmanned Aerial and Ground-Based Robotic Devices

Certain of our products utilize the radio spectrum to provide wireless voice, data and video communications services. The allocation of spectrum is regulated in the U.S. and other countries and limited spectrum space is allocated to wireless services and specifically to public safety users. We manufacture and market products in spectrum bands already made available by regulatory bodies. If current products do not comply with the regulations set forth by these governing bodies, we may be unable to sell our products or could incur penalties. Our results could be negatively affected by the rules and regulations adopted from time to time by the U.S. Federal Communications Commission (FCC), Innovation, Science and Economic Development Canada (ISED), the European Union Directorate-General for Environment or regulatory agencies in other countries. Regulatory changes in current spectrum bands may also require modifications to some of our products so they can continue to be manufactured and marketed.

Axon body worn cameras, docks, fleet vehicle cameras and signal devices are subject to the FCC’s rules and regulations in the United States, as well as local rules and regulations as applicable outside of the United States. These regulations affect CEDs with Signal technology, including the TASER 7, SPPM, and future CEDs implementing wireless technology. Compliance with government regulations could increase our operations and product costs and impact our future financial results.

Additionally, some of our products depend on drones or other unmanned aerial and ground-based systems which operate on the radio spectrum.  The Federal Aviation Administration and other agencies at the federal, state and local levels (as well as in foreign jurisdictions) are beginning to address some of the numerous certification, regulatory and legal challenges associated with drones, but a comprehensive set of standards and enforcement procedures will need to be developed. Changes to the regulation of drones or other unmanned aerial systems may impact our future financial results.

Axon and TASER Devices

For our TASER products, we rely on the opinions of the ATF, including the determination that a device that does not expel projectiles by the action of an explosive is not classified as a firearm. Changes in statutes, regulations, and interpretation outside of our control may result in our products being classified or reclassified as firearms. If this were to occur, our private citizen market could be substantially reduced because consumers would be required to comply with federal, state, or local firearm transfer requirements prior to purchasing our products.

Federal regulation of sales in the U.S.: The majority of our currently offered CEDs are not classified as firearms regulated by the ATF. However, the ATF regulates TASER 10 as a firearm under the Gun Control Act of 1968 due to a technological advancement specific to the propulsion design of the TASER 10 CED’s cartridges. While this classification will have little impact on Axon’s ability to sell TASER 10 to law enforcement and government entities, our private citizen and enterprise market could be substantially reduced because non-governmental end-users would be required to comply with federal, state, or local firearm transfer requirements prior to purchasing TASER 10. Additionally, Axon must maintain a federal firearms license to manufacture and sell the TASER 10, which subjects Axon to periodic compliance inspections by the ATF. License violations discovered by the ATF can result in fines, penalties, warning letters or license revocation, leading to disruptions in operations.

Our CED products are also subject to testing, safety and other standards by organizations such as the American National Standards Institute, the International Electrotechnical Commission, the National Institute of Standards and Technology, and Underwriters Laboratories. These regulations also affect CEDs with Axon Signal technology, including Signal Performance Power Magazine technology, and TASER 7 battery packs.

53

Federal regulation of international sales: Our CEDs are considered a “crime control” product by the U.S. Department of Commerce (DOC) for export directly from the U.S. which requires us to obtain an export license from the DOC for the export of our CED devices from the U.S. to any country other than Canada. Future products and services may require classifications from the DOC before they may be shipped internationally. Our inability to obtain DOC export licenses or classifications on a timely basis for sales of our products to our international customers could significantly and adversely affect our international sales. Although TASER 10 is regulated by the ATF for domestic sales, the U.S. DOC has ruled that the product’s unique propulsion design has no impact on its export classification and that the TASER 10 model’s export classification remains consistent with all other TASER CED models.

Federal regulation of foreign national employees: Our CED development and production is also considered controlled “technology” by the U.S. DOC and is categorized as a “deemed export” for any foreign national employees exposed to the technology within the U.S. Consequently, we must obtain export licenses from the DOC for any deemed export within the U.S. made to a foreign national employee exposed to the deemed controlled technology. Deemed export licenses are subject to DOC approvals and issued licenses require annual status reports for the stated employees. Inability to obtain proper licensing could curtail the company’s ability to execute R&D and production related to CED technology.

State and local regulation: Our CEDs are controlled, restricted or, less frequently, prohibited by some state and local governments. Other jurisdictions may ban or restrict the sale of our TASER-branded devices, or restrict their use through changes to use-of-force laws or regulations, and our product sales may be significantly affected by additional state, county and city governmental regulation. The change in TASER 10’s propulsion design may impact how TASER 10 is regulated at the state and/or local level depending on each state’s firearm laws.

International regulation of foreign imports and sales: Certain jurisdictions prohibit, restrict, or require a permit for the importation, sale, possession or use of CEDs, including in some countries by law enforcement agencies, limiting our international sales opportunities.

U.S. and International regulation of component movements globally: We rely on a global supply chain of components across our product lines with most final assembly occurring in the U.S. Export of these components from abroad is subject to shifting regulatory landscapes imposed by both the foreign government and U.S. authorities upon import. Abrupt changes to these regulations can result in delays or interruptions to final product supplies. Additionally, ATF regulation of certain imports of TASER 10 components may limit Axon’s supply chain agility.

International regulation of foreign-based operations: We maintain foreign operations in several countries globally for purposes of logistics, sales, general and administrative, and R&D support. Any failure to properly maintain or license could limit our ability to sell, support, or develop our products and services both internationally and in the U.S. market.

Privacy Regulations

We are subject to various risks and costs associated with the collection, processing, storage and transmission of personally identifiable information and other sensitive and confidential information. This data is wide ranging and relates to our employees, customers, third parties, and the subjects of law enforcement. Our compliance obligations include laws and regulations that dictate whether, how, and under what circumstances we can transfer, process and/or receive and hold certain data that is critical to our operations, including data shared between countries or regions in which we operate and data shared among our products and services. If one or more of the legal mechanisms for transferring data from other countries to the U.S. is invalidated, if we are unable to transfer data between and among countries and regions in which we operate, or if we are prohibited from sharing data among our products and services, it could affect the manner in which we provide our services or adversely affect our financial results. Countries may also pass legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our services and expose us to significant penalties for non-compliance. The European Parliament adopted the General Data Protection Regulation (“GDPR”), effective May 2018, that extended the scope of European privacy laws to any entity that controls or processes personal data of European Union residents in connection with the offer of goods or services or the monitoring of behavior and imposes new compliance obligations concerning the handling of personal data. We are also subject to U.S. laws and regulations, including, without limitation, the California Privacy Rights Act, which provides for enhanced consumer protections for California residents, a private right of action for data breaches and statutory fines and damages for data breaches or other California Consumer Privacy Act violations,

54

as well as a requirement of “reasonable” cybersecurity, which could subject us to additional compliance costs as well as potential fines, individual claims, class actions and commercial liabilities.

Any inability, or perceived inability, by us to adequately address privacy concerns, or comply with applicable laws, regulations, policies, industry standards and guidance, contractual obligations, or other legal obligations, even if unfounded, could result in significant regulatory and third party liability, increased costs, disruption of our business and operations, and a loss of confidence and other reputational damage. Furthermore, as new privacy- related laws and regulations are implemented, the time and resources needed for us to comply with such laws and regulations continues to increase and become a significant compliance workstream.

Environmental Regulations

We are subject to various state, federal and international laws and regulations governing the environment, including restricting the presence of certain substances in our products and making us financially responsible for the collection, treatment, recycling and disposal of such products. In addition, further environmental or climate change disclosure legislation may be enacted in other jurisdictions, including the U.S. (under federal and state laws) and other countries, the cumulative impact of which could be significant. New, or changes in, environmental safety laws, regulations or rules could also lead to increased costs of compliance, including remediations of any discovered issues, and changes to our operations, which may be significant. Any failures to comply could result in significant expenses, delays, or fines.

Our business is subject to evolving corporate governance and public disclosure regulations and expectations, including with respect to environmental, social and governance matters, that could expose us to numerous risks.

We are subject to changing rules and regulations promulgated by a number of governmental and self-regulatory organizations, including the SEC, the Nasdaq Stock Market and the Financial Accounting Standards Board. These rules and regulations continue to evolve in scope and complexity and many new requirements have been created in response to laws enacted by Congress, making compliance more difficult and uncertain. In addition, increasingly regulators, customers, investors, employees and other stakeholders are focusing on environmental, social and governance (“ESG”) matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. For example, developing and acting on initiatives within the scope of ESG, and collecting, measuring and reporting ESG related information and metrics can be costly, difficult and time consuming and is subject to evolving reporting standards, including the SEC’s recently proposed climate-related reporting requirements, and similar proposals by other international regulatory bodies.

Additionally, unfavorable perception regarding our social initiatives, governance practices, diversity initiatives, the perceived or actual impacts of our products and services, environmental policies or other growing concerns of our stakeholders, could adversely affect our reputation. Any negative effect on our reputation could have an adverse effect on the size of our customer base, which could adversely affect our business and financial results. We have been, and may be in the future, subject to informal private or public inquiries and formal proxy proposals by activists urging us to take certain corporate actions related to ESG matters, which may not be aligned with our best interests. These activities may adversely affect our business in a number of ways, since responding to inquiries or proposals can be costly, time consuming, and disruptive to our operations and could meaningfully divert the attention of our resources, including those of our management team and our employees.

We may also communicate certain initiatives and goals, regarding environmental matters, diversity, responsible sourcing and social investments and other ESG related matters, in our SEC filings or in other public disclosures. These initiatives and goals within the scope of ESG could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Further, statements about our ESG related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals within the scope of ESG on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.

55

Risks Related to our Convertible Notes

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our or their businesses to pay our substantial debt.

As of December 31, 2022, we had outstanding an aggregate principal amount of $690.0 million of our 0.50% Convertible Senior Notes due 2027 (the “Notes”). Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the notes.

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert their Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, we would be required to settle any converted principal amount of such Notes through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current, rather than long-term, liability, which would result in a material reduction of our net working capital.

Conversion of the Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.

The conversion of some or all of the Notes may dilute the ownership interests of our stockholders. Upon conversion of the Notes, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock in respect of the remainder, if any, of our conversion obligation in excess of the aggregate principal amount of the Notes being converted. If we elect to settle the remainder, if any, of our conversion obligation in excess of the aggregate principal amount of the Notes being converted in shares of our common stock or a combination of cash and shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.

Changes in the accounting treatment for the Notes could have a material effect on our reported financial results.

We have adopted Accounting Standards Update (“ASU 2020-06”) 2020-06 as of January 1, 2022.  Accordingly, we do not bifurcate the liability and equity components of the Notes on our balance sheet and we use the if-converted method of calculating diluted earnings per share. Under the “if-converted” method, diluted earnings per share will generally be calculated assuming that all the notes were converted solely into shares of common stock at the beginning of the reporting period, unless the result would be anti-dilutive, which could adversely affect our diluted earnings per share. Because the principal amount of the Notes upon conversion is required to be paid in cash, and only the excess is permitted to be settled in shares, the application of the if-converted method will produce a similar result as the treasury stock method prior to the adoption of ASU 2020-06. The effect of the treasury stock method is that the shares issuable upon conversion of such Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of such Notes exceeds their principal amount. 

In accordance with ASU 2020-06, the Notes are reflected as a liability on our consolidated balance sheets, with the initial carrying amount equal to the principal amount of the Notes, net of issuance costs. The issuance costs will be treated as a debt discount for accounting purposes, which will be amortized into interest expense over the term of the Notes.

56

As a result of this amortization, the interest expense that we expect to recognize for the Notes for accounting purposes will be greater than the cash interest payments we will pay on the Notes, which will result in lower reported income.

We cannot be sure whether future changes made to the current accounting standards related to the Notes will not have a material effect on our reported financial results.

The convertible note hedge and warrant transactions may affect the value of the Notes and our common stock.

In connection with the pricing of the Notes, we have entered into convertible note hedge transactions with the option counterparties. We have also entered into warrant transactions with the option counterparties. The convertible note hedge transactions are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted notes, as the case may be. However, the warrant transactions could have a dilutive effect on our common stock to the extent that the market price per share of our common stock exceeds the strike price of the warrants.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do in connection with any conversion of the Notes or redemption or repurchase of the Notes). This activity could cause or avoid an increase or a decrease in the market price of our common stock.

In addition, if any such convertible note hedge and warrant hedging transactions fail to become effective, the option counterparties or their respective affiliates may unwind their hedge positions with respect to our common stock, which could adversely affect the value of our common stock.

The potential effect, if any, of these transactions and activities on the market price of our common stock will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of our common stock.

We are subject to counterparty risk with respect to the convertible note hedge transactions.

The option counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the convertible note hedge transactions. Our exposure to the credit risk of the option counterparties will not be secured by any collateral.

If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the convertible note hedge transactions with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the option counterparties.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

57

Item 5.   Other Information

None.

58

Item 6.    Exhibits

3.1	Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the
	Quarterly Report on Form 10-Q, filed August 9, 2022)
3.2	Bylaws, as amended and restated (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q, filed August 9, 2022)
31.1*	Principal Executive Officer Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a)
31.2*	Principal Financial Officer Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a)
32**	Principal Executive Officer and Principal Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL

+Management contract or compensatory plan or arrangement

*     Filed herewith

**   Furnished herewith

59

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AXON ENTERPRISE, INC.
Date:	May 9, 2023
		By:	/s/ PATRICK W. SMITH
			Chief Executive Officer
			(Principal Executive Officer)
Date:	May 9, 2023	By:	/s/ BRITTANY BAGLEY
			Chief Financial Officer and Chief Business Officer
			(Principal Financial and
			Accounting Officer)

60

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

RULE 13a-14(a) or RULE 15d-14(a)

SECURITIES EXCHANGE ACT OF 1934

I, Patrick W. Smith, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 of Axon Enterprise, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 9, 2023	By:	/s/ Patrick W. Smith
			Patrick W. Smith
			Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

RULE 13a-14(a) or RULE 15d-14(a)

SECURITIES EXCHANGE ACT OF 1934

I, Brittany Bagley, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 of Axon Enterprise, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 9, 2023	By:	/s/ Brittany Bagley
			Brittany Bagley
			Chief Financial Officer and Chief Business Officer

EX-32

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Axon Enterprise, Inc. (the “Company”) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patrick W. Smith, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Patrick W. Smith

Patrick W. Smith

Chief Executive Officer

May 9, 2023

In connection with the Quarterly Report on Form 10-Q of Axon Enterprise, Inc. (the “Company”) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brittany Bagley, Chief Financial Officer and Chief Business Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brittany Bagley

Brittany Bagley

Chief Financial Officer and Chief Business Officer

May 9, 2023

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 05, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-16391
Entity Registrant Name	Axon Enterprise, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0741227
Entity Address, Address Line One	17800 North 85th Street
Entity Address, City or Town	Scottsdale
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85255
City Area Code	480
Local Phone Number	991-0797
Title of 12(b) Security	Common Stock, $0.00001 Par Value
Trading Symbol	AXON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		73,885,305
Entity Central Index Key	0001069183
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 263,414	$ 353,684
Marketable securities	54,810	39,240
Short-term investments	775,129	581,769
Accounts and notes receivable, net of allowance of $2,029 and $2,176 as of March 31, 2023 and December 31, 2022, respectively	379,887	358,190
Contract assets, net	216,869	196,902
Inventory	220,268	202,471
Prepaid expenses and other current assets	142,319	73,022
Total current assets	2,052,696	1,805,278
Property and equipment, net	172,674	169,843
Deferred tax assets, net	171,122	156,866
Intangible assets, net	11,270	12,158
Goodwill	44,982	44,983
Long-term investments	31,116	156,207
Long-term notes receivable, net	4,467	5,210
Long-term contract assets, net	54,886	45,170
Strategic investments	296,563	296,563
Other long-term assets	168,173	159,616
Total assets	3,007,949	2,851,894
Current liabilities:
Accounts payable	65,988	59,918
Accrued liabilities	120,607	155,934
Current portion of deferred revenue	408,061	360,037
Customer deposits	13,961	20,399
Other current liabilities	7,510	6,358
Total current liabilities	616,127	602,646
Deferred revenue, net of current portion	250,366	248,003
Liability for unrecognized tax benefits	16,198	10,745
Long-term deferred compensation	7,983	6,285
Deferred tax liability, net		1
Long-term lease liabilities	35,045	37,143
Convertible notes, net	674,724	673,967
Other long-term liabilities	4,511	4,613
Total liabilities	1,604,954	1,583,403
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
Common stock, $0.00001 par value; 200,000,000 shares authorized; 73,874,062 and 71,474,581 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	1	1
Additional paid-in capital	1,262,099	1,174,594
Treasury stock at cost, 20,220,227 shares as of March 31, 2023 and December 31, 2022	(155,947)	(155,947)
Retained earnings	302,161	257,022
Accumulated other comprehensive loss	(5,319)	(7,179)
Total stockholders' equity	1,402,995	1,268,491
Total liabilities and stockholders' equity	$ 3,007,949	$ 2,851,894

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$ 2,029	$ 2,176
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	73,874,062	71,474,581
Common stock, shares outstanding (in shares)	73,874,062	71,474,581
Treasury stock, shares (in shares)	20,220,227	20,220,227

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net sales	$ 343,043	$ 256,426
Cost of sales	138,941	100,687
Gross margin	204,102	155,739
Operating expenses:
Sales, general and administrative	116,567	90,129
Research and development	70,927	48,416
Total operating expenses	187,494	138,545
Income from operations	16,608	17,194
Interest and other income, net	25,276	55,299
Income before provision for income taxes	41,884	72,493
Provision for (benefit from) income taxes	(3,255)	17,622
Net income	$ 45,139	$ 54,871
Net income per common and common equivalent shares:
Basic (in dollars per share)	$ 0.62	$ 0.77
Diluted (in dollars per share)	$ 0.61	$ 0.76
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	72,638	70,950
Diluted (in shares)	73,880	72,349
Net income	$ 45,139	$ 54,871
Foreign currency translation adjustments	1,676	(1,072)
Unrealized gain (loss) on available-for-sale investments	184	(489)
Comprehensive income	46,999	53,310
Product
Net sales	219,389	176,204
Cost of sales	107,584	79,352
Service
Net sales	123,654	80,222
Cost of sales	$ 31,357	$ 21,335

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Beginning balance at Dec. 31, 2021	$ 1	$ 1,095,229	$ (155,947)	$ 109,883	$ (1,317)	$ 1,047,849
Beginning balance (in shares) at Dec. 31, 2021	70,896,856		20,220,227
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock		(70)				(70)
Issuance of common stock under employee plans, net		(1,388)				(1,388)
Issuance of common stock under employee plans, net (in shares)	99,802
Stock-based compensation		25,088				25,088
Net income				54,871		54,871
Other comprehensive income (loss), net					(1,561)	(1,561)
Ending balance at Mar. 31, 2022	$ 1	1,118,859	$ (155,947)	164,754	(2,878)	1,124,789
Ending balance (in shares) at Mar. 31, 2022	70,996,658		20,220,227
Beginning balance at Dec. 31, 2022	$ 1	1,174,594	$ (155,947)	257,022	(7,179)	1,268,491
Beginning balance (in shares) at Dec. 31, 2022	71,474,581		20,220,227
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock		33,650				33,650
Issuance of common stock (in shares)	154,500
Issuance of common stock under employee plans, net		(34,841)				(34,841)
Issuance of common stock under employee plans, net (in shares)	335,629
Stock options exercised		54,346				54,346
Stock options exercised (in shares)	1,901,535
Stock-based compensation		34,350				34,350
Issuance of common stock for business combination contingent consideration (in shares)	7,817
Net income				45,139		45,139
Other comprehensive income (loss), net					1,860	1,860
Ending balance at Mar. 31, 2023	$ 1	$ 1,262,099	$ (155,947)	$ 302,161	$ (5,319)	$ 1,402,995
Ending balance (in shares) at Mar. 31, 2023	73,874,062		20,220,227

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income	$ 45,139	$ 54,871
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,689	5,755
Amortization of issuance cost	756
Coupon interest expense	863
Loss on disposal and abandonment of intangible assets	10	40
Loss on disposal and impairment of property, equipment, and other assets, net	146	106
Unrealized gains on strategic investments and marketable securities, net	(15,570)	(55,851)
Stock-based compensation	34,350	25,088
Deferred income taxes	(9,660)	18,029
Unrecognized tax benefits	855	1,365
Bond amortization	(3,890)	159
Noncash lease expense	1,395	1,556
Provision for expected credit losses	28	228
Change in assets and liabilities:
Accounts and notes receivable and contract assets	(50,431)	7,495
Inventory	(15,811)	(14,260)
Prepaid expenses and other assets	(64,348)	(7,074)
Accounts payable, accrued and other liabilities	(37,043)	(9,580)
Deferred revenue	50,199	16,037
Net cash provided by (used in) operating activities	(56,323)	43,964
Cash flows from investing activities:
Purchases of investments	(145,124)
Proceeds from call / maturity of investments	81,088	7,200
Purchases of property and equipment	(8,513)	(17,098)
Proceeds from disposal of property and equipment		87
Purchases of intangible assets	(125)	(37)
Strategic investments		(500)
Net cash used in investing activities	(72,674)	(10,348)
Cash flows from financing activities:
Net proceeds from equity offering	33,650	(71)
Proceeds from options exercised	39,181
Income and payroll tax payments for net-settled stock awards	(34,841)	(1,388)
Net cash provided by (used in) financing activities	37,990	(1,459)
Effect of exchange rate changes on cash and cash equivalents	779	(157)
Net increase (decrease) in cash and cash equivalents	(90,228)	32,000
Cash and cash equivalents and restricted cash, beginning of period	355,552	356,438
Cash and cash equivalents and restricted cash, end of period	$ 265,324	$ 388,438

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Supplemental - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental disclosures:
Cash and cash equivalents	$ 263,414	$ 386,367
Restricted cash (Note 1)	1,910	2,071
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	265,324	388,438
Cash paid for income taxes, net of refunds	20,936	334
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	1,130	$ 888
Receivables from options exercised	$ 15,165

XML

Organization and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Organization and Summary of Significant Accounting Policies

Organization and Summary of Significant Accounting Policies

Note 1 - Organization and Summary of Significant Accounting Policies

Axon Enterprise, Inc. (“Axon”, the “Company”, "we", or "us") is a market-leading provider of law enforcement technology solutions. Our mission is to protect life in service of promoting peace, justice and strong institutions.

Our headquarters in Scottsdale, Arizona houses our executive management, sales, marketing, certain engineering, manufacturing, finance and other administrative support functions. Our global software hub is located in Seattle, Washington, and we also have subsidiaries and / or offices located in Australia, Canada, Finland, France, Germany, Hong Kong, India, Italy, the Netherlands, Spain, the United Kingdom, and Vietnam.

The accompanying unaudited condensed consolidated financial statements include the accounts of Axon Enterprise, Inc. and our subsidiaries. All material intercompany accounts, transactions, and profits have been eliminated.

Basis of Presentation and Use of Estimates

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2022, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2022. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:

● product warranty reserves,

● inventory valuation,

● revenue recognition,

● reserve for expected credit loss,

● valuation of goodwill, intangible and long-lived assets,

● valuation of strategic investments,

● recognition, measurement and valuation of current and deferred income taxes,

● stock-based compensation, and

● recognition and measurement of contingencies and accrued litigation expense.

Actual results could differ materially from those estimates.

Segment Information

Our operations comprise two reportable segments: the development, manufacture and sale of fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share and analyze video and other digital evidence (collectively, the "Software and Sensors" segment); and the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (collectively, the “TASER” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform

an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 15.

Geographic Information and Major Customers / Suppliers

For the three months ended March 31, 2023, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three months ended March 31, 2023, no customer represented more than 10% of total net sales. At March 31, 2023 and December 31, 2022, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets.

We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., China, Republic of Korea, Malaysia, Mexico, Sri Lanka, Taiwan, and Vietnam. We may source from other countries as well. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases. Although we have experienced supply chain disruptions relating to materials and port constraints, we have remained focused on closely managing our supply chain. We continue to bolster our strategic relationships in our supply chain, identifying secondary/alternate sourcing, adjusting build plans accordingly, and building in logistic modes in support of our increasing demand while working to minimize disruption to customers. We acquire most of our components on a purchase order basis and do not currently have significant long-term purchase contracts with most component suppliers.

Income per Common Share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The effects of outstanding stock options, unvested restricted stock units, our 2027 convertible senior notes (the “Notes” or “2027 Notes”), and warrants to acquire the number of shares of our common stock (the “Warrants” or “2027 Warrants”) are excluded from the computation of diluted net income per share in periods in which the effect would be antidilutive. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator for basic and diluted earnings per share:
Net income	$	45,139	$	54,871
Denominator:
Weighted average shares outstanding		72,638		70,950
Dilutive effect of stock-based awards		1,242		1,399
Diluted weighted average shares outstanding		73,880		72,349
Net income per common share:
Basic	$	0.62	$	0.77
Diluted	$	0.61	$	0.76

Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Stock-based awards		1,469		2,942
2027 Notes		3,017		—
2027 Warrants		3,017		—
Total potentially dilutive securities		7,503		2,942

For additional information regarding our convertible senior notes, refer to Note 9.

Standard Warranties

We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated on a quarterly basis based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying consolidated balance sheets.

Changes in our estimated product warranty liabilities were as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Balance, beginning of period	$	811	$	2,822
Utilization of reserve		(438)		(1,434)
Warranty expense		2,928		116
Balance, end of period	$	3,301	$	1,504

Fair Value Measurements and Financial Instruments

We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.

● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.

● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability.

We have cash equivalents and investments, which at March 31, 2023 comprised money market funds, commercial paper, corporate bonds, term deposits, U.S. Government bonds, municipal bonds, agency bonds and U.S. Treasury inflation-protected securities. Cash equivalents and investments at December 31, 2022 also included certificates of deposit and U.S. Treasury bills. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other long-term assets as of March 31, 2023 and December 31, 2022 was $5.1 million and $4.3 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.

We have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net.

We have strategic investments in eight unconsolidated affiliates as of March 31, 2023. The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic investments in privately held companies, we utilize observable data available to us as discussed further in Note 6.

We have convertible senior notes, for which the fair value is determined based on the closing trading price per $1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the Notes at March 31, 2023 to be a Level 2 measurement as they are not publicly traded. The fair value of the Notes is primarily affected by the trading price of our common stock and market interest rates.

Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet.

Restricted Cash

Restricted cash balances were $1.9 million as of March 31, 2023 and December 31, 2022, respectively. The balances were primarily related to funds held in an international bank account securing a guarantee and funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately $1.8 million was included in prepaid expenses and other assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.

Valuation of Goodwill, Intangibles and Long-lived Assets

We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.

We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year.

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

XML

Revenues

3 Months Ended

Mar. 31, 2023

Revenues.

Revenues

Note 2 - Revenues

Nature of Products and Services

The following tables present our revenues by primary product and service offering (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
TASER Devices (Professional)	$	67,472	$	—	$	67,472	$	63,164	$	—	$	63,164
Cartridges		46,800		—		46,800		37,825		—		37,825
Axon Evidence and Cloud Services		7,201		118,314		125,515		3,017		79,939		82,956
Extended Warranties		7,670		14,085		21,755		6,679		9,061		15,740
Axon Body Cameras and Accessories		—		38,797		38,797		—		38,517		38,517
Axon Fleet Systems		—		32,972		32,972		—		13,820		13,820
Other (1) (2)		5,139		4,593		9,732		3,675		729		4,404
Total	$	134,282	$	208,761	$	343,043	$	114,360	$	142,066	$	256,426

(1) TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.

(2) Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room and Axon Air.

The following table presents our revenues disaggregated by geography (in thousands):

	Three Months Ended March 31,
	2023				2022
United States	$	290,938	85	%	$	214,214	84	%
Other countries		52,105	15			42,212	16
Total	$	343,043	100	%	$	256,426	100	%

Contract Balances

The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the three months ended March 31, 2023 (in thousands):

	March 31, 2023
Contract assets, net	$	271,755
Contract liabilities (deferred revenue)		658,427
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period		133,707

Contract liabilities (deferred revenue) consisted of the following (in thousands):

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
Warranty:
TASER	$	13,333	$	18,198	$	31,531	$	14,207	$	17,618	$	31,825
Software and Sensors		28,105		15,467		43,572		26,229		15,338		41,567
		41,438		33,665		75,103		40,436		32,956		73,392
Hardware:
TASER		46,575		16,896		63,471		49,361		12,640		62,001
Software and Sensors		61,554		106,398		167,952		50,426		109,227		159,653
		108,129		123,294		231,423		99,787		121,867		221,654
Services:
TASER		6,016		9,425		15,441		7,637		9,501		17,138
Software and Sensors		252,478		83,982		336,460		212,177		83,679		295,856
		258,494		93,407		351,901		219,814		93,180		312,994
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
TASER	$	65,924	$	44,519	$	110,443	$	71,205	$	39,759	$	110,964
Software and Sensors		342,137		205,847		547,984		288,832		208,244		497,076
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

Remaining Performance Obligations

As of March 31, 2023, we had approximately $4.8 billion of remaining performance obligations, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. The remaining performance obligations are limited only to arrangements that meet the definition of a contract under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, as of March 31, 2023. We expect to recognize between 15% - 25% of this balance over the next twelve months, and generally expect the remainder to be recognized over the following ten years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.

XML

Cash, Cash Equivalents and Investments

3 Months Ended

Mar. 31, 2023

Cash, Cash Equivalents and Investments

Cash, Cash Equivalents and Investments

Note 3 - Cash, Cash Equivalents and Investments

The following tables summarize our cash, cash equivalents, marketable securities, and available-for-sale investments at March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	213,446	$	—	$	—	$	213,446	$	213,446	$	—	$	—	$	—
Level 1:
Money market funds		49,968		—		—		49,968		49,968		—		—		—
Agency bonds		160,615		39		(230)		160,424		—		—		154,688		5,736
Treasury bills		41,079		6		(2)		41,083		—		—		41,083		—
Marketable securities		90,000		—		(35,190)		54,810		—		54,810		—		—
Subtotal		341,662		45		(35,422)		306,285		49,968		54,810		195,771		5,736
Level 2:
State and municipal obligations		3,026		—		(14)		3,012		—		—		3,012		—
Term deposits		175,000		—		—		175,000		—		—		175,000		—
Corporate bonds		241,401		45		(1,081)		240,365		—		—		226,468		13,897
U.S. government		43,948		—		(158)		43,790		—		—		32,307		11,483
Treasury inflation-protected securities		2,525		17		—		2,542		—		—		2,542		—
Commercial paper		140,029		—		—		140,029		—		—		140,029		—
Subtotal		605,929		62		(1,253)		604,738		—		—		579,358		25,380
Total	$	1,161,037	$	107	$	(36,675)	$	1,124,469	$	263,414	$	54,810	$	775,129	$	31,116

As of March 31, 2023, we had $375.6 million of available-for-sale investments with unrealized losses. Of the $375.6 million of available-for-sale investments with unrealized losses, $17.6 million have been in a continuous unrealized loss position for 12 months or longer, with total gross unrealized losses of $0.6 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases.

During the year ended December 31, 2021, we acquired 9,000,000 shares of common stock of Cellebrite DI Ltd (“CLBT”) with a fair value of $90.0 million. The CLBT common stock is recorded as marketable securities in the accompanying condensed consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net. During the three months ended March 31, 2023, we recorded an unrealized gain on marketable securities of $15.6 million relating to CLBT.

	As of December 31, 2022
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	143,744	$	—	$	—	$	143,744	$	143,744	$	—	$	—	$	—
Level 1:
Money market funds		2,669		—		—		2,669		2,669		—		—		—
Agency bonds		164,486		6		(263)		164,229		—		—		69,862		94,367
Treasury bills		121,650		18		(3)		121,665		113,100		—		8,565		—
Marketable securities		90,000		—		(50,760)		39,240		—		39,240		—		—
Subtotal		378,805		24		(51,026)		327,803		115,769		39,240		78,427		94,367
Level 2:
State and municipal obligations		4,980		—		(33)		4,947		—		—		4,947		—
Certificate of deposits		5,002		—		—		5,002		—		—		5,002		—
Term deposits		200,000		—		—		200,000		25,000		—		175,000		—
Corporate bonds		257,422		33		(1,159)		256,296		28,883		—		168,074		59,339
U.S. Government		30,525		—		(159)		30,366		—		—		30,366		—
Treasury inflation-protected securities		2,503		—		(2)		2,501		—		—		—		2,501
Commercial paper		160,241		—		—		160,241		40,288		—		119,953		—
Subtotal		660,673		33		(1,353)		659,353		94,171		—		503,342		61,840
Total	$	1,183,222	$	57	$	(52,379)	$	1,130,900	$	353,684	$	39,240	$	581,769	$	156,207

XML

Expected Credit Losses

3 Months Ended

Mar. 31, 2023

Expected Credit Losses

Expected Credit Losses

Note 4 - Expected Credit Losses

We are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, notes receivable, and contract assets is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible.

We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions.

The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands):

	Three Months Ended March 31, 2023
	United States		Other countries		Total
Balance, beginning of period	$	3,064	$	566	$	3,630
Provision for expected credit losses		(76)		104		28
Amounts written off charged against the allowance		(353)		(5)		(358)
Balance, end of period	$	2,635	$	665	$	3,300

As of March 31, 2023 and December 31, 2022, the allowance for expected credit losses for each type of customer receivable was as follows (in thousands):

	March 31, 2023		December 31, 2022
Accounts receivable and notes receivable, current	$	2,029	$	2,176
Contract assets, net		1,211		1,360
Long-term notes receivable, net of current portion		60		94
Total allowance for expected credit losses on customer receivables	$	3,300	$	3,630

XML

Inventory

3 Months Ended

Mar. 31, 2023

Inventory

Inventory

Note 5 - Inventory

Inventories are stated at the lower of cost, determined on the first-in, first-out (“FIFO”) basis, or net realizable value, net of an inventory valuation allowance. We use a standard cost methodology to determine the cost basis for its inventories. Costs include allocations for materials, labor, and overhead. All variances between actual costs and standard costs are apportioned to inventory and cost of goods sold based upon inventory turnover. We evaluate inventory on a quarterly basis for obsolete or slow-moving items to ascertain if the recorded allowance is reasonable and adequate. Additional provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value.

Inventory consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Raw materials	$	86,607	$	72,740
Finished goods		133,661		129,731
Total inventory	$	220,268	$	202,471

XML

Strategic Investments

3 Months Ended

Mar. 31, 2023

Strategic Investments

Strategic Investments

Note 6 - Strategic Investments

Strategic investments include investments in a number of non-public technology-driven companies. We account for strategic investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investments. The investments are measured at cost less impairment, adjusted for observable price changes and are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

In conjunction with certain of our strategic investments, we have the ability to commit additional capital over time through warrants and call options; for some investments, the exercisability and exercise prices are conditional on the achievement of certain performance metrics.

The following tables provide a roll-forward of the balance of strategic investments (in thousands):

	Three Months Ended March 31, 2023								Three Months Ended March 31, 2022
	Strategic investments		Warrants			Call options	Total		Strategic investments		Warrants			Total
Balance, beginning of period	$	277,676	$	1,654	$	17,233	$	296,563	$	80,775	$	2,745	$	83,520
Investments		—		—		—		—		500		—		500
Observable price changes:
Unrealized gains		—		—		—		—		41,893		28,539		70,432
Unrealized losses		—		—		—		—		—		—		—
Exercises		—		—		—		—		—		—		—
Sales		—		—		—		—		—		—		—
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563	$	123,168	$	31,284	$	154,452

	Inception to date
	Strategic investments		Warrants			Call options	Total
Investments	$	109,482	$	3,047	$	17,233	$	129,762
Observable price changes:
Realized gains		12,312		—		—		12,312
Unrealized gains		74,817		29,073		—		103,890
Unrealized losses		(1,108)		(377)		—		(1,485)
Exercises		96,719		(30,089)		—		66,630
Sales		(14,546)		—		—		(14,546)
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563

As part of our strategy, we continuously evaluate opportunities for strategic investments that align with our mission. Examples of investment areas include real-time crime center software, drones and related software, biometric sensors, and weapon detection solutions.

XML

Variable Interest Entities

3 Months Ended

Mar. 31, 2023

Variable Interest Entities

Variable Interest Entities

Note 7 - Variable Interest Entities

We evaluate our investments and other significant relationships to determine whether any investee is a variable interest entity (“VIE”). If we conclude that an investee is a VIE, we evaluate our power to direct the activities of the investee, our obligation to absorb the expected losses of the investee and our right to receive the expected residual returns of the investee to determine whether we are the primary beneficiary of the investee. If we are the primary beneficiary of a VIE, we consolidate such entity and reflects the non-controlling interest of other beneficiaries of that entity.

We determine whether we are the primary beneficiary of a VIE by performing an analysis that principally considers:

● The VIE’s purpose, design, and risks the VIE was designed to create and pass through to its variable interest holders;

● The VIE’s capital structure;

● The terms between the VIE and its variable interest holders and other parties involved with the VIE; and

● Related-party affiliations.

The table below presents a summary of the nonconsolidated VIEs in which we hold variable interests:

	March 31, 2023		December 31, 2022
Total nonconsolidated variable interest entities:
Carrying value of variable interest - assets	$	11,530	$	11,530
Carrying value of variable interest - liabilities		—		—
Maximum exposure to loss:
Non-public equity (1)		11,530		11,530
Total	$	11,530	$	11,530

⁽¹⁾ The maximum exposure to loss is limited to the carrying value of the interest.

In the table above:

● The nature of our variable interest is described in the row under maximum exposure to loss.

● Our exposure to the obligations of the VIE is limited to our interest in the entity.

The primary purpose of our U.S-based, nonconsolidated VIE investments is to create strategic partnerships with market-leading providers of law enforcement technology solutions. We present all variable interests in unconsolidated VIEs as strategic investments within the long-term assets section of the condensed consolidated balance sheet.

We have provided financial support to the nonconsolidated VIEs in exchange for preferred equity as well as warrants and call options that give us the ability to commit additional capital overtime. Financial support provided to the nonconsolidated VIEs is used to continue to finance their operations. We have no explicit or implicit arrangements to provide additional financial support to the VIEs and we have no liabilities to the VIEs as of March 31, 2023 and December 31, 2022.

XML

Accrued Liabilities

3 Months Ended

Mar. 31, 2023

Accrued Liabilities

Accrued Liabilities

Note 8 - Accrued Liabilities

Accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Accrued salaries, benefits and bonus	$	63,975	$	97,882
Accrued professional, consulting and lobbying fees		6,840		3,861
Accrued warranty expense		3,301		811
Accrued income and other taxes		7,486		13,559
Accrued inventory in transit		11,318		10,548
Other accrued expenses		27,687		29,273
Accrued liabilities	$	120,607	$	155,934

XML

Convertible Senior Notes

3 Months Ended

Mar. 31, 2023

Convertible Senior Notes

Convertible Senior Notes

Note 9 – Convertible Senior Notes

2027 Notes

In December 2022, we issued $690.0 million aggregate principal amount of our 0.50% Convertible Senior Notes due 2027 in a private offering, which aggregate principal amount included the exercise in full of the initial purchasers’ option to purchase up to an additional $90.0 million principal amount of the Notes. The Notes mature on December 15, 2027 and bear interest at a fixed rate of 0.50% per annum, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023. The total net proceeds from the issuance of the Notes, after deducting initial purchasers' discounts and commissions and estimated debt issuance costs of $16.2 million, were approximately $673.8 million. The effective interest rate for the Notes was 0.99% and included interest payable and amortization of debt issuance cost.

If we undergo a fundamental change (as defined in the indenture governing the Notes), holders may require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, but excluding the fundamental change repurchase date. In addition, following certain corporate events or if we issue a notice of redemption, it will increase the conversion rate for holders who elect to convert their notes in connection with such corporate event or during the relevant redemption period.

The following table summarizes the carrying value of the Notes (in thousands):

	March 31, 2023		December 31, 2022
Principal	$	690,000	$	690,000
Unamortized debt issuance costs		(15,276)		(16,033)
Convertible notes carrying amount, net	$	674,724	$	673,967

We consider the fair value of the Notes to be a Level 2 measurement. The estimated fair value of the Notes at March 31, 2023 and December 31, 2022 is based on the closing trading price per $1,000 of the Notes as of the last day of trading for each period as follows (in millions):

	March 31, 2023		December 31, 2022
2027 Notes	$	812.3	$	687.3

Interest expense related to the Notes was as follows (in thousands):

	March 31, 2023		December 31, 2022
Contractual interest expense	$	863	$	211
Amortization of debt issuance costs		756		198
Total interest expense	$	1,619	$	409

Note Hedge

To reduce the impact of potential economic dilution upon conversion of the Notes, we entered into a convertible note hedge transaction (the “Note Hedge” or “2027 Note Hedge”) with certain investment banks, with respect to our common stock, concurrently with the issuance of the 2027 Notes.

	Purchase Price		Shares Purchased
2027 Note Hedge	$	194,994		3,016,680

The Note Hedge covers shares of our common stock at a strike price per share that corresponds to the initial conversion price of the respective Notes, subject to adjustment, and are exercisable upon conversion of the Notes. If exercised, we may elect to receive cash, shares of our common stock, or a combination of cash and shares. We have accounted for the aggregate amount of purchase price for the Note Hedge as a reduction to additional paid-in capital. The Note Hedge will expire upon the maturity of the Notes. The Note Hedge is intended to reduce the potential economic dilution upon conversion of the Notes in the event that the fair value per share of our common stock at the time of exercise is greater than the conversion price of the Notes. The Note Hedge is a separate transaction and is not part of the terms of the Notes. Holders of the Notes do not have any rights with respect to the Note Hedge. The Note Hedge does not impact earnings per share, as it was entered into to offset any dilution from the Notes. As of March 31, 2023, 3,016,680 shares remain subject to the Note Hedge.

Note Warrants

	Proceeds		Shares		Strike Price		First Expiration
2027 Warrants	$	124,269		3,016,680	$	338.86		March 15, 2028

Separately, we entered into warrant transactions with certain investment banks, whereby we sold warrants to acquire, subject to adjustment, the number of shares of our common stock shown in the table above. If the average market value per share of our common stock, on each expiration date exceeds the strike price of the Warrants expiring on that day, such Warrants would have a dilutive effect on our earnings per share to the extent we report net income. According to the terms of the Warrants, the Warrants will be automatically exercised over a 60-trading day period beginning on the first expiration date as set forth above.

XML

Income Taxes

3 Months Ended

Mar. 31, 2023

Income Taxes

Income Taxes

Note 10 - Income Taxes

We file income tax returns for federal purposes and in many states, as well as in multiple foreign jurisdictions. Our tax filings remain subject to examination by applicable tax authorities for a certain length of time, generally three to four years, but can be up to ten years in some jurisdictions following the tax year to which these filings relate.

Deferred Tax Assets

Net deferred income tax assets at March 31, 2023, primarily include R&D capitalization net of amortization, deferred revenue, convertible debt net of amortization, accruals and reserves, and stock-based compensation expense partially offset by accelerated depreciation expense, unrealized investment gains, and valuation allowance reserve. Our total net deferred tax assets at March 31, 2023 were $171.1 million.

In preparing our condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating our ability to recover our deferred income tax assets, management considers all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining our provision for income taxes, our deferred tax assets and liabilities, and our future taxable income for purposes of assessing our ability to utilize any future tax benefit from our deferred tax assets.

As of March 31, 2023, management continues to believe the positive evidence from projected future earnings outweighs the negative evidence and a valuation allowance is only needed on specific deferred tax assets. We have concluded that a valuation allowance is necessary against unrealized investment losses as well as transaction costs incurred in connection with certain investments. Additionally, we do have Arizona R&D tax credits expiring unutilized each year; therefore, management has concluded that it is more likely than not that our Arizona R&D deferred tax asset will not be realized, and a valuation allowance has been recorded against this net asset.

In Australia, we have determined that sufficient deferred tax liabilities will reverse in order to realize all assets except one long-lived intangible where there is not an expectation that the asset may be realized. Therefore, we continue to recognize a partial valuation allowance for Australia.

We complete R&D tax credit studies for each year that an R&D tax credit is claimed for federal and state income tax purposes. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $22.3 million as of March 31, 2023. Should the unrecognized benefit of $22.3 million be recognized, our effective tax rate would be favorably impacted. Approximately $5.0 million of the unrecognized tax benefit associated with R&D credits has been netted against the R&D deferred tax asset.

Effective Tax Rate

Our overall effective tax rate for the three months ended March 31, 2023, after discrete period adjustments, was -7.8%. Before discrete adjustments, the tax rate was 22.8%, which differs from the federal statutory rate, primarily due to the impact of R&D tax credits and a decrease in valuation allowance offset by the executive compensation limitation under Internal Revenue Code ("IRC") Section 162(m) and an increase in unrecognized tax benefits, on projected pre-tax income for the year. The effective tax rate was favorably impacted by a $13.0 million discrete tax benefit primarily associated with net windfalls related to stock-based compensation for restricted stock units (“RSUs”) and performance stock units (“PSUs”) that vested and stock options that were exercised during the three months ended March 31, 2023, primarily attributed to the vesting of tranche 10 of the XSPP in March 2023.  

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Stockholders' Equity

Stockholders' Equity

Note 11 - Stockholders’ Equity

CEO Performance Award

On May 24, 2018, our stockholders approved the Board of Directors’ grant of 6,365,856 stock option awards to Patrick W. Smith, our CEO (the “CEO Performance Award”). The CEO Performance Award consists of 12 vesting tranches with a vesting schedule based entirely on the attainment of both operational goals (performance conditions) and market capitalization goals (market conditions), assuming continued employment either as the CEO or as both Executive Chairman and Chief Product Officer and service through each attainment date. Each of the 12 vesting tranches of the CEO Performance Award have a 10-year contractual term and will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of the following eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA have been met for the previous four consecutive fiscal quarters. Adjusted EBITDA for purposes of the CEO Performance Award is defined as net income (loss) attributable to common stockholders before interest expense, interest and other income (such as dividends) earned on investments in marketable securities, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense.

Revenue Goal (1) (in thousands)	Achievement Status	Adjusted EBITDA (in thousands)	Achievement Status
Goal #1, $710,058	Achieved	Goal #1, $125,000	Achieved
Goal #2, $860,058	Achieved	Goal #2, $155,000	Achieved
Goal #3, $1,010,058	Achieved	Goal #3, $175,000	Achieved
Goal #4, $1,210,058	Achieved	Goal #4, $190,000	Achieved
Goal #5, $1,410,058	Not Applicable	Goal #5, $200,000	Achieved
Goal #6, $1,610,058	Not Applicable	Goal #6, $210,000	Achieved
Goal #7, $1,810,058	Not Applicable	Goal #7, $220,000	Achieved
Goal #8, $2,010,058	Not Applicable	Goal #8, $230,000	Achieved

(1) In connection with the business acquisition that was completed during the three months ended September 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement.

Stock-based compensation expense associated with the CEO Performance Award is recognized over the longer of the expected achievement period for each pair of market capitalization and operational goals, beginning at the point in time when the relevant operational goal is considered probable of being met. The probability of meeting an operational goal and the expected achievement point in time for meeting a probable operational goal are based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis. Even though no tranches of the CEO Performance Award vest unless a market capitalization and a matching operational goal are both achieved, stock-based compensation expense is recognized when an operational goal is considered probable of achievement regardless of whether a market capitalization goal is actually achieved. Stock-based compensation represents a non-cash expense and is recorded in sales, general, and administrative operating expense on our consolidated statements of operations and comprehensive income.

The first eleven market capitalization goals have been achieved as of March 31, 2023 while the final market capitalization goal was achieved in April 2023. As of March 31, 2023, 5.8 million stock options have been certified by the Compensation Committee and vested. As twelve operational goals have been achieved or are considered probable of achievement, we recorded stock-based compensation expense of $246.0 million related to the CEO Performance Award from the grant date through March 31, 2023, with no unamortized expense remaining. The number of stock options that are expected to vest upon certification by the Compensation Committee related to the remaining tranche is approximately 0.5 million shares.

On March 28, 2023, the Company's Board of Directors approved a new stock option grant to our CEO (the “2023 CEO Performance Award”), which is subject to shareholder approval at our upcoming Annual Meeting of Shareholders.  The 2023 CEO Performance Award will consist of 10 vesting tranches, each equal to 0.5% of the Company's outstanding common stock as of March 27, 2023, the business day prior to the date the award was approved by the Board of Directors. The stock options comprising the 2023 CEO Performance Award will have a per share exercise price equal to $218.59, which reflects the closing price for a share of the Company’s common stock as of the last trading day immediately preceding the grant date. The 2023 CEO Performance Award will not have a financial statement impact unless and until it is approved by shareholders at the Annual Meeting in May 2023.

eXponential Stock Performance Plan

On February 12, 2019, our shareholders approved the 2019 Stock Incentive Plan (the “2019 Plan”), which was adopted by the Board of Directors to reserve a sufficient number of shares to facilitate our eXponential Stock Performance Plan (“XSPP”) and grants of eXponential Stock Units (“XSUs”) under the plan. Initial awards under the plan were granted in January 2019, with additional employee awards granted since that date.

The XSUs are grants of Restricted Stock Units (“RSUs”), each with a term of approximately nine years, that vest in 12 equal tranches. Each of the 12 tranches will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA (CEO Performance Award) have been met for the previous four consecutive fiscal quarters. Beginning with the quarter ended June 30, 2021, new XSU grants are divided into a reduced number of tranches depending on employee eligibility and current market capitalization attainment.

The XSPP contains an anti-dilution provision incorporated into the plan based on shareholder feedback, which affects the calculation of the market capitalization goals in the plan. The plan defines a maximum number of shares outstanding that may be used in the calculation of the market capitalization goals (the “XSU Maximum”). If the actual number of shares outstanding exceeds the XSU Maximum guardrail, then the lower pre-defined number of shares in the XSU Maximum, rather than the higher actual number of shares outstanding, is used to calculate market capitalization for the determination of the market capitalization goals in the XSPP, which, together with the operational goals, determines whether XSUs vest for participating employees.

The XSU Maximum is defined as the actual number of shares outstanding on the original XSU grant date of January 2, 2019, increased by a 3% annual rate over the term of the XSPP and by shares issued upon the exercise of CEO Performance Award options. The XSU Maximum is also adjusted for acquisitions, spin-offs or other changes in the number of outstanding shares of common stock, if such changes have a corresponding adjustment on the market capitalization goals.

The market capitalization and operational goals are identical to the CEO Performance Award, but a different number of shares is used to calculate the market capitalization goals if shares outstanding exceed the XSU Maximum. Additionally, because the grant date is different than that of the CEO Performance Award, the measurement period for market capitalization is not identical. As of March 31, 2023, actual shares outstanding exceeded the XSU Maximum. Accordingly, market capitalization as calculated for the purposes of achieving additional goals uses the lower XSU Maximum share amount rather than actual shares outstanding.

The first ten market capitalization goals had been achieved as of March 31, 2023, and the final two market capitalization goals were achieved in April 2023. As all twelve operational goals have been achieved, we recorded stock-based compensation expense of $191.3 million related to the XSU awards from their respective grant dates through March 31, 2023. The number of XSU awards that would vest related to the remaining two tranches is approximately 0.8 million shares. As of March 31, 2023, we had $9.3 million of total unrecognized stock-based compensation expense, which will be recognized over a weighted-average period of 0.9 years.

Restricted Stock Units

The following table summarizes RSU activity for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,565	$	145.38
Granted	73		192.07
Released	(103)		135.31
Forfeited	(32)		152.72
Units outstanding, end of period	1,503		148.20	$	338,003

Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $224.85 multiplied by the number of RSUs outstanding. As of March 31, 2023, there was $176.3 million in unrecognized compensation costs related to RSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.2 years. RSUs are released when vesting requirements are met.

Certain RSUs that vested in the three months ended March 31, 2023 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to RSUs were approximately one thousand and had a value of $0.2 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital.

Performance Stock Units

The following table summarizes PSU activity, inclusive of XSUs, for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,369	$	43.43
Granted	—		—
Released	(401)		33.95
Forfeited	(12)		30.24
Units outstanding, end of period	956		47.58	$	214,939

Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $224.85 per share, multiplied by the number of PSUs outstanding. As of March 31, 2023, there was $12.3 million in unrecognized compensation costs related to PSUs under our stock plans for awards that are expected to vest. We expect to recognize the cost related to the PSUs over a weighted average period of 1.0 years. PSUs are released when vesting requirements are met.

Certain PSUs that vested in the three months ended March 31, 2023 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash

to the appropriate taxing authorities. Total shares withheld related to PSUs were 160 thousand and had a value of $34.7 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital.

Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2023 (number of options and aggregate intrinsic value in thousands):

				Weighted
		Weighted		Average
	Number	Average		Remaining
	of	Exercise		Contractual	Aggregate
	Options	Price		Life (years)	Intrinsic Value
Options outstanding, beginning of year	2,438	$	28.58
Granted	—		—
Exercised	(1,901)		—
Expired / terminated	—		—
Options outstanding, end of period	537		28.58	4.91	$	105,284
Options exercisable, end of period	6		28.58	4.91		1,165

Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock of $224.85 on March 31, 2023.

Of the total stock options exercised during the three months ended March 31, 2023, 0.9 million were immediately sold to cover the exercise price and the option holder’s tax obligation for the applicable income and other employment taxes. As of March 31, 2023, total options outstanding included 0.5 million unvested performance-based stock options, which relate to the CEO Performance Award and are probable of achievement.

Stock-based Compensation Expense

The following table summarizes the composition of stock-based compensation expense for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Cost of product sales and service sales	$	1,320	$	1,108
Sales, general and administrative expenses		15,445		12,982
Research and development expenses		17,585		10,998
Total stock-based compensation expense	$	34,350	$	25,088

Stock Incentive Plan

In May 2022, our shareholders approved the Axon Enterprise, Inc. 2022 Stock Incentive Plan (the “2022 Plan”) authorizing an additional 2.5 million shares, plus remaining available shares under prior plans, for issuance under the new plan. Combined with the 2019 Plan and other legacy stock incentive plans, there are 2.7 million shares available for grant as of March 31, 2023.

Stock Repurchase Plan

In February 2016, our Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of our outstanding common stock subject to stock market conditions and corporate considerations. During the three months ended March 31, 2023 and 2022, no common shares were purchased under the program. As of March 31, 2023, $16.3 million remains available under the plan for future purchases. Any future purchases will be discretionary.

At-the-Market equity offering

During the three months ended March 31, 2023, we sold 154,500 shares of our common stock under our "at-the-market" equity offering program (the “ATM”). We generated approximately $34.2 million in aggregate gross proceeds from sales under the ATM.  Aggregate net proceeds from the ATM were $33.7 million after deducting related expenses, including commissions to the sales agent and issuance costs of $0.5 million.

We may sell up to a total of 3.0 million shares of our common stock under the ATM, with 2.3 million shares remaining as of March 31, 2023. The ATM expires on April 20, 2024. We intend to use the net proceeds from this offering for general corporate purposes, which may include, among other things, providing capital to satisfy a portion of the tax obligations related to the vesting and settlement of stock compensation awards granted to our executive officers and other employees under our stock incentive plans, to support our growth, and to acquire or invest in product lines, products, services, technologies or facilities.

XML

Line of Credit

3 Months Ended

Mar. 31, 2023

Line of Credit.

Line of Credit

Note 12 - Line of Credit

In December 2022, we entered into a Credit Agreement that provides for a senior unsecured multi-currency revolving credit facility in an aggregate principal amount of up to $200.0 million, $30.0 million of which is available for the issuance of letters of credit. The credit agreement will mature on the earlier of December 15, 2027 or the date that is six months prior to the stated maturity date of the 0.50% convertible senior notes due 2027 unless such Notes have been redeemed, repurchased, converted or defeased in full. Additionally, the credit agreement has an accordion feature which allows for an increase in the total line of credit up to $300.0 million, subject to each lender’s sole discretion.

At March 31, 2023 and December 31, 2022, there were no borrowings under the line. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of March 31, 2023 we had letters of credit outstanding of approximately $7.0 million under the facility and available borrowing of $193.0 million, excluding amounts available under the accordion feature. Advances under the line of credit bear interest at Term SOFR plus 1.25 to 1.75% per year determined in accordance with a pricing grid based on our net debt to earnings before interest expense, taxes, depreciation and amortization ("EBITDA") ratio. EBITDA for the purposes of the credit agreement excludes investment interest income.

We are required to comply with a net leverage ratio, defined as consolidated total indebtedness to EBITDA, of no greater than 3.50 to 1.00 based upon a trailing four fiscal quarter period. At March 31, 2023, our leverage ratio was 0.78 to 1.00. Additionally, we must comply with a consolidated interest coverage ratio, defined as EBITDA to consolidated interest expense, of no less than 3.50 to 1.00 based upon a trailing four fiscal quarter end. We are compliant with the consolidated interest coverage ratio, which is not meaningful for the three months ended March 31, 2023.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies.

Commitments and Contingencies

Note 13 - Commitments and Contingencies

Product Litigation

As a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products.  We are currently named as a defendant in four lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn.  They seek compensatory and sometimes punitive damages, often in unspecified amounts.

We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results

of operations, or cash flows. We are self-insured for the first $5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period.

The litigation information in this note is current through the date of these financial statements.

U.S. Federal Trade Commission Litigation

The U.S. Federal Trade Commission (“FTC”) filed an administrative enforcement action in January 2020 regarding our May 2018 acquisition of an insolvent body worn camera competitor, Vievu LLC. The FTC alleges the merger was anticompetitive and adversely affected the body worn camera and digital evidence management market for “large metropolitan police departments,” which we deny. The administrative hearing is presently stayed pending our federal court constitutional challenges to the FTC’s structure. Even if we ultimately are required to divest Vievu and other assets, we do not expect that any such result will interfere with our ability to meet contractual obligations or implement our solutions.

Prior to the FTC’s enforcement action, on January 3, 2020 we sued the FTC in federal court in the District of Arizona for declaratory and injunctive relief alleging the FTC’s structure is unconstitutional. The district court dismissed the action, without prejudice, for lack of jurisdiction and the Ninth Circuit affirmed in a split decision. The U.S. Supreme Court granted our petition for certiorari in January 2022 and heard oral argument on November 7, 2022. On April 17, 2023, the Supreme Court issued a unanimous decision in Axon’s favor, confirming district court jurisdiction for constitutional challenges to the structure and existence of federal agencies like the FTC. The case will be remanded to district court for further proceedings on the merits of Axon’s claims.    

As always, we are open to evaluating strategic alternatives to litigation if achievable on terms agreeable to the FTC and Axon and determined to be in the best interests of shareholders and customers.

General

From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time.

Based on our assessment of outstanding litigation and claims as of the date of these financial statements, we have determined that it is not reasonably probable that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

Off-Balance Sheet Arrangements

Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At March 31, 2023, we had outstanding letters of credit issued under our credit facility

of $7.0 million that are expected to expire throughout 2023 and 2024. Additionally, we had $14.0 million of outstanding surety bonds at March 31, 2023, with $3.5 million expiring in 2023 and $10.5 million expiring in 2024.

XML

Accumulated Other Comprehensive Income (loss)

3 Months Ended

Mar. 31, 2023

Accumulated Other Comprehensive Income (loss).

Accumulated Other Comprehensive Income (loss)

Note 14 – Accumulated Other Comprehensive Income (loss)

The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands):

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2022	$	(1,251)	$	(5,928)	$	(7,179)
Other comprehensive income		184		1,676		1,860
Balance, March 31, 2023	$	(1,067)	$	(4,252)	$	(5,319)

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2021	$	(207)	$	(1,110)	$	(1,317)
Other comprehensive loss		(489)		(1,072)		(1,561)
Balance, March 31, 2022	$	(696)	$	(2,182)	$	(2,878)

XML

Segment Data

3 Months Ended

Mar. 31, 2023

Segment Data

Segment Data

Note 15 - Segment Data

Our operations comprise two reportable segments: the TASER segment and the Software and Sensors segment.

Information relative to our reportable segments was as follows (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
Net sales from products	$	127,081	$	92,308	$	219,389	$	111,154	$	65,050	$	176,204
Net sales from services		7,201		116,453		123,654		3,206		77,016		80,222
Net sales		134,282		208,761		343,043		114,360		142,066		256,426
Cost of product sales		50,583		57,001		107,584		40,625		38,727		79,352
Cost of service sales		180		31,177		31,357		—		21,335		21,335
Cost of sales		50,763		88,178		138,941		40,625		60,062		100,687
Gross margin	$	83,519	$	120,583	$	204,102	$	73,735	$	82,004	$	155,739
Research and development	$	16,080	$	54,847	$	70,927	$	9,896	$	38,520	$	48,416

XML

Organization and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Organization and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2022, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2022. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:

● product warranty reserves,

● inventory valuation,

● revenue recognition,

● reserve for expected credit loss,

● valuation of goodwill, intangible and long-lived assets,

● valuation of strategic investments,

● recognition, measurement and valuation of current and deferred income taxes,

● stock-based compensation, and

● recognition and measurement of contingencies and accrued litigation expense.

Actual results could differ materially from those estimates.

Segment Information

Segment Information

Our operations comprise two reportable segments: the development, manufacture and sale of fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share and analyze video and other digital evidence (collectively, the "Software and Sensors" segment); and the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (collectively, the “TASER” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform

an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 15.

Geographic Information and Major Customers / Suppliers

Geographic Information and Major Customers / Suppliers

For the three months ended March 31, 2023, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three months ended March 31, 2023, no customer represented more than 10% of total net sales. At March 31, 2023 and December 31, 2022, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets.

We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., China, Republic of Korea, Malaysia, Mexico, Sri Lanka, Taiwan, and Vietnam. We may source from other countries as well. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases. Although we have experienced supply chain disruptions relating to materials and port constraints, we have remained focused on closely managing our supply chain. We continue to bolster our strategic relationships in our supply chain, identifying secondary/alternate sourcing, adjusting build plans accordingly, and building in logistic modes in support of our increasing demand while working to minimize disruption to customers. We acquire most of our components on a purchase order basis and do not currently have significant long-term purchase contracts with most component suppliers.

Income per Common Share

Income per Common Share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The effects of outstanding stock options, unvested restricted stock units, our 2027 convertible senior notes (the “Notes” or “2027 Notes”), and warrants to acquire the number of shares of our common stock (the “Warrants” or “2027 Warrants”) are excluded from the computation of diluted net income per share in periods in which the effect would be antidilutive. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator for basic and diluted earnings per share:
Net income	$	45,139	$	54,871
Denominator:
Weighted average shares outstanding		72,638		70,950
Dilutive effect of stock-based awards		1,242		1,399
Diluted weighted average shares outstanding		73,880		72,349
Net income per common share:
Basic	$	0.62	$	0.77
Diluted	$	0.61	$	0.76

Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Stock-based awards		1,469		2,942
2027 Notes		3,017		—
2027 Warrants		3,017		—
Total potentially dilutive securities		7,503		2,942

For additional information regarding our convertible senior notes, refer to Note 9.

Standard Warranties

Standard Warranties

We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated on a quarterly basis based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying consolidated balance sheets.

Changes in our estimated product warranty liabilities were as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Balance, beginning of period	$	811	$	2,822
Utilization of reserve		(438)		(1,434)
Warranty expense		2,928		116
Balance, end of period	$	3,301	$	1,504

Fair Value Measurements and Financial Instruments

Fair Value Measurements and Financial Instruments

We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.

● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.

● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability.

We have cash equivalents and investments, which at March 31, 2023 comprised money market funds, commercial paper, corporate bonds, term deposits, U.S. Government bonds, municipal bonds, agency bonds and U.S. Treasury inflation-protected securities. Cash equivalents and investments at December 31, 2022 also included certificates of deposit and U.S. Treasury bills. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other long-term assets as of March 31, 2023 and December 31, 2022 was $5.1 million and $4.3 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.

We have an investment in marketable securities, for which changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net.

We have strategic investments in eight unconsolidated affiliates as of March 31, 2023. The estimated fair value of the investments was determined based on Level 3 inputs. In determining the estimated fair value of our strategic investments in privately held companies, we utilize observable data available to us as discussed further in Note 6.

We have convertible senior notes, for which the fair value is determined based on the closing trading price per $1,000 of the Notes as of the last day of trading for the period. We consider the fair value of the Notes at March 31, 2023 to be a Level 2 measurement as they are not publicly traded. The fair value of the Notes is primarily affected by the trading price of our common stock and market interest rates.

Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the condensed consolidated balance sheet.

Restricted Cash

Restricted Cash

Restricted cash balances were $1.9 million as of March 31, 2023 and December 31, 2022, respectively. The balances were primarily related to funds held in an international bank account securing a guarantee and funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately $1.8 million was included in prepaid expenses and other assets on our condensed consolidated balance sheet, with the remainder in other long-term assets.

Valuation of Goodwill, Intangibles and Long-lived Assets

Valuation of Goodwill, Intangibles and Long-lived Assets

We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.

We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year.

Reclassification of Prior Year Presentation

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

XML

Organization and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Organization and Summary of Significant Accounting Policies

Schedule of weighted average number of shares outstanding and earnings per share

The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator for basic and diluted earnings per share:
Net income	$	45,139	$	54,871
Denominator:
Weighted average shares outstanding		72,638		70,950
Dilutive effect of stock-based awards		1,242		1,399
Diluted weighted average shares outstanding		73,880		72,349
Net income per common share:
Basic	$	0.62	$	0.77
Diluted	$	0.61	$	0.76

Schedule of potentially dilutive securities excluded in calculation of diluted net income per share

Potentially dilutive securities that are not included in the calculation of diluted net income per share because doing so would be antidilutive are as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Stock-based awards		1,469		2,942
2027 Notes		3,017		—
2027 Warrants		3,017		—
Total potentially dilutive securities		7,503		2,942

Summary of changes in our estimated warranty reserve

Changes in our estimated product warranty liabilities were as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Balance, beginning of period	$	811	$	2,822
Utilization of reserve		(438)		(1,434)
Warranty expense		2,928		116
Balance, end of period	$	3,301	$	1,504

XML

Revenues (Tables)

3 Months Ended

Mar. 31, 2023

Revenues.

Summary of Revenue by Product and Service Offering and Geography

The following tables present our revenues by primary product and service offering (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
TASER Devices (Professional)	$	67,472	$	—	$	67,472	$	63,164	$	—	$	63,164
Cartridges		46,800		—		46,800		37,825		—		37,825
Axon Evidence and Cloud Services		7,201		118,314		125,515		3,017		79,939		82,956
Extended Warranties		7,670		14,085		21,755		6,679		9,061		15,740
Axon Body Cameras and Accessories		—		38,797		38,797		—		38,517		38,517
Axon Fleet Systems		—		32,972		32,972		—		13,820		13,820
Other (1) (2)		5,139		4,593		9,732		3,675		729		4,404
Total	$	134,282	$	208,761	$	343,043	$	114,360	$	142,066	$	256,426

(1) TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.

(2) Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room and Axon Air.

The following table presents our revenues disaggregated by geography (in thousands):

	Three Months Ended March 31,
	2023				2022
United States	$	290,938	85	%	$	214,214	84	%
Other countries		52,105	15			42,212	16
Total	$	343,043	100	%	$	256,426	100	%

Summary of contract with customer, assets and liabilities

The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the three months ended March 31, 2023 (in thousands):

	March 31, 2023
Contract assets, net	$	271,755
Contract liabilities (deferred revenue)		658,427
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period		133,707

Contract liabilities (deferred revenue) consisted of the following (in thousands):

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
Warranty:
TASER	$	13,333	$	18,198	$	31,531	$	14,207	$	17,618	$	31,825
Software and Sensors		28,105		15,467		43,572		26,229		15,338		41,567
		41,438		33,665		75,103		40,436		32,956		73,392
Hardware:
TASER		46,575		16,896		63,471		49,361		12,640		62,001
Software and Sensors		61,554		106,398		167,952		50,426		109,227		159,653
		108,129		123,294		231,423		99,787		121,867		221,654
Services:
TASER		6,016		9,425		15,441		7,637		9,501		17,138
Software and Sensors		252,478		83,982		336,460		212,177		83,679		295,856
		258,494		93,407		351,901		219,814		93,180		312,994
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

	March 31, 2023						December 31, 2022
	Current		Long-Term		Total		Current		Long-Term		Total
TASER	$	65,924	$	44,519	$	110,443	$	71,205	$	39,759	$	110,964
Software and Sensors		342,137		205,847		547,984		288,832		208,244		497,076
Total	$	408,061	$	250,366	$	658,427	$	360,037	$	248,003	$	608,040

XML

Cash, Cash Equivalents and Investments (Tables)

3 Months Ended

Mar. 31, 2023

Cash, Cash Equivalents and Investments

Summary of Cash, Cash Equivalents, Marketable Securities, and Available-for-Sale Investments

The following tables summarize our cash, cash equivalents, marketable securities, and available-for-sale investments at March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	213,446	$	—	$	—	$	213,446	$	213,446	$	—	$	—	$	—
Level 1:
Money market funds		49,968		—		—		49,968		49,968		—		—		—
Agency bonds		160,615		39		(230)		160,424		—		—		154,688		5,736
Treasury bills		41,079		6		(2)		41,083		—		—		41,083		—
Marketable securities		90,000		—		(35,190)		54,810		—		54,810		—		—
Subtotal		341,662		45		(35,422)		306,285		49,968		54,810		195,771		5,736
Level 2:
State and municipal obligations		3,026		—		(14)		3,012		—		—		3,012		—
Term deposits		175,000		—		—		175,000		—		—		175,000		—
Corporate bonds		241,401		45		(1,081)		240,365		—		—		226,468		13,897
U.S. government		43,948		—		(158)		43,790		—		—		32,307		11,483
Treasury inflation-protected securities		2,525		17		—		2,542		—		—		2,542		—
Commercial paper		140,029		—		—		140,029		—		—		140,029		—
Subtotal		605,929		62		(1,253)		604,738		—		—		579,358		25,380
Total	$	1,161,037	$	107	$	(36,675)	$	1,124,469	$	263,414	$	54,810	$	775,129	$	31,116

	As of December 31, 2022
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	143,744	$	—	$	—	$	143,744	$	143,744	$	—	$	—	$	—
Level 1:
Money market funds		2,669		—		—		2,669		2,669		—		—		—
Agency bonds		164,486		6		(263)		164,229		—		—		69,862		94,367
Treasury bills		121,650		18		(3)		121,665		113,100		—		8,565		—
Marketable securities		90,000		—		(50,760)		39,240		—		39,240		—		—
Subtotal		378,805		24		(51,026)		327,803		115,769		39,240		78,427		94,367
Level 2:
State and municipal obligations		4,980		—		(33)		4,947		—		—		4,947		—
Certificate of deposits		5,002		—		—		5,002		—		—		5,002		—
Term deposits		200,000		—		—		200,000		25,000		—		175,000		—
Corporate bonds		257,422		33		(1,159)		256,296		28,883		—		168,074		59,339
U.S. Government		30,525		—		(159)		30,366		—		—		30,366		—
Treasury inflation-protected securities		2,503		—		(2)		2,501		—		—		—		2,501
Commercial paper		160,241		—		—		160,241		40,288		—		119,953		—
Subtotal		660,673		33		(1,353)		659,353		94,171		—		503,342		61,840
Total	$	1,183,222	$	57	$	(52,379)	$	1,130,900	$	353,684	$	39,240	$	581,769	$	156,207

XML

Expected Credit Losses (Tables)

3 Months Ended

Mar. 31, 2023

Expected Credit Losses

Schedule of roll-forward of allowance for credit losses

The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands):

	Three Months Ended March 31, 2023
	United States		Other countries		Total
Balance, beginning of period	$	3,064	$	566	$	3,630
Provision for expected credit losses		(76)		104		28
Amounts written off charged against the allowance		(353)		(5)		(358)
Balance, end of period	$	2,635	$	665	$	3,300

Schedule of allowance for expected credit losses for each type of customer receivable

As of March 31, 2023 and December 31, 2022, the allowance for expected credit losses for each type of customer receivable was as follows (in thousands):

	March 31, 2023		December 31, 2022
Accounts receivable and notes receivable, current	$	2,029	$	2,176
Contract assets, net		1,211		1,360
Long-term notes receivable, net of current portion		60		94
Total allowance for expected credit losses on customer receivables	$	3,300	$	3,630

XML

Inventory (Tables)

3 Months Ended

Mar. 31, 2023

Inventory

Inventory

Inventory consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Raw materials	$	86,607	$	72,740
Finished goods		133,661		129,731
Total inventory	$	220,268	$	202,471

XML

Strategic Investments (Tables)

3 Months Ended

Mar. 31, 2023

Strategic Investments

Schedule of Roll-Forward of Strategic Investments

The following tables provide a roll-forward of the balance of strategic investments (in thousands):

	Three Months Ended March 31, 2023								Three Months Ended March 31, 2022
	Strategic investments		Warrants			Call options	Total		Strategic investments		Warrants			Total
Balance, beginning of period	$	277,676	$	1,654	$	17,233	$	296,563	$	80,775	$	2,745	$	83,520
Investments		—		—		—		—		500		—		500
Observable price changes:
Unrealized gains		—		—		—		—		41,893		28,539		70,432
Unrealized losses		—		—		—		—		—		—		—
Exercises		—		—		—		—		—		—		—
Sales		—		—		—		—		—		—		—
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563	$	123,168	$	31,284	$	154,452

	Inception to date
	Strategic investments		Warrants			Call options	Total
Investments	$	109,482	$	3,047	$	17,233	$	129,762
Observable price changes:
Realized gains		12,312		—		—		12,312
Unrealized gains		74,817		29,073		—		103,890
Unrealized losses		(1,108)		(377)		—		(1,485)
Exercises		96,719		(30,089)		—		66,630
Sales		(14,546)		—		—		(14,546)
Balance, end of period	$	277,676	$	1,654	$	17,233	$	296,563

XML

Variable Interest Entities (Tables)

3 Months Ended

Mar. 31, 2023

Variable Interest Entities

Schedule of the nonconsolidated VIEs

	March 31, 2023		December 31, 2022
Total nonconsolidated variable interest entities:
Carrying value of variable interest - assets	$	11,530	$	11,530
Carrying value of variable interest - liabilities		—		—
Maximum exposure to loss:
Non-public equity (1)		11,530		11,530
Total	$	11,530	$	11,530

⁽¹⁾ The maximum exposure to loss is limited to the carrying value of the interest.

XML

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2023

Accrued Liabilities

Schedule of Accrued liabilities

Accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Accrued salaries, benefits and bonus	$	63,975	$	97,882
Accrued professional, consulting and lobbying fees		6,840		3,861
Accrued warranty expense		3,301		811
Accrued income and other taxes		7,486		13,559
Accrued inventory in transit		11,318		10,548
Other accrued expenses		27,687		29,273
Accrued liabilities	$	120,607	$	155,934

XML

Convertible Senior Notes (Tables)

3 Months Ended

Mar. 31, 2023

Convertible Senior Notes

Schedule of net carrying amount of convertible senior notes

	March 31, 2023		December 31, 2022
Principal	$	690,000	$	690,000
Unamortized debt issuance costs		(15,276)		(16,033)
Convertible notes carrying amount, net	$	674,724	$	673,967

	March 31, 2023		December 31, 2022
2027 Notes	$	812.3	$	687.3

Schedule of interest expense of convertible senior notes

	March 31, 2023		December 31, 2022
Contractual interest expense	$	863	$	211
Amortization of debt issuance costs		756		198
Total interest expense	$	1,619	$	409

Schedule of convertible note hedge transaction

	Purchase Price		Shares Purchased
2027 Note Hedge	$	194,994		3,016,680

Schedule of warrants details of convertible senior notes

	Proceeds		Shares		Strike Price		First Expiration
2027 Warrants	$	124,269		3,016,680	$	338.86		March 15, 2028

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Stockholders' Equity

Equity Compensation Goals

Revenue Goal (1) (in thousands)	Achievement Status	Adjusted EBITDA (in thousands)	Achievement Status
Goal #1, $710,058	Achieved	Goal #1, $125,000	Achieved
Goal #2, $860,058	Achieved	Goal #2, $155,000	Achieved
Goal #3, $1,010,058	Achieved	Goal #3, $175,000	Achieved
Goal #4, $1,210,058	Achieved	Goal #4, $190,000	Achieved
Goal #5, $1,410,058	Not Applicable	Goal #5, $200,000	Achieved
Goal #6, $1,610,058	Not Applicable	Goal #6, $210,000	Achieved
Goal #7, $1,810,058	Not Applicable	Goal #7, $220,000	Achieved
Goal #8, $2,010,058	Not Applicable	Goal #8, $230,000	Achieved

(1) In connection with the business acquisition that was completed during the three months ended September 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement.

Summary of Restricted Stock Unit Activity

The following table summarizes RSU activity for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,565	$	145.38
Granted	73		192.07
Released	(103)		135.31
Forfeited	(32)		152.72
Units outstanding, end of period	1,503		148.20	$	338,003

Summary of Performance Stock Unit Activity

The following table summarizes PSU activity, inclusive of XSUs, for the three months ended March 31, 2023 (number of units and aggregate intrinsic value in thousands):

	Number of	Weighted Average		Aggregate
	Units	Grant-Date Fair Value		Intrinsic Value
Units outstanding, beginning of year	1,369	$	43.43
Granted	—		—
Released	(401)		33.95
Forfeited	(12)		30.24
Units outstanding, end of period	956		47.58	$	214,939

Summary of the Company's Stock Options Activity

The following table summarizes stock option activity for the three months ended March 31, 2023 (number of options and aggregate intrinsic value in thousands):

				Weighted
		Weighted		Average
	Number	Average		Remaining
	of	Exercise		Contractual	Aggregate
	Options	Price		Life (years)	Intrinsic Value
Options outstanding, beginning of year	2,438	$	28.58
Granted	—		—
Exercised	(1,901)		—
Expired / terminated	—		—
Options outstanding, end of period	537		28.58	4.91	$	105,284
Options exercisable, end of period	6		28.58	4.91		1,165

Reported Share-Based Compensation

The following table summarizes the composition of stock-based compensation expense for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Cost of product sales and service sales	$	1,320	$	1,108
Sales, general and administrative expenses		15,445		12,982
Research and development expenses		17,585		10,998
Total stock-based compensation expense	$	34,350	$	25,088

XML

Accumulated Other Comprehensive Income (loss) (Tables)

3 Months Ended

Mar. 31, 2023

Accumulated Other Comprehensive Income (loss).

Summary of changes in accumulated other comprehensive income (loss), net of tax

The following tables reflect the changes in accumulated other comprehensive income (loss), net of tax (in thousands):

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2022	$	(1,251)	$	(5,928)	$	(7,179)
Other comprehensive income		184		1,676		1,860
Balance, March 31, 2023	$	(1,067)	$	(4,252)	$	(5,319)

		Unrealized Gains (Losses)
		on Available-for-Sale		Foreign Currency
		Investments		Translation	Total
Balance, December 31, 2021	$	(207)	$	(1,110)	$	(1,317)
Other comprehensive loss		(489)		(1,072)		(1,561)
Balance, March 31, 2022	$	(696)	$	(2,182)	$	(2,878)

XML

Segment Data (Tables)

3 Months Ended

Mar. 31, 2023

Segment Data

Summary of Operational Information Relative to the Company's Reportable Segments

Information relative to our reportable segments was as follows (in thousands):

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
			Software and						Software and
	TASER		Sensors		Total		TASER		Sensors		Total
Net sales from products	$	127,081	$	92,308	$	219,389	$	111,154	$	65,050	$	176,204
Net sales from services		7,201		116,453		123,654		3,206		77,016		80,222
Net sales		134,282		208,761		343,043		114,360		142,066		256,426
Cost of product sales		50,583		57,001		107,584		40,625		38,727		79,352
Cost of service sales		180		31,177		31,357		—		21,335		21,335
Cost of sales		50,763		88,178		138,941		40,625		60,062		100,687
Gross margin	$	83,519	$	120,583	$	204,102	$	73,735	$	82,004	$	155,739
Research and development	$	16,080	$	54,847	$	70,927	$	9,896	$	38,520	$	48,416

XML

Organization and Summary of Significant Accounting Policies - Narrative (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($) customer item country segment	Dec. 31, 2022 USD ($) customer
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment	2
Warranty period	1 year
Cash surrender value of corporate-owned life insurance policies	$ 5,100,000	$ 4,300,000
Investments in number of unconsolidated affiliates | item	8
Denomination of notes used for determination of fair value	$ 1,000
Restricted cash balance	1,900,000	$ 1,900,000
Prepaid expenses and other assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash balance	1,800,000
Other long-term assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash balance	$ 100,000
Net Sales | Geographic Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of countries outside the U.S. representing more than 10% of total net sales | country	0
Net Sales | Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of major customers | customer	0
Accounts and notes receivable and contract assets | Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of major customers | customer	0	0

XML

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator for basic and diluted earnings per share:
Net income	$ 45,139	$ 54,871
Denominator:
Weighted average shares outstanding - basic (in shares)	72,638	70,950
Dilutive effect of stock-based awards (in shares)	1,242	1,399
Diluted weighted average shares outstanding (in shares)	73,880	72,349
Net income per common share:
Basic (in dollars per share)	$ 0.62	$ 0.77
Diluted (in dollars per share)	$ 0.61	$ 0.76

XML

Organization and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of EPS (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive securities excluded from computation of earnings per share
Total potentially dilutive securities	7,503	2,942
Stock-based awards
Antidilutive securities excluded from computation of earnings per share
Total potentially dilutive securities	1,469	2,942
2027 Notes
Antidilutive securities excluded from computation of earnings per share
Total potentially dilutive securities	3,017
2027 Warrants
Antidilutive securities excluded from computation of earnings per share
Total potentially dilutive securities	3,017

XML

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Warranty Reserve (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Standard and Extended Product Warranty
Balance, beginning of period	$ 811	$ 2,822
Utilization of reserve	(438)	(1,434)
Warranty expense	2,928	116
Balance, end of period	$ 3,301	$ 1,504

XML

Revenues - Revenues By Products And Service Offerings (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 343,043	$ 256,426
TASER Devices (Professional)
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	67,472	63,164
Cartridges
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	46,800	37,825
Axon Evidence and cloud services
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	125,515	82,956
Extended warranties
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	21,755	15,740
Axon Body and Camera Accessories
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	38,797	38,517
Axon Fleet Systems
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	32,972	13,820
Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	9,732	4,404
TASER
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	134,282	114,360
TASER | TASER Devices (Professional)
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	67,472	63,164
TASER | Cartridges
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	46,800	37,825
TASER | Axon Evidence and cloud services
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	7,201	3,017
TASER | Extended warranties
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	7,670	6,679
TASER | Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	5,139	3,675
Software and Sensors
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	208,761	142,066
Software and Sensors | Axon Evidence and cloud services
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	118,314	79,939
Software and Sensors | Extended warranties
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	14,085	9,061
Software and Sensors | Axon Body and Camera Accessories
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	38,797	38,517
Software and Sensors | Axon Fleet Systems
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	32,972	13,820
Software and Sensors | Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 4,593	$ 729

XML

Revenues - Revenues By Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 343,043	$ 256,426
United States
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	290,938	214,214
Other countries
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 52,105	$ 42,212
Revenue from Contract with Customer | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	100.00%	100.00%
Revenue from Contract with Customer | Geographic Concentration Risk | United States
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	85.00%	84.00%
Revenue from Contract with Customer | Geographic Concentration Risk | Other countries
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	15.00%	16.00%

XML

Revenues - Contract Assets, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Revenues.
Contract assets, net	$ 271,755
Contract liabilities (deferred revenue)	658,427	$ 608,040
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period	$ 133,707

XML

Revenues - Schedule Of Contract Liabilities - Deferred revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Current	$ 408,061	$ 360,037
Long-Term	250,366	248,003
Total	658,427	608,040
TASER
Disaggregation of Revenue [Line Items]
Current	65,924	71,205
Long-Term	44,519	39,759
Total	110,443	110,964
Software and Sensors
Disaggregation of Revenue [Line Items]
Current	342,137	288,832
Long-Term	205,847	208,244
Total	547,984	497,076
Warranty
Disaggregation of Revenue [Line Items]
Current	41,438	40,436
Long-Term	33,665	32,956
Total	75,103	73,392
Warranty | TASER
Disaggregation of Revenue [Line Items]
Current	13,333	14,207
Long-Term	18,198	17,618
Total	31,531	31,825
Warranty | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	28,105	26,229
Long-Term	15,467	15,338
Total	43,572	41,567
Hardware
Disaggregation of Revenue [Line Items]
Current	108,129	99,787
Long-Term	123,294	121,867
Total	231,423	221,654
Hardware | TASER
Disaggregation of Revenue [Line Items]
Current	46,575	49,361
Long-Term	16,896	12,640
Total	63,471	62,001
Hardware | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	61,554	50,426
Long-Term	106,398	109,227
Total	167,952	159,653
Services
Disaggregation of Revenue [Line Items]
Current	258,494	219,814
Long-Term	93,407	93,180
Total	351,901	312,994
Services | TASER
Disaggregation of Revenue [Line Items]
Current	6,016	7,637
Long-Term	9,425	9,501
Total	15,441	17,138
Services | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	252,478	212,177
Long-Term	83,982	83,679
Total	$ 336,460	$ 295,856

XML

Revenues - Revenue Performance Obligations (Details) $ in Billions	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 4.8
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage)	15.00%
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage)	25.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2033-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	10 years

XML

Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$ 1,161,037	$ 1,183,222
Gross Unrealized Gains	107	57
Gross Unrealized Losses	(36,675)	(52,379)
Fair Value	1,124,469	1,130,900
Cash and Cash Equivalents	263,414	353,684
Marketable Securities	54,810	39,240
Short-Term Investments	775,129	581,769
Long-Term Investments	31,116	156,207
Debt securities, available-for-sale, unrealized Loss	375,600
Continuous unrealized loss position of available-for-sale investments, unrealized losses	17,600
Continuous unrealized loss position of available-for-sale investments, gross unrealized losses	600
Share Purchase Agreement with CLBT
Restricted Cash and Cash Equivalents Items [Line Items]
Marketable securities, unrealized gain (loss)	15,600
Common stock | Share Purchase Agreement with CLBT
Restricted Cash and Cash Equivalents Items [Line Items]
Marketable Securities			$ 90,000
Investment owned, shares held			9,000,000
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	341,662	378,805
Gross Unrealized Gains	45	24
Gross Unrealized Losses	(35,422)	(51,026)
Fair Value	306,285	327,803
Cash and Cash Equivalents	49,968	115,769
Marketable Securities	54,810	39,240
Short-Term Investments	195,771	78,427
Long-Term Investments	5,736	94,367
Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	605,929	660,673
Gross Unrealized Gains	62	33
Gross Unrealized Losses	(1,253)	(1,353)
Fair Value	604,738	659,353
Cash and Cash Equivalents		94,171
Short-Term Investments	579,358	503,342
Long-Term Investments	25,380	61,840
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	213,446	143,744
Fair Value	213,446	143,744
Cash and Cash Equivalents	213,446	143,744
Money market funds | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	49,968	2,669
Fair Value	49,968	2,669
Cash and Cash Equivalents	49,968	2,669
Agency bonds | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	160,615	164,486
Gross Unrealized Gains	39	6
Gross Unrealized Losses	(230)	(263)
Fair Value	160,424	164,229
Short-Term Investments	154,688	69,862
Long-Term Investments	5,736	94,367
Treasury bills | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	41,079
Gross Unrealized Gains	6
Gross Unrealized Losses	(2)
Fair Value	41,083
Short-Term Investments	41,083
Marketable securities | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	90,000	90,000
Gross Unrealized Losses	(35,190)	(50,760)
Fair Value	54,810	39,240
Marketable Securities	54,810	39,240
State and municipal obligations | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	3,026	4,980
Gross Unrealized Losses	(14)	(33)
Fair Value	3,012	4,947
Short-Term Investments	3,012	4,947
Corporate bonds | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost		257,422
Gross Unrealized Gains		33
Gross Unrealized Losses		(1,159)
Fair Value		256,296
Cash and Cash Equivalents		28,883
Short-Term Investments		168,074
Long-Term Investments		59,339
Treasury bills | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost		121,650
Gross Unrealized Gains		18
Gross Unrealized Losses		(3)
Fair Value		121,665
Cash and Cash Equivalents		113,100
Short-Term Investments		8,565
Certificates of deposit | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost		5,002
Fair Value		5,002
Short-Term Investments		5,002
Term deposits | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	175,000	200,000
Fair Value	175,000	200,000
Cash and Cash Equivalents		25,000
Short-Term Investments	175,000	175,000
Corporate bonds | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	241,401
Gross Unrealized Gains	45
Gross Unrealized Losses	(1,081)
Fair Value	240,365
Short-Term Investments	226,468
Long-Term Investments	13,897
Commercial paper | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	140,029	160,241
Fair Value	140,029	160,241
Cash and Cash Equivalents		40,288
Short-Term Investments	140,029	119,953
U.S. government | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	43,948	30,525
Gross Unrealized Losses	(158)	(159)
Fair Value	43,790	30,366
Short-Term Investments	32,307	30,366
Long-Term Investments	11,483
Treasury inflation-protected securities | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	2,525	2,503
Gross Unrealized Gains	17
Gross Unrealized Losses		(2)
Fair Value	2,542	2,501
Short-Term Investments	$ 2,542
Long-Term Investments		$ 2,501

XML

Expected Credit Losses (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	$ 3,630
Provision for expected credit losses	28
Amounts written off charged against the allowance	(358)
Balance, end of period	3,300
United States
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	3,064
Provision for expected credit losses	(76)
Amounts written off charged against the allowance	(353)
Balance, end of period	2,635
Other countries
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	566
Provision for expected credit losses	104
Amounts written off charged against the allowance	(5)
Balance, end of period	$ 665

XML

Expected Credit Losses - Type Of Customer Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Expected Credit Losses
Accounts receivable and notes receivable, current	$ 2,029	$ 2,176
Contract assets, net	1,211	1,360
Long-term notes receivable, net of current portion	60	94
Total allowance for expected credit losses on customer receivables	$ 3,300	$ 3,630

XML

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory
Raw materials	$ 86,607	$ 72,740
Finished goods	133,661	129,731
Total inventory	$ 220,268	$ 202,471

XML

Strategic Investments (Details) - USD ($) $ in Thousands	3 Months Ended		37 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	$ 296,563	$ 83,520
Investments		500	$ 129,762
Observable price changes, Realized gains			12,312
Observable price changes, Unrealized gains	0	70,432	103,890
Observable price changes, Unrealized losses			(1,485)
Exercises			66,630
Sales			(14,546)
Balance, end of period	296,563	154,452	296,563
Strategic investments
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	277,676	80,775
Investments		500	109,482
Observable price changes, Realized gains			12,312
Observable price changes, Unrealized gains	0	41,893	74,817
Observable price changes, Unrealized losses			(1,108)
Exercises			96,719
Sales			(14,546)
Balance, end of period	277,676	123,168	277,676
Warrants
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	1,654	2,745
Investments			3,047
Observable price changes, Unrealized gains	0	28,539	29,073
Observable price changes, Unrealized losses			(377)
Exercises			(30,089)
Balance, end of period	1,654	$ 31,284	1,654
Call options
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	17,233
Investments			17,233
Observable price changes, Unrealized gains	0
Balance, end of period	$ 17,233		$ 17,233

XML

Variable Interest Entities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Total nonconsolidated variable interest entities:
Carrying value of variable interest - assets	$ 3,007,949	$ 2,851,894
Carrying value of variable interest - liabilities	1,604,954	1,583,403
Nonconsolidated VIEs
Total nonconsolidated variable interest entities:
Carrying value of variable interest - assets	11,530	11,530
Maximum exposure to loss:
Non-public equity	11,530	11,530
Total	$ 11,530	$ 11,530

XML

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Accrued Liabilities
Accrued salaries, benefits and bonus	$ 63,975	$ 97,882
Accrued professional, consulting and lobbying fees	6,840	3,861
Accrued warranty expense	3,301	811	$ 1,504	$ 2,822
Accrued income and other taxes	7,486	13,559
Accrued inventory in transit	11,318	10,548
Other accrued expenses	27,687	29,273
Accrued liabilities	$ 120,607	$ 155,934

XML

Convertible Senior Notes - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2022	Mar. 31, 2023
Senior Convertible Notes
Denomination of notes used for determination of fair value		$ 1,000
2027 Notes
Senior Convertible Notes
Aggregate principal amount	$ 690,000,000	$ 690,000,000
Interest rate (as a percent)	0.50%
Issuance costs	$ 16,200,000
Net proceeds from issuance of notes	$ 673,800,000
Effective interest rate	0.99%
Repurchase price (as percentage)		100.00%
Denomination of notes used for determination of fair value	$ 1,000	$ 1,000
Fair value of notes	687,300,000	$ 812,300,000
2027 Notes | Maximum
Senior Convertible Notes
Additional principal amount purchase option	$ 90,000,000.0

XML

Convertible Senior Notes - Net carrying amount (Details) - 2027 Notes - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Senior Convertible Notes
Principal	$ 690,000	$ 690,000
Unamortized debt issuance costs	(15,276)	(16,033)
Convertible notes carrying amount, net	$ 674,724	$ 673,967

XML

Convertible Senior Notes - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Senior Convertible Notes
Amortization of debt issuance costs	$ 756
Convertible Note Hedge 2027
Senior Convertible Notes
Contractual interest expense	863	$ 211
Amortization of debt issuance costs	756	198
Total interest expense	$ 1,619	$ 409

XML

Convertible Senior Notes - Hedge (Details) - 2027 Note Hedge	Mar. 31, 2023 USD ($)
Senior Convertible Notes
Purchase price	$ 194,994
Shares purchased	3,016,680

XML

Convertible Senior Notes - Warrants (Details) - 2027 Warrant	3 Months Ended
	Mar. 31, 2023 USD ($) D $ / security shares
Senior Convertible Notes
Proceeds | $	$ 124,269
Shares | shares	3,016,680
Strike Price | $ / security	338.86
Warrants exercise trading day period | D	60

XML

Income Taxes (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Income Taxes
Deferred tax assets, net	$ 171.1
Liability for unrecognized tax benefits	22.3
Research and development tax credit studies	$ 5.0
Effective tax rate (as a percentage)	(7.80%)
Effective tax rate, before discrete period adjustment (as a percentage)	22.80%
Discrete tax benefit, stock-based compensation	$ 13.0

XML

Stockholders' Equity - CEO Performance Award - Additional Information (Details) $ / shares in Units, $ in Thousands			3 Months Ended	58 Months Ended
	Mar. 28, 2023 tranche $ / shares	May 24, 2018 USD ($) item tranche shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market capitalization goal for such tranche		$ 2,500,000
Market capitalization goal increment		$ 1,000,000
Recorded share-based compensation expense				$ 246,000
Number of awards expected to vest | shares			500,000	500,000
Revenue goal number 1			$ 710,058	$ 710,058
Revenue goal number 2			860,058	860,058
Revenue goal number 3			1,010,058	1,010,058
Revenue goal number 4			1,210,058	1,210,058
Revenue goal number 5			1,410,058	1,410,058
Revenue goal number 6			1,610,058	1,610,058
Revenue goal number 7			1,810,058	1,810,058
Revenue goal number 8			2,010,058	2,010,058
Adjusted EBITDA goal number 1			125,000	125,000
Adjusted EBITDA goal number 2			155,000	155,000
Adjusted EBITDA goal number 3			175,000	175,000
Adjusted EBITDA goal number 4			190,000	190,000
Adjusted EBITDA goal number 5			200,000	200,000
Adjusted EBITDA goal number 6			210,000	210,000
Adjusted EBITDA goal number 7			220,000	220,000
Adjusted EBITDA goal number 8			$ 230,000	230,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares authorized (in shares) | shares		6,365,856
Number of options vested | shares			5,800,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting tranches of share-based awards | tranche		12
Vesting period		10 years
Number of performance goals, revenue | item		8
Number of performance goals, adjusted EBITDA | item		8
Chief Executive Officer | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting tranches of share-based awards | tranche	10
Outstanding percentage of common stock	0.50%
Weighted average exercise price (in dollars per share) | $ / shares	$ 218.59
Unrecognized stock-based compensation expense			$ 0	$ 0

XML

Stockholders' Equity - eXponential Stock Performance Plan (Details) shares in Millions, $ in Millions			3 Months Ended	50 Months Ended	58 Months Ended
	Feb. 12, 2019 USD ($) item tranche	May 24, 2018 USD ($)	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market capitalization goal for such tranche		$ 2,500.0
Market capitalization goal increment		$ 1,000.0
Recorded share-based compensation expense					$ 246.0
Number of awards expected to vest | shares			0.5	0.5	0.5
eXponential Stock Units | 2019 eXponential Stock Performance Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	9 years
Number of vesting tranches of share-based awards | tranche	12
Market capitalization goal for such tranche	$ 2,500.0
Market capitalization goal increment	$ 1,000.0
Number of performance goals, revenue | item	8
Number of performance goals, adjusted EBITDA | item	8
Anti-dilution provision, maximum shares growth rate per year			3.00%
Recorded share-based compensation expense				$ 191.3
Number of awards expected to vest | shares			0.8	0.8	0.8
Unrecognized stock-based compensation expense			$ 9.3	$ 9.3	$ 9.3
Weighted average period over which costs are recognized			10 months 24 days

XML

Stockholders' Equity - Summary of RSU and PSU Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year (in shares) | shares	1,565
Number of Units, Granted (in shares) | shares	73
Number of Units, Released (in shares) | shares	(103)
Number of Units, Forfeited (in shares) | shares	(32)
Number of Units outstanding, end of period (in shares) | shares	1,503
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares	$ 145.38
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	192.07
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares	135.31
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares	152.72
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares	$ 148.20
Aggregate intrinsic value at end of period | $	$ 338,003
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year (in shares) | shares	1,369
Number of Units, Released (in shares) | shares	(401)
Number of Units, Forfeited (in shares) | shares	(12)
Number of Units outstanding, end of period (in shares) | shares	956
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares	$ 43.43
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares	33.95
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares	30.24
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares	$ 47.58
Aggregate intrinsic value at end of period | $	$ 214,939

XML

Stockholders' Equity - RSU and PSU - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		58 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recorded share-based compensation expense			$ 246,000
Tax payments, for net share settlement of share based award	$ 34,841	$ 1,388
Stock options exercised	$ 54,346
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)	$ 224.85		$ 224.85
Shares withheld, for net share settlement of share based award (in shares)	900
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)	$ 224.85		$ 224.85
Unrecognized stock-based compensation expense	$ 176,300		$ 176,300
Weighted average period over which costs are recognized	2 years 2 months 12 days
Shares withheld, for net share settlement of share based award (in shares)	1
Tax payments, for net share settlement of share based award	$ 200
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)	$ 224.85		$ 224.85
Unrecognized stock-based compensation expense	$ 12,300		$ 12,300
Weighted average period over which costs are recognized	1 year
Shares withheld, for net share settlement of share based award (in shares)	160
Tax payments, for net share settlement of share based award	$ 34,700

XML

Stockholders' Equity - Stock Option Activity - Additional Information (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)	$ 224.85
Shares sold to cover tax obligation	900
Stock options exercised (in shares)	1,901
Number of options outstanding (in shares)	537	2,438
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	500

XML

Stockholders' Equity - Summary of the Company's Stock Options Activity (Details) - Stock Options $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Options outstanding, beginning of year (in shares)	2,438
Number of options, Exercised (in shares)	(1,901)
Number of options, Options outstanding, end of year (in shares)	537
Number of options, Options exercisable, end of period (in shares)	6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding, beginning of year (in dollars per share) | $ / shares	$ 28.58
Weighted average exercise price, Options outstanding, end of period (in dollars per share) | $ / shares	28.58
Weighted average exercise price, Options exercisable, end of period (in dollars per share) | $ / shares	$ 28.58
Weighted average remaining contractual life, Options outstanding, end of period	4 years 10 months 28 days
Weighted average remaining contractual life, Options exercisable, end of period	4 years 10 months 28 days
Aggregate intrinsic value, Options outstanding, end of period | $	$ 105,284
Aggregate intrinsic value, Options exercisable, end of period | $	$ 1,165

XML

Stockholders' Equity - Reported Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 34,350	$ 25,088
Cost of product sales and service sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,320	1,108
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	15,445	12,982
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 17,585	$ 10,998

XML

Stockholders' Equity - Stock Repurchase Plan - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	May 31, 2022	Feb. 29, 2016
2022 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)			2,500,000
2016 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding common stock repurchase program authorized amount (up to)				$ 50,000,000.0
Shares repurchased during period (in shares)	0	0
Remaining authorized repurchase amount	$ 16,300,000
2022 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	2,700,000

XML

Stockholders' Equity - At-the-Market equity offering - Additional Information (Details) - ATM Offering $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock (in shares) | shares	154,500
Gross proceeds | $	$ 34.2
Net proceeds | $	33.7
Commissions | $	$ 0.5
Maximum number of common stock shares to be sold | shares	3,000,000.0
Number of shares remaining to be sold | shares	2,300,000

XML

Line of Credit (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt instrument covenant consolidated leverage ratio	0.78
Senior Unsecured Multi Currency Revolving Credit Facility
Debt Instrument [Line Items]
Total availability under line of credit agreement		$ 200.0
Line of Credit
Debt Instrument [Line Items]
Total availability under line of credit agreement		30.0
Accordion feature allowing for increase in borrowing capacity		300.0
Letters of credit outstanding amount	$ 7.0
Available borrowing under letter of credit	193.0
Line of credit borrowings	$ 0.0	$ 0.0
Line of Credit | 2027 Notes
Debt Instrument [Line Items]
Debt Instrument, Maturity, Prior to Stated Maturity of Convertible Senior Notes		6 months
Percentage of convertible senior notes		0.50%
Minimum
Debt Instrument [Line Items]
Debt instrument covenant consolidated interest coverage ratio	3.50
Minimum | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate (as a percentage)	1.25%
Maximum
Debt Instrument [Line Items]
Debt instrument covenant consolidated leverage ratio	3.50
Maximum | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate (as a percentage)	1.75%

XML

Commitments and Contingencies (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) lawsuit
Loss Contingencies [Line Items]
Number of lawsuits against Company | lawsuit	4
Amount self-insured for any product claim	$ 5.0
Surety Bond
Loss Contingencies [Line Items]
Letters of credit outstanding amount	7.0
Bonds outstanding	14.0
Expiring in 2023 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	3.5
Expiring in 2024 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	$ 10.5

XML

Accumulated Other Comprehensive Income (loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accumulated other comprehensive income (loss):
Beginning balance	$ 1,268,491	$ 1,047,849
Other comprehensive income (loss)	1,860	(1,561)
Ending balance	1,402,995	1,124,789
Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss):
Beginning balance	(7,179)	(1,317)
Other comprehensive income (loss)	1,860	(1,561)
Ending balance	(5,319)	(2,878)
Unrealized Gains (Losses) on Available-for-Sale Investments
Accumulated other comprehensive income (loss):
Beginning balance	(1,251)	(207)
Other comprehensive income (loss)	184	(489)
Ending balance	(1,067)	(696)
Foreign Currency Translation
Accumulated other comprehensive income (loss):
Beginning balance	(5,928)	(1,110)
Other comprehensive income (loss)	1,676	(1,072)
Ending balance	$ (4,252)	$ (2,182)

XML

Segment Data (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments of company | segment	2
Net sales	$ 343,043	$ 256,426
Cost of sales	138,941	100,687
Gross margin	204,102	155,739
Research and development	70,927	48,416
TASER
Segment Reporting Information [Line Items]
Net sales	134,282	114,360
Cost of sales	50,763	40,625
Gross margin	83,519	73,735
Research and development	16,080	9,896
Software and Sensors
Segment Reporting Information [Line Items]
Net sales	208,761	142,066
Cost of sales	88,178	60,062
Gross margin	120,583	82,004
Research and development	54,847	38,520
Product
Segment Reporting Information [Line Items]
Net sales	219,389	176,204
Cost of sales	107,584	79,352
Product | TASER
Segment Reporting Information [Line Items]
Net sales	127,081	111,154
Cost of sales	50,583	40,625
Product | Software and Sensors
Segment Reporting Information [Line Items]
Net sales	92,308	65,050
Cost of sales	57,001	38,727
Service
Segment Reporting Information [Line Items]
Net sales	123,654	80,222
Cost of sales	31,357	21,335
Service | TASER
Segment Reporting Information [Line Items]
Net sales	7,201	3,206
Cost of sales	180	0
Service | Software and Sensors
Segment Reporting Information [Line Items]
Net sales	116,453	77,016
Cost of sales	$ 31,177	$ 21,335